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ABSTRACT 
In the present context of worldwide-prevalent obesity, optimisation of existing weight loss 
strategies and development of novel population-wide interventions is critical. 
Roux-en-Y gastric bypass (RYGB) is considered the gold-standard treatment for obesity. 
Weight loss is recommended prior to surgery to reduce liver size and risks of complications. 
However, little is known regarding the optimal pre-operative diet type and duration. In a first 
investigation, I examined the effect of three pre-operative diets on liver fat content (IHCL), as 
a proxy of liver volume, in obese patients undergoing RYGB. I compared the effects of a 2-
week and 6-week liquid formula 800kcal/day low-calorie diet (LCD) with a low-carbohydrate, 
high-protein 1000kcal/day conventional food diet (control) prescribed routinely in bariatric 
clinics.  
The 2-week and 6-week LCD induced a 40% and 67% reduction in IHCL respectively 
compared with the control diet, which did not induce any significant loss in IHCL.  
In the overweight population, dietary changes remain the first-line treatment strategy to 
induce weight loss. Certain food components promote satiety by altering gastro-intestinal 
(GI) hormone release, and may therefore play a role in the prevention of obesity and type-2 
diabetes mellitus (T2DM). Mycoprotein, a novel fungal food containing protein and fibre, 
reduces energy intake acutely and improves glucose homeostasis in lean individuals. In a 
second investigation, I explored the effect of mycoprotein on energy intake, glucose 
homeostasis, and GI hormones release in overweight volunteers. 
Mycoprotein significantly reduced acute energy intake by 10% compared with chicken in 
overweight individuals, without significantly altering GI hormones, and gastric emptying. 
Furthermore, mycoprotein reduced post-prandial insulin and improved insulin sensitivity 
compared with chicken, showing its potential health benefit in overweight individuals. 
These studies suggest that a 2-week pre-operative LCD may be optimal in the preparation 
for RYGB and that mycoprotein might be of benefit in the dietetic prevention of obesity and 
T2DM. 
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Abstract 
Obesity increases the risk of developing serious co-morbidities such as type-2 diabetes 
mellitus (T2DM) and cardiovascular disease (CVD), thus reducing life expectancy. In 
addition to the health and social cost of obesity, it represents a serious financial burden to 
society. This first chapter gives an introduction to the problem of obesity, its physiological 
and non-physiological causes and the current treatments available as well as an overview of 
the appetite regulation system. Appetite is regulated by homeostatic and non-homeostatic 
signals from the body and the environment. The homeostatic control of energy intake 
involves communication between the gut and the brain via the production and circulation of 
short and long-term signals. 
Research in the last decades has enlightened the importance of fat distribution in the 
development of the metabolic syndrome. Individuals with increased abdominal adipose 
tissue, characterised by increased waist circumference, are at great risk of developing CVD 
and T2DM. Particularly, increased ectopic fat content in the liver, the pancreas and the heart 
has been associated with the malfunctioning of these organs over the long-term. Obesity has 
also been shown to be associated with modifications of the metabolic system leading to 
attenuated satiety signals, and resistance to long-term storage signals.  
At the present time, metabolic surgery is considered the gold-standard treatment for morbid 
obesity. Roux-en-Y gastric bypass (RYGB) induces sustained weight loss by energy 
restriction and changes in metabolism. However, optimisation is still required to reduce the 
risk of complications and maximise post-operative outcomes. A pre-operative diet is required 
prior to morbidly obese individuals undergoing RYGB. There is, however, no consensus on 
the type and duration of the diet and limited evidence on the effect of different pre-operative 
diets on body composition and surgery outcomes is available. 
Overweight individuals, for whom lifestyle modifications remain the first line treatment, may 
benefit from the supplementation of satiating agents. Dietary fibre and protein are both 
thought to reduce appetite by modifying satiety signals. Mycoprotein (Quorn™), a high-fibre 
high-protein fungal product, was shown to decrease energy intake in lean volunteers. The 
effect of mycoprotein on gastro-intestinal (GI) signals is unknown. 
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1.1 Obesity, a major worldwide public health issue  
Obesity is now officially recognized as a disease by the American Medical Association, the 
World Health Organization (WHO) and the National Institutes of Health (NIH) (AMA, 2013). 
Obesity has reached epidemic proportions worldwide, bringing with it a burden of associated 
co-morbidities and a negative impact on quality of life. In order to understand the evolution of 
obesity in the past decades and to find adequate treatments, it is important to define the 
concept of obesity, and recognise both its physiological causes and its consequences on 
health and societies. 
1.1.1 Definition and classification of obesity 
Overweight and obesity are defined by the WHO as an abnormal or excessive accumulation 
of fat in the body to the extent that health may be impaired (WHO, 2013b). A crude 
measurement of obesity can be obtained by using the body mass index (BMI), a simple 
index which is defined as an individual‟s weight in kilograms divided by the square of height 
in meters (kg/m2). Individuals can be classified according to their BMI into the following 
categories shown in table 1.1. In the literature, a BMI of 35 or more can also be referred to 
as severe obesity, a BMI of 40 or more as morbid obesity and a BMI of 50 or more as super 
obesity (Renquist, 1998). 
Table 1.1: WHO classification of BMI categories 
Classification Body Mass Index (kg/m
2
) 
Underweight <18.5 
Normal weight 18.5-24.9 
Overweight 25-29.9 
Obesity, class I 30-34.9 
Obesity, class II 35-39.9 
Obesity, class III ≥40 
Individuals can be categorised into classes according to their BMI 
The use of BMI classes to diagnose obesity has been discussed intensively in the past 
(Hubbard, 2000). In the considerations, it is important to note that, for some ethnic groups, 
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the cut-off points have been modified in order to better mirror health-related risk factors. For 
example, Japanese and Chinese populations have set their BMI cut-off for obesity at 25 and 
28 kg/m2 respectively since their populations develop co-morbidities at a lower BMI 
compared with European populations (Kanazawa et al., 2002, Bei-Fan, 2002). By contrast, 
Pacific Islanders have lower body fat than Europeans for a given BMI and higher cut-off 
points should therefore be identified for this population (Swinburn et al., 1999).  
Furthermore, the definition of obesity according to BMI classes remains a poor reflection of 
fat distribution and associated co-morbidities (Huxley et al., 2010). For example, individuals 
may present with a normal BMI but increased central adiposity and risk of metabolic disease; 
such individuals have a Thin on the Outside Fat on the Inside (TOFI) phenotype (Thomas et 
al., 2012). Conversely, there are metabolically healthy obese individuals who have a 
relatively low proportion of their adipose tissue stored internally (fat-fit) (O'Donovan et al., 
2009, Thomas et al., 2012, Stefan et al., 2008). In the United States of America (US) 
National Health and Nutrition Examination Survey (NHANES) study, 24% of normal-weight 
adults were shown to be metabolically abnormal and conversely 32% of obese individuals 
were shown to be metabolically healthy (Wildman et al., 2008). Other measurements such 
as waist circumference are therefore of great importance in the assessment of mortality risk 
for overweight and obese people (NHI, 2000). Nonetheless, the BMI has widespread 
applications in the assessment of obesity in large population studies due to its practicality 
and low cost (Whitlock et al., 2009). 
1.1.2 Trends in obesity prevalence 
In 2008, the WHO estimated the number of overweight adults at 1.4 billion worldwide 
including 500 million obese adults making obesity one of the most prevalent non 
communicable diseases in the world (WHO, 2011a). Overweight and obesity are the fifth 
leading risk for global death worldwide. They increase the risk of developing several co-
morbidities such as cardiovascular diseases (CVD), type-2 diabetes mellitus (T2DM), 
musculoskeletal disorders and some types of cancer including colon and breast cancer thus 
predicted to reduce life expectancy by 3 to 13 years (Peeters et al., 2003).  
In the United Kingdom (UK), the latest WHO statistics from 2008 show that 64.2% and 
26.9% of the population were overweight and obese respectively (WHO, 2011b). These 
figures have nearly doubled since 1993. The latest National Health Service (NHS) Statistics 
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report presents the decrease in the percentage of the population with normal BMI before the 
increase in the overweight and obesity prevalence, emphasising the fact that overweight has 
become „the norm‟ (NHS, 2013). Overweight and obesity prevalence are also increasing in 
children. In 2010, more than 40 million children under 5 years old were overweight in the 
world (WHO, 2011a) and around 30% and 16% of children aged 2 to 15 were classified as 
overweight and obese respectively in England (NHS, 2012). Although the increase in obesity 
prevalence has slowed down in Western Countries in the past few years, it is increasing at 
alarming rate in developing countries (Martorell, 2001). In developing countries, the rise in 
overweight and obesity may be linked to rapid urbanisation and industrialisation combined 
with changes in lifestyle (Hoffman, 2001).  
1.1.3 Obesity, a costly problem 
Overweight and obesity represent a serious economic cost. In the UK, the direct cost of 
overweight and obesity to the NHS was estimated to reach £4.2 billion in 2007 (Klim 
McPherson, 2007). Furthermore, overweight and obesity have a more general cost to the 
society and the economy caused by reduced productivity, quality of life and longevity. The 
total impact of obesity on employment has been estimated at £10 billion (McCormick and 
Stone, 2007).  Altogether, although hard to estimate, the annual financial burden of 
overweight and obesity on society may be as high as is £16 billion in the UK (Klim 
McPherson, 2007). Without any action taken to limit the rise in overweight and obesity 
prevalence, the cost to the NHS and society may reach £9.7 billion and £50 billion 
respectively by 2050 (Bryony Butland, 2007).  
1.1.4 Obesity, an energy imbalance maintained over the long-term 
In order to maintain body weight, energy intake and energy expenditure, represented in 
figure 1.1, should be equal. Energy intake results from the consumption of nutrients.  Energy 
expenditure is the sum of energy spent on resting metabolic rate, diet-induced 
thermogenesis and activity thermogenesis including exercise and non-exercise activity. 
While resting energy expenditure is mainly influenced by lean body mass (Cunningham, 
1991, Nelson et al., 1992), there are great variations in activity thermogenesis (Passmore 
and Durnin, 1955). Physiologically, overweight and obesity result from a chronic imbalance 
between energy intake and energy expenditure due to excessive consumption of energy and 
limited physical activity. 
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Figure 1.1: Components of energy balance 
Energy intake is composed of carbohydrates (CHO), lipids (FAT), and protein (PROTEIN). Energy 
expenditure is the sum of resting energy expenditure (REE), diet-induced thermogenesis (DIT), and 
activity thermogenesis (AT). AT is divided between exercise (EAT) and non-exercise activity 
thermogenesis (NEAT). In order to maintain body weight, energy intake and energy expenditure 
should be equal.  
The thrifty gene hypothesis speculates that over the last millennium, periods of famine and 
scarce food supply lead to the selection of genes in the benefit of energy storage in the body 
for survival purposes (Neel, 1962). Since we now live sedentarily in an abundance of high-
energy foods, this long-term gene selection may have now turned to our disadvantage 
(Ravussin and Bogardus, 2000). This hypothesis has however been disputed both by the 
drifty gene hypothesis and other alternative hypotheses based on genetic and environmental 
observations (Speakman, 2008). Heritability is thought to play a causal role in obesity; the 
heritability of BMI has been estimated between 30 and 70% from family and twin studies 
(Lyon and Hirschhorn, 2005, Allison et al., 1996). Studies of gene-environment interactions 
show that some individuals may be more susceptible to body weight gain than other under 
the same environmental conditions (Tremblay et al., 2004). 
1.1.4.1 Energy expenditure and physical activity 
Between 1980 and 2008, the worldwide prevalence of obesity almost doubled. Changes in 
food production, transport, and lifestyle all account for the current obesogenic environment. 
Since the industrial revolution, energy expenditure has decreased as the result of a 
reduction in physical activity, increased sedentary lifestyle due to modernisation, improved 
transports, and urbanisation (WHO, 2013b). Since resting energy expenditure (REE) is the 
main component of energy expenditure in the normal population, body composition is of 
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great importance and particularly lean mass. However, differences in activity thermogenesis 
(AT) highly depend on daily activity (Passmore and Durnin, 1955). In the UK, the estimated 
prevalence of physical inactivity, defined as inactive leisure time, was 66.5% in 2008 (WHO, 
2011b). Physical inactivity has been identified as one of the leading causes of preventable 
death worldwide and could partly explain the increase in obesity prevalence (Lindstrom et 
al., 2003, Lopez et al., 2006).  
1.1.4.2 Energy intake and food choices 
The evolution of daily energy intake over the past centuries is difficult to quantify. However, it 
is possible to analyse daily energy intake during the past decades. In the US for example, a 
study of the population food consumption estimated that the average daily energy intake 
increased by 335kcal and 168 kcal in women and men respectively between 1971 and 2004 
(Wright et al., 2004). During the same period, the obesity prevalence doubled from around 
15% in 1971 to 30% in 2000 (Flegal et al., 2002). Most of the extra energy intake was due to 
an excessive intake of carbohydrates, particularly from excessive consumption of sugar 
sweetened beverages, which has been associated with the rise in obesity in several studies 
(Barrio-Lopez et al., 2013, Schulze et al., 2004, Malik et al., 2010, Ludwig et al., 2001).  
The composition of diets has changed drastically in the past 50 years in developed 
countries. Progresses in food technology have enabled industries to respond to a customer 
demand of ready-to-eat and processed products. Consequently, the use of fresh products 
and unrefined carbohydrates such as whole grains and pulses has decreased to the benefit 
of processed food with low content of dietary fibre and high content of simple sugars, 
saturated fat and salt. As an example, the intake of dietary fibres has decreased to 12-15g in 
most Western countries instead of the 18g or 25g per day recommended by UK Dietary 
Reference Value and the European Food Safety Authority respectively. In England, only 
24% of men and 29% of women consumed the daily recommended 5 portions of fruits and 
vegetables in 2011 (NHS, 2013). Treating obesity is therefore a challenging fight that also 
needs to involve governments as well as food industries (AMA, 2013).  
In conclusion, the current obesity epidemic results from an interaction of genetic, behavioural 
and environmental causes. Physiologically, obesity results from a chronic energy imbalance. 
Energy intake is regulated by homeostatic and non-homeostatic control involving cross-talk 
between the gut and the brain which will be summarised in the next section.  
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1.2 Non-homeostatic and homeostatic control of energy intake 
Food intake is driven by the feeling of hunger or the physiological drive to eat. During food 
intake, hunger decreases until satiation (from Latin satis, sufficient), the process by which an 
eating episode reaches its end. Following food intake, satiety, the condition of repletion, 
leads to the inhibition of hunger and eating. Appetite, the desire for food, is the result of 
these feelings as well as other external factors including food palatability, memory and 
psychological aspects among others. Physiologically, food intake is tightly regulated. In the 
past decades, research has highlighted the importance of the peripheral and central 
regulation of food intake in order to maintain energy homeostasis (Murphy and Bloom, 
2006). However, the rise in obesity shows that many other external non-homeostatic factors 
can override the homeostatic control of energy intake. The increase in energy-dense food 
availability and food palatability as well as the reward pathways triggered by high-fat, high-
sugar foods are part of a hedonic food behaviour which contribute to excessive energy 
intake and, over the long-term, obesity (Berthoud, 2006). 
1.2.1 Non-homeostatic control of appetite and reward centres 
Appetite is under the influence of many non-homeostatic factors. These include 
psychological and emotional influences such as stress, depression or eating disorders, 
socio-cultural factors such as isolation and cooking traditions, economic factors such as food 
availability and affordability, education, and hedonic factors including food palatability, all of 
which are relative to each individual. In particular, there are several centres in the brain 
involved in reward mechanisms and emotional eating situated in the corticolimbic and higher 
cortical brain regions (Gottfried et al., 2003, Arana et al., 2003). These centres are involved 
in other processes such as memory, fear, pain, and learning and communicate closely with 
homeostatic appetite centres in the hypothalamus (Berthoud, 2004). Often, non-homeostatic 
factors can override the physiological need for food, leading to overweight or obesity if 
sustained over the long-term.  
1.2.2 Homeostatic control of appetite 
Despite great fluctuations in food intake on a daily basis, body weight remains relatively 
stable over time in lean human adults. In the past few decades, scientists have discovered 
that interactions between hormonal signals released by the gastro-intestinal tract, the 
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adipose tissue and the brain enable a fine communication along the gut-brain axis in order to 
maintain body weight (Murphy and Bloom, 2006). Energy intake is therefore physiologically 
regulated; this is called energy homeostasis. Some signals, released prior to or in response 
to the ingestion of a meal from various parts of the gastro-intestinal tract, influence hunger 
and satiety feelings; they are part of a short-term regulation system. Others, considered to 
be long-term signals, are involved in energy storage. These signals can be perceived via 
specific receptors by several organs and by the central nervous system in the brain where 
they are integrated (Morton et al., 2006).  
1.2.2.1 Appetite centres involved in the central nervous system 
The central nervous system (CNS) is the central integrator of the appetite regulation system. 
It permanently receives messages from nutrients, appetite regulating hormones and 
peripheral adiposity signals via the circulatory system or neuronal afferents via the vagus 
nerve and the spinal cord regarding energy status and storage (Morton et al., 2006). The 
CNS also centralises information from the environment, the reward system, emotional 
responses and other factors. Signals are received by different areas within the brain. One of 
these areas, the hypothalamus, plays a major role in the homeostatic regulation of appetite 
(Anand and Brobeck, 1951).  
1.2.2.1.1 The hypothalamus 
The hypothalamus has been long known to play a major role in food intake regulation 
(Anand and Brobeck, 1951). The hypothalamus is composed of several clusters of nuclei, 
connected to each other and also connected to the brainstem and higher cortical structures 
in the brain. Among these nuclei, the arcuate nucleus (ARC) is thought to be of primary 
importance in the sensing of peripheral signals and nutrients. Indeed, studies suggest that 
the blood brain barrier (BBB), which normally separates the cerebrospinal fluid from the 
blood therefore preventing the penetration of circulating hormonal signals into the brain, may 
be incomplete at the median eminence near the ARC, allowing nuclei to sense circulating 
signals and nutrients (Broadwell and Brightman, 1976).  
Within the ARC, there are two well-characterised neuronal populations involved in the 
regulation of energy intake. The first population co-expresses orexigenic neuropeptides such 
as neuropeptide Y (NPY) and agouti-related peptide (AgRP) which stimulate food intake 
(Hahn et al., 1998). The second population of neurons in the ARC co-expresses pro-
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opiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART) 
which are involved in feeding suppression and satiety (Kristensen et al., 1998). These are 
first-order populations of neurons as they are first to receive information which they then 
transmit to other centres by second order neuronal projections. Several other centres within 
the hypothalamus, which communicates closely with other neuronal populations by neuronal 
projections, are involved in appetite regulation (Yu and Kim, 2012).  
1.2.2.1.2 The brainstem 
Signals from nutrients and hormones can also be transmitted to the hypothalamus directly 
via the vagus nerve and the brainstem (Ricardo and Koh, 1978). The brainstem is located in 
the posterior part of the brain and includes the midbrain, pons and medulla oblongata. Within 
the brainstem, the dorsal vagal complex includes the nucleus of the tractus solitarius (NTS), 
the area postrema (AP) and the dorsal motor nucleus of the vagus, which have been 
implicated in the regulation of energy homeostasis as reviewed by Murphy and Bloom 
(Murphy and Bloom, 2006). Appetite signals can reach the brainstem from the GI tract to the 
NTS via vagal afferents which then relay signals to the ARC and other appetite centres in 
the hypothalamus (Grill and Kaplan, 2002). Similarly to the median eminence in the 
hypothalamus, the area postrema in the brainstem has been shown to present a defective 
BBB allowing sensing of peripheral circulating factors by the brainstem and further neuronal 
communication to the hypothalamus (Gotow and Hashimoto, 1979). 
1.2.2.2 Appetite regulating hormones  
Over the past decades, the GI tract has been discovered as one of the most important 
endocrine organ transmitting information on nutritional status, energy intake and other 
metabolic activities to the CNS via the bloodstream or vagal afferents. Some hormones, 
known as anorectic hormones, are released during and after food intake and are involved in 
satiety signalling, while others, orexigenic hormones, are released following a period of 
fasting and play a role in promoting hunger and food intake (Murphy and Bloom, 2006). Both 
groups act in the short-term. Other hormones reflect storage of energy in the body and act in 
the long-term. A great number of GI hormones with various roles in appetite regulation have 
been discovered so far and only selected hormones which are relevant to this work will be 
discussed in this section.  
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1.2.2.2.1 Anorectic hormones 
Peptide Tyrosine Tyrosine (PYY) 
PYY is a 36 amino-acid peptide released post-prandially from the L-cells of the GI tract with 
highest concentrations found in the colon (Adrian et al., 1985). PYY belongs to the 
pancreatic polypeptide-fold family which also includes pancreatic polypeptide (PP) and 
neuropeptide Y (NPY). There are two forms of PYY, PYY1-36, and PYY3-36, the biologically 
active form which results from the cleavage of PYY1-36 at the N-terminal by the enzyme 
dipeptidyl-peptidase IV (DPP-IV) (Grandt et al., 1994).  
Peripheral administration of PYY increases c-fos expression in the ARC suggesting neuronal 
activation and direct injection of PYY into the ARC inhibits food intake (Batterham et al., 
2002). The anorectic effects of PYY in the hypothalamus are regulated via the Y2 receptor 
(Batterham et al., 2002). PYY is also thought to act on other appetite regulation centres such 
as the corticolimbic and higher cortical brain regions (Batterham et al., 2007) and via vagal 
afferents (Abbott et al., 2005).   
Plasma concentrations of PYY are low in the fasted state, increasing in proportion to energy 
intake following a meal, to reach a peak after 1 to 2 hours and remain elevated for several 
hours following the consumption of a meal (Adrian et al., 1985). Protein and fat are the most 
potent stimulators of PYY release (Batterham et al., 2006). Peripheral administration of 
PYY3-36 in rodents reduces food intake and body weight and intravenous administration of 
PYY3-36 decreases appetite and food intake in lean and obese humans therefore highlighting 
the role of PYY in food intake suppression (Batterham et al., 2002, Batterham et al., 2003). 
PYY is also thought to play a role in the ileal brake by delaying gastric emptying and slowing 
further nutrient transit in the upper part of the GI in response to food intake (Talsania et al., 
2005).  
Glucagon-like peptide-1 (GLP-1) 
GLP-1 is a 30 amino-acid peptide co-released with PYY from the L-cells in the GI tract 
although it can also be found in the brain and the pancreas (Eissele et al., 1992). It is 
transcribed from the expression of the proglucagon gene which can be selectively cleaved to 
form GLP-2, oxyntomodulin (OXM) and glucagon (Tucker et al., 1996). The truncated GLP-
17-36 amide is the most abundant circulating form of GLP-1 in humans (Orskov et al., 1994). 
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Both GLP-17-37 and GLP-17-36 amide forms bind to the receptor GLP-1R which is widely 
distributed in the brain, the GI tract and the pancreas (Yamato et al., 1997).  GLP-1 can also 
act on the NTS via vagal afferents (Abbott et al., 2005).  
GLP-1 is secreted following food intake with low fasting levels (5 to 10 pmol/l) rising post-
prandially in response to energy intake (Ghatei et al., 1983, Orskov et al., 1994). GLP-1 was 
shown to be an incretin hormone i.e. following the ingestion of a carbohydrate-rich meal, 
GLP-1 stimulates the secretion of insulin in a glucose-dependent manner (Kreymann et al., 
1987). GLP-1 reduces appetite and induces satiety in rodents (Turton et al., 1996) and both 
lean (Flint et al., 1998) and obese humans (Naslund et al., 1999). GLP-1 also suppresses 
glucagon secretion, delays gastric emptying and is thought to be involved in the ileal brake, 
along with PYY, regulating the passage of nutrients through the GI tract (Drucker, 2006, 
Verdich et al., 2001).  
GLP-1 is eliminated rapidly from plasma by DPP-IV and therefore has a short half-life of a 
few minutes, limiting its potential as a pharmacological treatment for obesity (Kieffer et al., 
1995). Nevertheless, Exendin-4 or exenatide, a GLP1-R agonist resistant to the DPPIV 
enzyme was shown to improve glucose homeostasis, suppress energy intake, and decrease 
body weight in diabetic rodents and monkeys (Eng et al., 1992, Parkes et al., 2001, Young et 
al., 1999). In humans, exenatide suppresses energy intake in healthy volunteers  (Edwards 
et al., 2001) and improves glucose homeostasis and decreases body weight in diabetic 
humans (DeFronzo et al., 2005). Other GLP-1 analogues, such as Liraglutide, have shown 
promising effects on body weight (Astrup et al., 2012).  
1.2.2.2.2 Orexigenic hormones 
At the present time, only one orexigenic GI hormone has been identified, ghrelin. Ghrelin is a 
28 amino-acid peptide produced by the P/D1 cells of the fundus in the stomach and by the 
epsilon cells in the Islets of Langerhans in the pancreas (Kojima et al., 1999). It was reported 
for the first time in 1999 following the discovery of its receptor, the growth hormone 
secretatogue receptor 1a (GHSR1a) in 1996 (Howard et al., 1996, Kojima et al., 1999). 
Ghrelin is produced from the cleavage of the ghrelin/obestatin prepropeptide (also known as 
the growth hormone secretagogue). The active form of ghrelin, also called acyl-ghrelin, binds 
to GHSR1a whereas the unacylated form is unable to bind to the receptor (Bednarek et al., 
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2000). In the hypothalamus, ghrelin activates the NPY/AgRP neurons in the ARC and other 
appetite centres (Nakazato et al., 2001). 
Serum concentrations of ghrelin are elevated in the fasted state and decrease following food 
intake with protein and carbohydrates being the most potent macronutrients to suppress 
ghrelin and fat the weakest (Tschop et al., 2001a, Foster-Schubert et al., 2008, Al Awar et 
al., 2005). Furthermore, administration of ghrelin was shown to stimulate food intake and 
body weight gain and reduce fat utilisation when administered centrally to rodents and 
peripherally to humans (Tschop et al., 2000, Wren et al., 2000). Ghrelin is therefore thought 
to play a role in meal initiation. Plasma ghrelin concentrations are inversely correlated with 
body weight and normally rise after weight loss (Tschop et al., 2001b, Cummings et al., 
2002) which may contribute to the difficulty of weight loss maintenance by energy restriction. 
1.2.2.3 Peripheral adiposity signals 
1.2.2.3.1 Insulin  
Insulin is secreted following a meal by the β-cells of the Langerhans islets in the pancreas 
and has well-characterised hypoglycaemic effects (Polonsky et al., 1988).  However, the 
hormone is also thought to act as a long-term anorectic signal within the CNS (Bruning et al., 
2000). Circulating insulin levels have been shown to correlate with body weight and insulin 
sensitivity is closely correlated to adipose tissue content (Bagdade et al., 1967, Kahn et al., 
1993). Furthermore, it was shown that central administration of insulin in rodents and 
baboons reduces food intake and body weight (Porte and Woods, 1981, Air et al., 2002). 
Insulin is thought to enter the central nervous system through the BBB and act on its 
receptors, highly expressed in the ARC (Pardridge et al., 1985, Marks et al., 1990). Central 
administration of insulin inhibits the expression of orexigenic NPY/AgRP neurons and 
activates the expression of POMC neurons (Schwartz et al., 1992, Benoit et al., 2002). 
Beside the hypothalamus, the evidence shows that insulin may also act in other areas of the 
CNS involved in appetite regulation (Pardini et al., 2006, Corp et al., 1986).  
1.2.2.3.2 Leptin 
The effects of mutations on the leptin gene ob were observed as early as 1950 in obese 
leptin deficient ob/ob mice (Ingalls et al., 1950). The gene itself was only isolated in 1994 
(Zhang et al., 1994). The 167 amino-acid hormone is the product of the ob gene and 
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secreted mainly by the adipocytes of the adipose tissue. Leptin binds to several types of 
receptors among which the main one is the Ob-Rb receptor encoded by the lepr gene, highly 
expressed in the hypothalamus (Baskin et al., 1999). To bind to the receptor, leptin is 
thought to cross the BBB by a saturable transporter system (Banks et al., 1996) and act in 
the ARC on the anorectic and orexigenic neuronal populations. A mutation on the Ob-Rb 
receptor causes obesity in db/db mice (Chen et al., 1996). 
Serum concentrations of leptin are strongly correlated to adipose tissue content (Considine 
et al., 1996). Leptin levels follow a pulsatile, diurnal rhythm reaching peaks at night (Saad et 
al., 1998) but leptin levels do not change acutely following food intake (Korbonits et al., 
1997). Some studies have shown that fasting, weight loss and physical exercise can lower 
leptin levels (Reseland et al., 2001). However, the decrease in leptin concentrations does 
not necessarily follow a linear relationship with adipose tissue content reduction during 
weight loss (Keim et al., 1998). Leptin deficient ob/ob mice exhibit hyperphagia and obesity 
which can be reversed by leptin administration (Halaas et al., 1995). Subsequently, 
subcutaneous administration of recombinant leptin reduces fat mass, hyperinsulinemia and 
hyperlipidemia in obese children with congenital leptin deficiency (Farooqi et al., 1999). 
Leptin plays a role in long-term appetite regulation by reducing food intake and increasing 
energy expenditure (Pelleymounter et al., 1995). However, serum levels of leptin, which are 
elevated in obese subjects, do not correlate with a reduction in food intake showing that 
obese humans may develop leptin resistance (Considine et al., 1996). Consequently, leptin 
for the treatment of common obesity is ineffective. 
1.2.2.4 Nutrient signals 
In addition to the appetite hormones and peripheral adiposity signals previously mentioned, 
some nutrients are also thought to act as signalling molecules in the central nervous system. 
Glucose, for example, can act via several glucose-sensing mechanisms in the hypothalamus 
where it has been shown to activate the anorectic neuronal population (Oomura et al., 1969). 
Interestingly, fructose, the isoenergetic isomer of glucose, was shown to activate different 
areas within the hypothalamus, and enhanced feeding behaviour (Page et al., 2013, Lane 
and Cha, 2009). Other nutrients such as poly-unsaturated fatty acids were shown to reduce 
hypothalamic inflammation in obesity (Cintra et al., 2012). Similarly, certain amino acids may 
be sensed in the hypothalamus, for example central administration of leucine has been 
shown to decrease food intake in rodents (Cota et al., 2006).  
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1.2.3 Overview of the homeostatic control of appetite   
Figure 1.2 displays an overview of the homeostatic control of appetite involving a close 
interaction between the GI tract, adipose tissue and pancreas, producing hormonal signals, 
and the main clusters of nuclei involved in appetite regulation in the hypothalamus and the 
brainstem. Food intake causes changes in gut hormones peripheral concentrations such as 
ghrelin, PYY and GLP-1 which then signal to the CNS. Other cognitive and external factors 
act on the higher brain centres which integrate the information and modulates food intake 
accordingly. 
Several other hormones, including cholecystokinin (CCK), PP, somatostatin, oxyntomodulin, 
secretin, amylin, obestatin and motilin, are also involved in the appetite regulation system. 
They play various roles such as modulating gastric and gut motility, altering gallbladder 
contractions, promoting or preventing gastric and pancreatic secretions, which have been 
summarized in several reviews (Chaudhri et al., 2006, Suzuki et al., 2010, Hussain and 
Bloom, 2013).  
In conclusion energy intake physiologically relies on a close communication between the GI 
tract, adipose tissue and the brain. The central nervous system is responsible for the 
regulation of appetite based on long-term energy storage indicated by peripheral adiposity 
signals and acute nutrient intake indicated by short-term anorectic and orexigenic signals. In 
obesity, changes in nutrient balance and over-feeding results in alterations of the appetite 
regulation system and metabolism which increase the risk of co-morbidities as discussed in 
the next section. 
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Figure 1.2: Homeostatic and non-homeostatic appetite regulation systems  
Hormones released from the GI tract, the pancreas and the adipose tissue are proposed to act on 
energy homeostasis through different pathways: the direct neural pathway via the vagus nerve or the 
bloodstream via an incomplete BBB at the AP and the ME. Nuclei in the brainstem and the 
hypothalamus are connected to each other by neuronal projections and relay the information to the 
corticolimbic centre which also integrates external cues. 
Key: AgRP, Agouti-related peptide; AP, area postrema; ARC, arcuate nucleus; BBB, blood-brain 
barrier; CART, cocaine- and amphetamine-regulated transcript; CCK, cholecystokinin; CNS, central 
nervous system; GI tract, gastro-intestinal tract; GLP-1, glucagon-like peptide-1; ME, median 
eminence; NPY neuropeptide Y; NTS, nucleus of the tractus solitaries; POMC, pro‐opiomelanocortin; 
PP, pancreatic polypeptide; PYY, peptide tyrosine-tyrosine. 
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1.3 Alterations in body composition, metabolism, and appetite 
regulation in obesity 
The importance of body composition and fat distribution in the development of obesity-
associated co-morbidities has been greatly emphasized in the past decades. This next 
section will summarize how alterations in body composition and particularly fat distribution 
affect metabolism in various organs.  
1.3.1 Body composition and fat distribution 
In overweight and obese individuals, chronic positive energy imbalance leads to the storage 
of energy in the form of adipose tissue within different compartments. White adipose tissue, 
composed mainly of adipocytes used as energy stores by the body, is now recognised as a 
major endocrine organ (Yang, 2008). The metabolic outcome of excess adipose tissue in 
obese subjects is greatly dependent on the distribution rather than the overall content of 
adipose tissue.  
1.3.1.1 Subcutaneous adipose tissue  
The subcutaneous adipose tissue (SAT) lies beneath the skin and is widely distributed in the 
body, particularly in women. Peripheral adiposity and lower-body adiposity, characterised by 
high levels of SAT but relatively low visceral adipose tissue content, do not necessarily 
correlate with high risk of co-morbidities (Thomas et al., 2012, Kuk et al., 2006, Demerath et 
al., 2008).  
1.3.1.2 Abdominal adipose tissue 
Lately, the concept of central adiposity has emerged to better recognise obese subjects who 
are at high risks of CVD and T2DM. Central obesity or abdominal adiposity is defined by the 
accumulation of adipose tissue in the abdominal region and characterised by raised waist 
circumference or waist-on-hip ratio (NHI, 2000). In individuals with central obesity, the 
accumulation of adipose tissue in the abdomen is associated with greater risks of developing 
the metabolic syndrome and other associated co-morbidities (Despres and Lemieux, 2006, 
Yusuf et al., 2005, Chan et al., 1994). The metabolic syndrome is a combination of medical 
disorders which increase the risk of developing CVD and T2DM. There are various 
definitions and criteria set for the metabolic syndrome but most organizations agree on the 
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consensus that metabolic syndrome is present where at least three of the following 
conditions are met: central adiposity defined by increased waist or waist-on-hip ratio, 
dyslipidaemia defined by elevated triglycerides and/or reduced high-density lipoprotein 
(HDL), raised blood pressure, and elevated fasting glucose concentration (NIH, 2011, IDF, 
2006, WHO, 1999).  
1.3.1.3 Visceral adipose tissue 
Abdominal adipose tissue is composed of both abdominal SAT and visceral adipose tissue 
(VAT). VAT lies inside the abdominal cavity surrounding vital organs such as the liver, the 
pancreas and the heart. VAT has been associated with impairment of glucose and lipid 
metabolism and consequently, increased VAT has been recognised as a greater risk factor 
for the metabolic syndrome, CVD and T2DM than abdominal adiposity alone (Fujioka et al., 
1987, Kuk et al., 2006, Neeland et al., 2012, Barzilai et al., 1999). 
Several factors may influence the distribution of fat including sex and age (Thomas et al., 
2012, Lemieux et al., 1993). Indeed, males generally present with lower overall body fat 
content than females but a higher degree of central adiposity compared with females 
(Lemieux et al., 1993). Ethnicity was also shown to be of particular importance in fat 
distribution. Despite higher rates of upper-body obesity and fat accumulation, VAT was 
shown to be lower in black women compared with white women (Conway et al., 1995, Albu 
et al., 1997). 
1.3.2 Ectopic fat and metabolic risks 
Over the long-term, excessive intake of dietary fat may lead to adipocytes hypertrophy and 
adipose tissue dysfunction in some individuals. The resulting increase in free fatty acids and 
inflammatory cytokines leads to the redirection of lipid supply towards non adipose organs 
that normally contain small amounts of fat such as the liver, the heart, the muscle and the 
pancreas (Snel et al., 2012). The accumulation of lipids within non adipose organs, known 
as ectopic fat, aggravates insulin resistance in the skeletal muscle and liver (Koska et al., 
2008, Hwang et al., 2007, Stefan et al., 2008) and has been associated with increased risk 
of developing serious metabolic diseases including CVD and T2DM as illustrated in figure 
1.3.  
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Figure 1.3: The ectopic fat model and resulting metabolic diseases  
Source: (Despres and Lemieux, 2006). Chronic positive energy balance results in increased adipose 
tissue. The surplus can be stored in the form of subcutaneous adipose tissue or, in genetically 
susceptible individuals, in the form of visceral adipose tissue. In deficient or insulin resistant adipose 
tissue with limited ability to store triglycerides, excess lipid accumulation results in the deposition of 
ectopic fat in undesirable organs consequently leading to the development of metabolic diseases. 
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1.3.2.1 Accumulation of intra-hepato cellular lipid content (IHCL) 
The liver is particularly sensitive to the accumulation of lipids (Seppala-Lindroos et al., 2002). 
In individuals with hepatic steatosis and no cause for secondary hepatic fat accumulation, 
the deposition of lipid in the liver to the extent that fat represents 5% or more of the liver is 
called non-alcoholic fatty liver disease (NAFLD). NAFLD is considered to be the hepatic 
manifestation of the metabolic syndrome and is often associated with obesity, dyslipidemia 
and insulin resistance (Chalasani et al., 2012). The prevalence of NAFLD is estimated to 
stand around 20% worldwide (Vernon et al., 2011). BMI and particularly visceral adiposity 
are recognised risk factors for NAFLD and the prevalence of NAFLD in severe obese 
patients undergoing metabolic surgery can be as high as 90% (Machado et al., 2006, 
Vernon et al., 2011). T2DM is also a well-documented risk factor for NAFLD (Beymer et al., 
2003). Other factors such as age, sex and ethnicity are also associated with differential 
prevalence of NAFLD (Vernon et al., 2011).  
NAFLD can be further categorized into two major subtypes: Non-alcoholic fatty liver (NAFL), 
which is defined as the presence of hepatic steatosis with no evidence of hepatocellular 
injury, and non-alcoholic steatohepatitis (NASH), the progressive form of NAFLD, which 
occurs when NAFLD leads to liver cell injury and inflammation (Matteoni et al., 1999). While 
NAFLD does not necessarily correlate with increased mortality, NASH increases the risk of 
cirrhosis and liver failure and is associated with increased risks of CVD (Matteoni et al., 
1999, Ekstedt et al., 2006). NASH is closely related to the metabolic syndrome and insulin 
resistance (Marchesini et al., 2003, Ryan et al., 2005, Marchesini et al., 1999).  
1.3.2.2 Accumulation of pancreatic lipid content  
Similarly to the liver, fat deposition in the pancreas can lead to non-alcoholic fatty pancreas 
disease (NAFPD). However, although the deleterious effects of NASH are well documented, 
there is limited evidence regarding the effect of NAPFD on pancreatic function. Although one 
study suggested that increased pancreatic fat may be correlated with beta-cell dysfunction in 
non-diabetic males (Tushuizen et al., 2007), other large studies found no association 
between pancreatic fat and beta-cell function (Saisho et al., 2007).  
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1.3.3 Insulin resistance and type-2 diabetes 
T2DM is a metabolic disorder characterised by hyperglycaemia and altered lipid metabolism 
due to inadequate insulin response to energy over-intake. While there is evidence that T2DM 
has a strong genetic cause, obesity is a major independent risk factor for insulin resistance 
and T2DM (McCarthy, 2010, Stumvoll et al., 2008, Haffner, 1998, Chan et al., 1994). An 
estimated 320 million people worldwide have T2DM (WHO, 2013a). T2DM is associated with 
higher risk of heart disease, kidney failure, nerve damage and blindness (Danaei et al., 
2006, Klein, 1995). T2DM also has a direct elevated cost through medication and care and 
an indirect cost to society through reduced productivity (Yang, 2013, Kanavos, 2012). 
Lifestyle changes, including healthy diet and regular physical activity, are the first-line 
treatment in diabetic patients. Furthermore, weight loss can result in significant improvement 
of insulin resistance and T2DM (Bjorntorp et al., 1970, Knowler et al., 2002, Tuomilehto et 
al., 2001). Treatment by blood glucose lowering medication can be implemented to support 
the effect of lifestyle changes where needed. 
To explain the association between obesity and increased risk of T2DM, several 
mechanisms have been suggested including elevated levels of non-esterified fatty acids 
(NEFA), inflammatory cytokines, lipotoxicity and glucotoxicity (Stumvoll et al., 2005). During 
a chronic state of positive energy balance, elevated NEFA and triglycerides concentrations 
in the blood stream contribute to reduced beta-cell function and insulin gene expression 
(Zhou and Grill, 1995, Jacqueminet et al., 2000). In genetically susceptible individuals, 
T2DM may develop as a result of chronic fuel surfeit (Nolan et al., 2011). In such individuals, 
β-cells fail to compensate for energy imbalance and elevated nutrient concentrations leading 
to hyperglycaemia, expansion of VAT, production of inflammatory signals, and hepatic and 
peripheral insulin resistance (Nolan et al., 2011). While it is not conclusively known whether 
the reduction in insulin secretion or the development of insulin resistance is the primary 
defect in the development of T2DM, it does seem clear that these two factors exacerbate the 
other, eventually leading to beta cell failure.  
1.3.4 Changes in the homeostatic control of appetite 
The evidence shows that obesity is associated with a variety of dysfunctions within the 
appetite system (Suzuki et al., 2012). Obese humans have lower fasting and post-prandial 
circulating levels of PYY and GLP-1 compared with lean subjects (Batterham et al., 2003, le 
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Roux et al., 2006b, Ranganath et al., 1996). This delayed and attenuated PYY response to 
nutrient ingestion may explain partly the sustained hunger and impaired satiety experienced 
by obese subjects post-prandially and consequently the difficulty to lose weight (le Roux et 
al., 2006b).  
Interestingly, obese humans were shown to have lower fasting ghrelin levels (Tschop et al., 
2001b). Fasting ghrelin levels negatively correlate with body fat, fasting insulin levels and 
leptin, which are elevated in obese subjects (Colman et al., 1995, Considine et al., 1996). 
This suggests that the down-regulation of ghrelin levels in obesity might be the consequence 
of raised insulin or leptin levels. Obese subjects should therefore feel less hungry when 
fasted that lean subjects. However, because PYY and GLP-1 levels were shown to be 
attenuated following food intake in obese humans, they experience blunted satiety and an 
early return of hunger compared with lean humans. Weight loss has been shown to increase 
circulating levels of ghrelin probably as a defence mechanism against weight loss (Hansen 
et al., 2002). This may partly explain why sustaining weight loss over the long-term has 
proven difficult for obese individuals. 
1.3.5 Other significant changes  
1.3.5.1 Changes in the reward centre activation 
Studies investigating the response of obese individuals to high-calorie food cues using 
functional Magnetic Resonance Imaging (fMRI) have shown that, both in the fasted and fed 
state, obese individuals have greater activation in several brain regions implicated in food 
reward than lean individuals (Stoeckel et al., 2008, Rothemund et al., 2007, Dimitropoulos et 
al., 2012). Recent fMRI studies also showed that GI hormones may modulate the activation 
of the food reward centres. For example, the infusion of PYY or GLP-1 to fasted lean 
subjects reduced activation in the reward centres to the same extent as a 500kcal breakfast 
(De Silva et al., 2011). Obese individuals, who have attenuated anorectic GI hormone 
response to a meal, may therefore experience greater activation in brain regions involved in 
food reward thus leading to overeating. Interestingly, data in rodents show that certain 
changes in reward centre activation are reversible by weight loss, suggesting that the 
modifications of reward pathways in obese subjects may be a consequence of obesity rather 
than a cause (Berthoud et al., 2012). 
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1.3.5.2 Changes in the gut microbiota 
The human gut microbiota or gut flora, the ecological community of commensal, symbiotic, 
and pathogenic microorganisms that are present in the human intestinal tract, carries a vast 
genetic diversity (Lederberg and McCray, 2001). Indeed, the human gut has been estimated 
to carry approximately 1014 cells representing around 3 million genes influencing the 
physiology of the host (Luckey, 1970, Gordon and Pesti, 1971). Among the various roles of 
the gut microbiota, the fermentation of undigested carbohydrates to short-chain fatty acids 
that are absorbable by the human organs is of great importance. The importance of the 
microbiome composition in health and disease has long been emphasized (Savage, 1977, 
Gordon and Pesti, 1971). In particular, obesity is thought to be associated with a shift in gut 
microbiota ratio (Sweeney and Morton, 2013). Although these changes are beyond the 
scope of this thesis, this section will provide a short summary of the recent evidence.  
Rodent and human studies have shown that obese subjects have a lower abundance of 
Bacteroidetes and a greater abundance of Firmicutes compared with lean subjects (Ley et 
al., 2005, Ley et al., 2006). In obese rodents, the difference in the relative abundance of 
bacterial divisions led to increased energy harvest from the diet (Turnbaugh et al., 2006, 
Turnbaugh et al., 2009). The changes have been shown to be inducible and reversible with 
high-fat ad-libitum diet and energy restriction respectively (Hildebrandt et al., 2009, Murphy 
et al., 2010).  One study also showed that the colonisation of germ-free mice with the 
microbiota of obese mice resulted in these mice having a greater body weight than when 
colonised with the microbiota of lean mice (Turnbaugh et al., 2006). This suggests that the 
gut microbiota may be an important contributing factor to obesity.  Despite variations induced 
by dietary changes, gut microbiota are shared among family members, increasing the 
likelihood of obesity in the offspring (Turnbaugh et al., 2009). Early gut bacteria species, 
acquired from parents, remain relatively stable throughout life and may exert their metabolic 
effect for long periods of time (Faith et al., 2013).  However, the stability of the bacterial 
strains is largely dependent on weight constancy rather than time (Faith et al., 2013). Weight 
loss in obese individuals was shown to be associated with changes in bacterial populations 
in the gut (Ley et al., 2006). The gut microbiota could therefore provide a potential target for 
new obesity treatments. 
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1.4 Prevention and management of obesity 
Obesity has detrimental consequences on health, quality of life and society; it has therefore 
become a priority to fight this complex metabolic disorder and prevent any further increase in 
obesity prevalence (Haslam and James, 2005). At the present time, there is no simple 
solution to tackle the obesity pandemic. Lifestyle interventions, such as dietary intervention 
and behavioural therapy, remain the first-line non-surgical treatment in overweight and 
obese people. Pharmacotherapy treatments are available for subjects with BMI >30kg/m2 
who are unable to lose weight with lifestyle intervention alone. Metabolic surgery induces 
considerable and sustainable weight loss in morbidly obese subjects but is not applicable to 
the current scale of obesity. Because obesity has multi-factorial causes, the treatment of 
obesity should be based on a multi-disciplinary approach involving governments, food 
industries, health practitioners, as well as individual lifestyle changes (WHO, 2004). Previous 
evidence shows that a weight loss of 4 to 5kg may be sufficient to decrease risk of 
developing CVD and T2DM (Knowler et al., 2002, Dattilo and Kris-Etherton, 1992, Stevens 
et al., 2001).  
1.4.1 Lifestyle changes 
Lifestyle changes remain the first-line choice in the treatment and prevention of obesity. 
Governments and health agencies promote healthy lifestyle including increased physical 
activity and reduced energy, total fat and salt intake. The food industry can also play a 
significant role in promoting healthy diets by increasing the affordability and availability of 
fresh healthy products, reducing the sugar, fat and salt intake of their products, and 
supporting the display of easy-to-understand nutritional information (WHO, 2004). Whilst 
energy restriction and physical activity can be effective for inducing up to 10% weight loss in 
the short-term, weight maintenance in the long-term is poor even with dietary counselling 
(Dansinger et al., 2005, Weiss et al., 2007, Dansinger et al., 2007, Wadden et al., 2007).  
Lifestyle changes require high motivation levels and compliance in order to sustain the 
weight loss; and adherence in the long-term remains challenging (Astrup et al., 2004, 
Bravata et al., 2003). If treatment is stopped, patients usually regain 30 to 35% of their lost 
weight within a year (Wadden et al., 2007). There are an incommensurable number of 
weight loss diets available which are outside the scope of this thesis and will not be 
discussed here. During weight loss, it is essential that protein intake remain adequate for the 
maintenance of lean body mass. Energy expenditure was shown to be reduced by weight 
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loss, therefore physical activity should be implemented at the same time as energy 
restriction (Leidy et al., 2007).  
To improve the effect of dietary changes on body weight, scientists and industries are 
directing their efforts on the development of novel ingredients capable of reducing appetite, 
limiting weight gain and increasing satiety when associated with caloric restriction. Among 
them, dietary fibre and protein supplements have been shown to be of particular interest for 
body weight loss and will be further discussed in Chapter 1 section 1.6 (Krieger et al., 2006, 
Brown et al., 1999, Du et al., 2010, Liu et al., 2003).  
1.4.2 Pharmacological therapies  
Current pharmacological therapies, which are used as a complement to lifestyle 
modifications, can induce a weight loss of 5 to 10% (Rucker et al., 2007). For approval by 
the U.S. Food and Drug Administration, an obesity treatment needs to induce a minimal 5% 
weight loss maintained over a period of 12 months compared with a placebo. The evidence 
suggests that pharmacological therapies may be more effective when combined with lifestyle 
intervention (Wadden et al., 2005).  
Pharmacological therapies are classified into three categories based on their mechanism of 
action: appetite suppressants, inhibitors of fat absorption, and stimulators of energy 
expenditure and thermogenesis. At the present time, the only licensed obesity medication on 
the European market is Orlistat (Xenical®, Roche Pharmaceuticals or Alli®, 
GlaxoSmithKline) which partly prevents the absorption of fat in the GI tract by inhibiting 
pancreatic lipases and thus the breakdown of triglycerides into free fatty acids. Orlistat has 
been shown to induce an average of 2.9 kg weight loss (Rucker et al., 2007) but can be 
associated with GI side effects such as steatorrhea if low-fat diet is not maintained. Previous 
licensed medications included Sibutramine (Reductil®, Abbott Laboratories), a serotonin-
norepinephrine reuptake inhibitor which was withdrawn from the European and American 
market in 2010 due to its association with increased cardiovascular risks (Williams, 2010, 
James et al., 2010) and Rimonabant (Acomplia®, Sanofi-Aventis) a cannabinoid receptor 
CB1 antagonist, withdrawn from the market in 2008 due to its association with increased 
psychiatric problems such as anxiety and depression. Several new pharmacotherapies are 
currently under development (Hussain and Bloom, 2011, Gadde et al., 2011, Fidler et al., 
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2011, Greenway et al., 2009). However, due to safety issues and adverse-events in previous 
medications, new medical therapies are facing strict approval assessments.  
Research in the past decades has significantly improved our understanding of the appetite 
regulation system. Gut hormones and brain signals were shown to provide potential targets 
for new pharmacological therapies. However, there are several limitations the use of appetite 
signals in the treatment of obesity. Firstly, some signals have a limited half-life such as GLP-
1. To overcome this issue, analogues, which are resistant to enzymatic degradation, are 
being developed.  Exenatide and Liraglutide, long-lasting GLP-1 receptor agonists, are both 
successfully being used in the treatment of T2DM and provide significant weight loss in 
diabetic patients (Buse et al., 2009). Secondly, several gut hormones, despite showing 
interesting potential to reduce food intake, induce significant feelings of nausea (Batterham 
et al., 2003). To overcome this, therapies combining low levels of two or more hormones or 
hormone analogues are being currently investigated (Tan et al., 2013, De Silva et al., 2011, 
Finan et al., 2013). The combination of hormones may induce synergic effects on body 
weight and reduce side-effects such as nausea. 
At the present time, medication for the treatment of obesity is limited and there is an urgent 
need for new treatments to be developed.  
1.4.3 Metabolic surgery  
1.4.3.1 Types of metabolic surgery 
Metabolic surgery, also called bariatric or weight loss surgery, is considered one of the gold-
standard treatment for morbid obesity and is currently the only method providing significant 
and sustainable weight loss in a majority of patients treated. Metabolic surgery is only 
accessible under the NHS to individuals with morbid obesity (BMI ≥40 kg/m2) or severe 
obesity (BMI ≥ 35 kg/m2) with at least one co-morbidity that may improve with weight loss 
and who have failed to achieve and maintain significant weight loss in the past (NICE, 2006). 
Most common current procedures performed are described in figure 1.4 and include gastric 
banding, sleeve gastrectomy, and Roux-en-Y gastric bypass (RYGB).  
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Figure 1.4: Common metabolic surgery procedures  
Source: (Neff et al., 2013). The adjustable gastric banding (A), the sleeve gastrectomy (B), and the 
Roux-en-Y gastric bypass (C) are the most common metabolic procedures in the UK. A. The gastric 
banding is a restrictive procedure involving the placement of an adjustable silicone device on the 
upper-part of the stomach to create a small stomach pouch. B. The sleeve gastrectomy is a restrictive 
procedure involving the creation of a tube-shaped stomach by removal of 85% of the initial stomach 
following the major curve. C. The Roux-en-Y gastric bypass is a restrictive and malabsorptive 
procedure involving the partition of the stomach into a small thumb-sized upper pouch and a large 
remnant stomach and the rearrangement of the small intestine to enable drainage of both and the 
bypass of the duodenum and the first portion of the jejunum. 
Most procedures are now laparoscopic, involving several small incisions rather than a large 
open cut, thus reducing the risk of pain, haemorrhage and incisional hernia, shortening 
recovery time and limiting scarring. Other devices such as the intra-gastric balloon or the 
EndoBarrier™ gastro-intestinal Liner are currently being optimised (Schouten et al., 2010, 
Imaz et al., 2008). 
1.4.3.2 Increasing number of procedures 
Since the first performed bariatric surgeries in around 1960, the number of procedures has 
dramatically increased worldwide. The US account for most of them, with around 110,000 
bariatric procedures performed each year (Livingston, 2010). In the UK, the number of 
gastric bypass performed in NHS hospitals has risen by 530% from 858 cases in 2006 to 
5407 cases in 2012 (NHS, 2012). Furthermore, it is estimated that a similar number of 
procedures are being performed in the private sector (NICE, 2012). These numbers are 
predicted to continue to rise in the UK. However, the limited number of surgeons and 
centres, the risks involved with the procedures as well as the high cost of £8000 to £14000 
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per surgery may limit both the availability of bariatric surgery -therefore tightening the 
eligibility criteria- and the enthusiasm for them in the future. The number of cases in the U.S. 
reached a plateau in 2009 and is thought to have remained approximately stable since 
(Kohn et al., 2009).  
1.4.3.3 Risks of complications and pre-operative weight loss 
The early and late mortality risks are as low as 0.5 to 1% (Buchwald et al., 2007). However, 
the risk of peri- and post-complications, although difficult to estimate, is thought to be much 
higher. One review including 10 clinical trials found that complications occurred in 13.6% 
cases (472 out of 3464 procedures) with stomal stenosis (4.7%), bowel obstruction (2.9%) 
and wound infection (3.0%) being the most common (Podnos et al., 2003). Other studies 
reported complications rates of 4.3% up to 50% in studies including patients at higher risk 
such as type-2 diabetic patients (Ikramuddin et al., 2013, Perugini et al., 2003). In a recent 
meta-analysis involving 164 studies and 161 756 patients, Chang et al.  found a complication 
rate of 17% (Chang et al., 2014). When controlled for surgeon experience, studies show that 
the risks of complications are mainly associated with previous history of deep-vein 
thrombosis (DVT) or pulmonary embolism, diagnosis of obstructive sleep apnoea (OSA), 
increased BMI, older age and male gender (Mason et al., 1992, Flum et al., 2009).  
In order to improve the surgical field of view during the procedure and limit the risk of liver 
laceration, pre-operative weight loss is required by most bariatric clinics. Indeed, previous 
studies suggested that pre-operative weight loss may reduce the size of the liver, and 
consequently decrease the difficulty and the duration of the procedure as well as the risk of 
post-operative complications (Alvarado et al., 2005, Fris, 2004, Benotti et al., 2009). There 
is, however, no consensus on the type and duration of the optimal pre-operative diet. 
1.5 Roux-en-Y gastric bypass, from pre-operative optimisation to 
post-operative changes in body composition and metabolism 
Laparoscopic RYGB, one of the most common procedures performed induces an average 
weight loss of 30% over 24 months and induces significant reduction in SAT and VAT 
(Buchwald et al., 2009, Weiss et al., 2009). The weight loss is attributed to a combination of 
effects including energy restriction, rearrangement of the GI tract, and modification of GI 
hormone and bile acids secretion (Pournaras et al., 2012, Ionut et al., 2013). Although 
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weight loss cannot be predicted following the procedure, several factors have been 
associated with greater weight loss including male sex, younger age and pre-operative lean 
mass independently of age and sex (Robert et al., 2013). Despite its success, the procedure 
carries significant risks of peri-operative and post-operative complications including wound 
or chest infection, bleeding, leakage, and thrombo-embolism (Flum et al., 2009). Most clinics 
currently require patients undergoing metabolic surgery to follow a pre-operative diet prior to 
the procedure in order to improve surgical field-of-view and limit the risk of liver laceration.  
1.5.1 Pre-operative weight loss prior to RYGB, summary of the evidence 
RYGB is currently considered the gold-standard treatment for morbid obesity. Although the 
mortality rate only stands around 0.5-1%, the procedure still carries a high risk of 
complications (Buchwald et al., 2007). Studies reporting both the peri-operative and long-
term post-operative rates of complications remain scarce and report discrepant results from 
5 to 20% (Buchwald et al., 2007, Mason et al., 1992, Nguyen et al., 2011). Several factors 
were suggested to increase the risk of death or complications. These include gender (male), 
age, co-morbidities (OSA, CVD, T2DM) and a greater pre-operative weight (Mason et al., 
1992, Flum et al., 2009, Nguyen et al., 2011). While gender and age cannot be modified, 
treatment of co-morbidities can be optimised by medications and pre-operative weight can 
be reduced by energy restriction. 
Pre-operative weight loss is recommended by most bariatric clinics prior to the procedure. 
There is, however, no consensus on the type or duration of the pre-operative diet. Patients 
with severe abdominal adiposity are asked to diet for longer in order to decrease the liver 
size but this is based on weight, BMI or visual diagnosis of abdominal obesity rather than an 
accurate assessment of body composition. Morbidly obese patients especially those with 
abdominal adiposity have thick abdominal wall, omentum, mesentery and a great volume of 
intra-abdominal adipose tissue. NAFLD is also very common in morbidly obese patients, with 
a prevalence of 80-90% (Machado et al., 2006, Vernon et al., 2011). Individuals with 
increased central adiposity and NAFDL have enlarged liver which translates into poor 
surgical view of the upper-stomach and gastro-oesophageal area as shown in figure 1.5. 
Consequently, enlarged liver represent the main risk for liver laceration or conversion to 
open procedures (Schwartz et al., 2003).  
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Figure 1.5: View of the stomach and gastro-oesophageal area  
Source: UCSF website. The figure shows the left lobe of the stomach lying on the gastro-oesophageal 
area. Enlargement of the liver left lobe translates into poor surgical view of the area and increases the 
risk of liver laceration during traction. 
Previous research has shown that pre-operative weight loss may decrease liver size, reduce 
operative time and limit the risks of complications (Benotti et al., 2009, Alami et al., 2007, 
Alvarado et al., 2005). However, other studies found no effect of pre-operative weight loss 
and recent systematic reviews found discrepant results on the effect of pre-operative weight 
loss on both complication rates and post-operative weight loss (Cassie et al., 2011, Kadeli et 
al., 2012, Livhits et al., 2009). Although the use of pre-operative diets has been widely 
adopted in bariatric clinics, their effects on surgical outcomes and post-operative weight loss 
magnitude remain to be confirmed.  
1.5.2 Low-calorie diets, effects on body composition and metabolism 
Weight loss in obese individuals can be achieved by decreased energy intake, increased 
energy expenditure or the combination of both for greater results. However, many obese 
patients have difficulty in exercising due arthritis, functional limitation, poor compensatory 
hyperventilation during exercise, and suffer from skin friction (Hootman et al., 2011, 
Parameswaran et al., 2006, Hulens et al., 2003). Obese individuals have been shown to be 
substantially less active than lean and overweight individuals which may further result in the 
maintenance of obesity (Cooper et al., 2000, Hansen et al., 2013a). Until significant weight 
loss can be achieved and individuals can engage in regular physical activity, energy 
restriction therefore remains the first-line option to induce significant weight loss initially.  
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Very-low-calorie diets (VLCD) and low-calorie diets (LCD), defined as meal replacements in 
the form of powder mixed with low-energy liquid providing 500-800kcal (VLCD) or 800-1200 
kcal (LCD) per day, have been commonly used in clinical trials as a safe approach to induce 
rapid weight loss (Wadden et al., 1983, Mustajoki and Pekkarinen, 2001, Tsai and Wadden, 
2006). Previous studies show that VLCDs may induce greater weight loss than low-
carbohydrate high-protein diets (Rolland et al., 2009). 
1.5.2.1 Optimisation of pre-operative weight loss by LCD 
The weight loss reported during VLCD and LCD varies from 1.5 to 2.5 kg per week 
depending on the energy intake, the design of the study, and the patient cohort (Edholm et 
al., 2011, Lewis et al., 2006, Van Nieuwenhove et al., 2011, Fris, 2004).  
Previous research has showed that significant reductions in hepatic fat content and liver size 
can be achieved by weight loss induced by LCD or VLCD (Fris, 2004, Lewis et al., 2006, 
Edholm et al., 2011). In their study, Lewis et al., showed that a 6-week VLCD of 450kcal-
800kcal per day induced a significant 72.5% reduction in liver fat and 16.3% reduction in 
liver size in patients with liver steatosis (Lewis et al., 2006). Interestingly,  in patients without 
liver steatosis, the weight loss did not have any impact on liver fat but induced a significant 
9.4% reduction in liver size (Lewis et al., 2006). The results showed significant correlations 
between liver fat content and liver size (r=0.633, p=0.005) and between changes in liver fat 
content and liver size (r=0.610, p=0.012). Colles et al. investigated changes in liver size at 
regular intervals (2, 4, 8, 12 weeks) in obese individuals (BMI 47.5kg/m2) during a 12-week 
VLCD (456-680kcal/day) (Colles et al., 2006). Interestingly, the authors reported that 80% of 
the reduction in liver volume occurred between baseline and week 2 suggesting that a 2-
week VLCD may induce sufficient reductions in liver volume to operate safely and that 
further weight loss may not benefit patients in terms of surgical outcome. More recently, 
Edholm et al. achieved a 7.5 kg weight loss using a 4-week LCD (800-1100kcal/day) prior to 
RYGB surgery in 15 obese patients (mean BMI 42.9kg/m2) (Edholm et al., 2011). The 
weight loss was associated with a 40% reduction in hepatic fat and 12% reduction in liver 
volume which lead to improved surgical exposure and reduced psychological stress for the 
surgeon. The authors showed that the LCD also resulted in lower perceived surgery 
complexity.  
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In support of these results, a large randomised multi-centered study by Van Nieuwenhove et 
al.,  compared the effect of a 2-week VLCD (Optifast, 800kcal per day) with no pre-operative 
weight loss in 294 patients (1/3 males, 2/3 females) (Van Nieuwenhove et al., 2011). The 
average weight loss achieved in the VLCD group was 4.9 kg in 2 weeks. Using a VAS score 
to assess procedure difficulty, the procedure was perceived as less difficult by the surgeon in 
the VLCD group than in the control group (35 vs 26, p=0.04. No differences were found in 
operative time, intra-operative complication rates or post-operative weight loss at 30 days. 
There was a significantly lower rate of post-operative complications in the VLCD group (18 
vs 8, p=0.04).  
In conclusion, VLCDs and LCDs were shown to be efficient in achieving weight loss and liver 
size reduction.  Whether these reductions are associated with reductions in operative time, 
peri-operative, and post-operative complications and long-term weight loss outcome remains 
to be confirmed. It is unknown whether different durations of pre-operative diet induce 
different effects on surgical outcomes. Many previous studies were characterized by the lack 
of control group or long-term post-operative assessment of outcomes. 
1.5.2.2 Changes in body composition during acute weight loss 
Several studies have investigated the effect of weight loss on fat distribution and body 
composition. The vast majority used indices of body composition, computed tomography 
(CT), dual X-ray absorptiometry (DEXA), and magnetic resonance imaging (MRI).  
During weight loss, fat-free mass sparing is of great importance in order to maintain resting 
energy expenditure. A systematic review reported the proportion of fat-free mass (FFM) loss 
during weight loss induced by energy restriction or surgical procedure in 55 studies (Chaston 
et al., 2007). The review showed that LCD alone induced % FFM loss of 6 to 26% depending 
on the duration of the diet, and the initial cohort. This was increased from 23% to 37% using 
VLCD of 800kcal or less. RYGB was associated with % FFM loss of 22% to 33%. Men 
tended to lose more FFM than women and exercise significantly reduced the loss of FFM.  
The degree of energy restriction was positively associated with the % FFML loss. The 
authors emphasized the lack of clinical trials investigating changes in body composition after 
RYGB. Changes in fat mass, fat free mass, and water content have been shown to be 
dependent upon the energy deficit of the diet, the macronutrient composition of the diet and 
the duration of the diet (Kreitzman, 1992). Importantly, there are major differences in fuel 
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utilisation between short-term and long-term weight loss. During short-term weight loss, the 
utilisation of glycogen stores from the liver and muscle and the loss of associated water 
primarily account for a 2 to 2.5kg of initial weight loss, mainly as fat free mass. During long-
term weight loss, on a VLCD, the production of ketone bodies limits the mobilisation of body 
protein by gluconeogenesis (Kreitzman, 1992). 
Using anthropometric measurements, several studies suggested differential changes in body 
composition during weight loss (Wadden et al., 1988, Hainer et al., 1992). Indices of upper-
body versus lower-body obesity such as waist circumference, and waist:hip ratio should 
therefore be included in further analysis investigating changes in body composition during 
weight loss. In support of these results, another study using CT found that individuals with 
increased visceral adiposity lost more VAT than individuals who had lower VAT during a low-
calorie diet (Fujioka et al., 1991).  
Using different MRI techniques (whole abdomen, multi-slice, single-slice), Kanaley et al. 
showed that there might be significant differential changes in fat distribution within the 
abdomen during weight loss (Kanaley et al., 2007). Inferior regions below L2-L3 showed 
greater changes in VAT than superior regions. The study highlighted the importance of 
quantifying VAT in the whole abdomen as opposed to a single slice.   
In regards to the weight loss method, Dixon et al. suggested differential loss of FFM with 
LAGB and orlistat, which may be due to significant changes in food choices (Ernst et al., 
2009). It is unknown whether similar results may apply to weight loss induced by RYGB 
compared with LCD. A systematic review by Chaston and Dixon showed no preferential loss 
of VAT versus SAT with metabolic surgery compared with other methods of restriction 
(Chaston and Dixon, 2008). However, the review included results from LAGB procedures 
only and was limited to results from 4 clinical trials. The authors highlighted the lack of data 
from other metabolic procedures as well as the lack of randomised controlled trials. In the 
study, the percentage weight loss was the only predictive factor of the %change in VAT 
versus SAT. Interestingly, some studies have suggested that weight loss in the short-term 
induces preferential loss of VAT but that the effect is lost when weight loss is prolonged 
(Chaston and Dixon, 2008). Gender, age, and method of weight loss (dietary, exercise, 
pharmaco-therapy, LAGB) were not associated with preferential loss of VAT over SAT 
(Chaston and Dixon, 2008, Christiansen et al., 2009).  
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1.5.2.3 Changes in glucose homeostasis induced by low-calorie diet  
Several studies investigated the effect of acute weight loss using VLCD or LCD on glucose 
homeostasis, beta-cell function and T2DM. In 2011, Lim et al. showed that it was possible to 
reverse T2DM using a VLCD of 600kcal/day for 8 weeks in overweight and obese diabetic 
volunteers (BMI 33.6kg/m2) who were not on insulin (Lim et al., 2011). The authors found 
that, in these diabetic patients, an average weight loss of 15.3 ± 1.2 kg resulted in 
normalisation of fasting glucose, beta cell function and hepatic insulin sensitivity and that the 
normalisation was associated with significant reductions in hepatic and pancreatic lipid 
content. Other studies compared the effects of equivalent weight loss by VLCD and RYGB 
and found similar improvements in insulin sensitivity and beta-cell  function (Jackness et al., 
2013). Furthermore, one study showed that both the degree of calorie restriction and the 
magnitude of weight loss had significant independent effects on glucose homeostasis and 
insulin sensitivity (Wing et al., 1994). In support of these results, another study compared 
beta-cell function after equivalent weight loss by RYGB and 800kcal VLCD in diabetic 
volunteers and found that participants needed longer time to achieve the weight loss in the 
VLCD group and had significantly less improvements in beta-cell function (Plum et al., 
2011).   
Insulin resistance and T2DM have been shown to be strongly associated with increased VAT 
(Gallagher et al., 2009, Fujioka et al., 1987).  Many studies have therefore investigated 
changes in abdominal fat distribution during weight loss and improvements of glycaemic 
function. Fujioka et al. showed that the improvement of glucose and lipid metabolism 
following a LCD were more strongly correlated with a decrease in VAT/SAT ratio and VAT 
volume than with total weight loss or fat loss (Fujioka et al., 1991). Another study 
investigated the effect of a 14-week LCD (800-1000kcal) on fat distribution and 
improvements in glycaemic function using MRI and DEXA (Bosy-Westphal et al., 2010). The 
authors found that an 8.5kg weight loss resulted in significant improvements in insulin 
sensitivity and beta-cell function. Improvement in insulin sensitivity (estimated by HOMA-IR) 
and beta-cell function were strongly correlated with a decrease in IHCL, which itself 
correlated with a decrease in VAT.  
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1.5.3 Appetite regulation and metabolism following RYGB 
The core mechanisms that explain the large weight loss following bariatric surgery involve 
limitation of food intake, physiological modifications of the gastro-intestinal system and 
alterations of the appetite regulation system (Buchwald et al., 2004). Indeed, the capacity of 
the stomach is reduced from approximately one litre to 15 to 30mL for a RYGB.  However, 
the evidence in rodents using pair-fed animals shows that mechanical restriction alone does 
not explain all the metabolic changes following bariatric surgery and that sustained loss of 
appetite has a significant impact on overall weight loss (le Roux et al., 2006a, Sclafani et al., 
1978). Indeed, post-operative volunteers have increased and sustained levels of anorectic 
hormones and increased satiety following a meal when compared with lean and obese 
control volunteers (Pournaras et al., 2010, le Roux et al., 2006a, Rodieux et al., 2008, 
Korner et al., 2005).  
1.5.3.1 Changes in body composition  
Subjects undergoing RYGB normally lose around 30% of their weight over 10 years (Attiah 
et al., 2012, Garb et al., 2009, Buchwald et al., 2004). Pre-operative FFM has been shown to 
predict post-operative weight loss independently of age and sex. Furthermore, although the 
weight loss is a combination of both lean and fat mass loss (Carey et al., 2006), weight 
regain can be expected when excessive lean body mass is lost following the procedure 
(Robert et al., 2013, Faria et al., 2009). This highlights the importance of assessing body 
composition and particularly lean mass when monitoring weight loss following RYGB.  
1.5.3.2 Changes in glucose metabolism and remission of T2DM 
A number of studies have shown that metabolic surgery is more effective than intensive 
lifestyle therapy at treating T2DM (Schauer et al., 2012, Ikramuddin et al., 2013). The 
remission of T2DM following RYGB was reported to occur in around 80% of patients in 
previous studies (Schauer et al., 2012, Buchwald et al., 2009). However, a long-term study 
showed that among patients who experience early remission of their T2DM, as many as 
50% may have recurrence of the disease at a later time (Sjostrom et al., 2004). This is 
mostly associated with limited weight loss or weight regain (DiGiorgi et al., 2010).  
Interestingly, a large number of studies have showed that diabetic patients experience an 
improvement in glucose homeostasis or resolution of T2DM within days of the RYGB 
procedure before weight loss has even occurred (Buchwald et al., 2009, Mingrone and 
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Castagneto-Gissey, 2009). The mechanisms behind this early remission may involve the 
negative energy balance, the rearrangement of the gut, the increase in gut hormones and 
especially GLP-1 and, over the longer-term, the decrease in body weight, and IHCL and 
pancreatic lipid content (Falken et al., 2011, Mingrone and Castagneto-Gissey, 2009, Lim et 
al., 2011). It was recently suggested that the early remission of T2DM is due to 
reprogramming of intestinal glucose metabolism. Indeed, the exposure of the Roux limb to 
undigested nutrients following the procedure was shown to result in increased mass of the 
gut wall (Hansen et al., 2013b, Mumphrey et al., 2013). In order to support intestinal tissue 
growth and maintenance, reprogramming of the intestinal glucose metabolism was 
suggested to take place thereby improving whole body glucose homeostasis (Saeidi et al., 
2013).  
1.5.3.3 Other significant changes affecting body weight 
1.5.3.3.1 Changes in the appetite regulation system 
There has been a great interest over the past decades in gut hormone changes following 
bariatric procedures. The evidence shows that post-operative volunteers have increased and 
sustained levels of anorectic hormones and increased satiety following a meal when 
compared with lean and obese control volunteers (Beckman et al., 2010). Indeed, gastric 
bypass surgery was shown to induce a sustained post-prandial increase in PYY and GLP-1 
levels in humans within days after the surgery when significant weight loss has not taken 
place yet (le Roux et al., 2007). Over the long term, GLP-1 and PYY levels were shown to 
remain elevated in post-operative gastric bypass patients when compared with both pre-
operative weight-matched controls (obese subjects), post-operative weight-matched controls 
(overweight), lean controls and gastric banding patients (Korner et al., 2009, Pournaras et 
al., 2010, Rodieux et al., 2008, Korner et al., 2005, le Roux et al., 2006a).   
This may explain why gastric bypass patients maintain around 20% weight loss for up to 20 
years (Sjostrom et al., 2012). To determine whether this was related to the weight loss or the 
surgical procedure per se, the GLP-1 and PYY levels have been compared following similar 
weight loss induced by dietary restriction or RYGB. GLP-1 and PYY levels were found to be 
significantly higher in RYGB patients suggesting that RYGB is responsible for the changes in 
hormones (Laferrere et al., 2008, Evans et al., 2012). This confirms that changes in gut 
hormones following RYGB are due to the rearranging of the digestive system leading to the 
early delivery of nutrients to the L-cells rather than the weight loss. Furthermore, some but 
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not all, studies have reported both total and active ghrelin levels to be reduced following 
RYGB compared with pre-operative patients, obese, overweight, or lean controls possibly 
contributing to the weight reducing effect of the procedure (Beckman et al., 2010, Cummings 
et al., 2002). Some studies have suggested that a greater increase in GI hormones PYY, 
GLP-1, and CCK levels correlates with superior weight loss and sustained decreased hunger 
following RYGB surgery (le Roux et al., 2007, Dirksen et al., 2013). In support of these 
results, it was shown that the blockade of PYY using rabbit antibodies in post RYGB rodents 
resulted in the return of food intake (le Roux et al., 2006a).  
As expected, changes in leptin and insulin levels were associated with changes in BMI, 
weight and fat mass following RYGB, therefore restoring the pre-resistance state in post-
operative patients (Beckman et al., 2010). 
1.5.3.3.2 Changes in reward pathways 
Alterations in the food reward pathways have been reported following RYGB surgery 
(Naslund et al., 1997, Ochner et al., 2011). As a consequence, gastric bypass patients 
usually experience a decrease of interest in energy-dense food and a change of sensitivity to 
sweet taste therefore increasing the appeal of unsweetened fresh products which results in 
healthier eating habits. Recent fMRI studies showed that in post-operative obese subjects, 
the response to high-calorie food in the reward centres was attenuated compared with the 
same pre-operative individuals (Ochner et al., 2011). These changes are thought to be 
related to changes in gut hormones rather than weight loss per se as previous research 
showed that weight loss by dietary means increases the reward response to high-calorie 
food (Rosenbaum et al., 2008). 
1.5.3.3.3 Changes in gut microbiota 
The gut microbiota is also thought to play an important role in weight loss following gastric 
bypass surgery. Indeed changes in gut microbiota independent of weight loss and energy 
restriction were observed in both rodents and humans following gastric bypass (Liou et al., 
2013, Sweeney and Morton, 2013, Furet et al., 2010). In RYGB rodents, the concentration of 
Proteobacteria was shown to be higher whereas both Firmicutes and Bacteroidetes 
concentrations decreased when compared with sham–operated rats (Li et al., 2011). 
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1.5.4 Overview of the changes following RYGB  
Figure 1.6 summarises the previously mentioned changes in metabolism and appetite 
regulation following RYGB surgery. The hepatic, GI, and neuronal systems closely interact 
with one another. Consequently, the changes that follow RYGB surgery in each of the 
systems further modulate the response of the other systems which, over the long-term, leads 
to sustained weight loss and health improvements.  
 
Figure 1.6: Hepatic, gastro-intestinal and neuronal systems following RYGB 
Following Roux-en-Y gastric bypass (RYGB), changes in the hepatic, gastro-intestinal and central 
nervous system combined with energy restriction and dietary modifications result in sustained weight 
loss and modification of body composition, ultimately leading to a reduction in co-morbidities such as 
type-2 diabetes mellitus and cardiovascular disease. 
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1.5.5 Previous findings and gap in the literature    
In conclusion, previous studies suggest that pre-operative weight loss reduces liver fat and 
improves surgical outcomes in obese individuals undergoing RYGB. The evidence on the 
effect of the pre-operative diet on the duration of the procedure, the number of peri- and 
post-operative complications, and the long-term outcomes remains scarce and controversial. 
Furthermore, previous studies compared the effect of a pre-operative diet with no pre-
operative weight loss. Although all bariatric clinics use different pre-operative diets, no study 
has compared the effect of different pre-operative diets on surgical outcomes.  
Previous research highlighted the importance of VAT in the development of the metabolic 
syndrome. However, there is limited data on the changes in body composition following 
RYGB. As this area of research is relatively new, it is characterised by the lack of 
randomised controlled trials. A significant number of studies have not used control groups or 
have not randomised the different treatments among the groups.  
1.6 Role of specific nutrients on appetite and body weight 
Metabolic surgery induces a number of changes in food intake, gut microbiota, metabolism 
and appetite regulation which result in sustained weight loss. However, although considered 
the gold-standard, metabolic surgery is costly, risky, and highly selective. At the present 
time, obese individuals with no co-morbidities and overweight subjects cannot benefit from 
the procedure.  For this population, lifestyle changes remain the first-line treatment strategy. 
Although lifestyle changes induce weight loss, calorie restriction is difficult to maintain over 
the long-term and most subjects regain the weight they have lost rapidly once they 
discontinue energy restriction (Weiss et al., 2007, Dansinger et al., 2007). Research 
scientists have therefore focused their work on the identification of satiating components. 
Indeed, certain food components have been shown to promote satiety, and alter gut 
hormone release, which may encourage reduction in energy intake and help in the 
maintenance of body weight over the long-term. In this section, the effect of dietary fibre and 
protein on appetite will be discussed.  
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1.6.1 Dietary fibre and appetite regulation 
Dietary fibre is the edible part of plant or analogous carbohydrates that is left undigested by 
the human alimentary enzymes but completely or partially fermented by bacteria in the colon 
(IFST, 2007). Dietary fibres are carbohydrates composed of linked units of monosaccharides 
(or simple sugars). They can be formed of 3 to 10 units (oligosaccharides) or several 
hundred to thousands of units (polysaccharides). Dietary fibre can be classified into four 
main categories (IFST, 2007) and two categories based on their solubility (viscous and non-
viscous fibres).  
- Non-starch polysaccharides (NSP) such as cellulose, hemicelluloses, pectins, 
gums, mucilages, β-glucans... 
- Resistant oligosaccharides such as fructo-oligosaccharides 
- Resistant starch (protected starch molecules, unswollen granules, or retrograded 
starch) 
- Lignin 
Dietary fibres have long been thought to be beneficial for health (Trowell, 1976). A study 
showed that a daily increase of dietary fibre by 10g was associated with a 27% decrease in 
the risk from death of coronary diseases (Pereira et al., 2004). A large cohort study found 
that total fibre intake was inversely correlated with body weight and waist circumference in 
Europeans (Du et al., 2010). In the last few decades, many studies have investigated their 
effect on appetite and metabolism as part of a search for functional food components 
capable of reducing appetite and body weight (Wanders et al., 2011).  
Dietary fibres have been suggested to reduce body weight by several mechanisms including 
reduced energy density, altered gastric emptying, fermentation to short-chain fatty acids, 
increased fat oxidation and increase release of anorectic gut hormones as seen in figure 1.7 
(Slavin, 2005). For example, several studies in rodents and humans have suggested that low 
glycaemic index diets, high in dietary fibres, result in increased fat oxidation, improved 
insulin sensitivity and reduced liver fat compared with high glycaemic index diets (Stevenson 
et al., 2006, Solomon et al., 2013, Isken et al., 2010, Sievenpiper et al., 2009).  
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Figure 1.7: Suggested mechanisms of action of dietary fibres 
Source: (Slavin, 2005). Dietary fibres are thought to act on body weight through several mechanisms 
including fermentation to short-chain fatty acids, delayed gastric emptying, increased fat oxidation and 
improved insulin sensitivity. 
However, the large diversity of dietary fibres available makes the specific mechanisms of 
action for each fibre difficult to investigate. A systematic review of the literature found that 
viscous fibres had a greater effect on appetite and acute energy intake than non-viscous 
fibres (Wanders et al., 2011). This demonstrates that differences in the physico-chemical 
properties of the fibres may be partly responsible for the variability in their effect.  
Among the fibres that have been thoroughly investigated, β-glucans seem to be of particular 
interest for their effect on glycaemic control (Tosh, 2013, Wursch and Pi-Sunyer, 1997). β-
glucans are common in cereals and grains such as oats and barley, and in yeast, 
mushroom, and fungi. Chemically, β-glucans are polysaccharides comprised of a backbone 
of D-glucose monomers linked by β-(1,3)-glycosidic bonds with attached β-(1,4) or β-(1,6)-
branch points depending on their origin. For example, oats and barley are rich in soluble β-
(1,3-1,4) glucans which are thought to be responsible for their effects on gastric emptying, 
fermentation and satiety. Mushrooms and fungi are, however, rich in insoluble β-(1,3-1,6) 
glucans which have been shown to play an important role in the immune system (Rop et al., 
2009). The differences in linkages as well as the frequency, location and length of the 
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branches are of great importance as they lead to variation in chemical structure and physico-
chemical properties including solubility in water.  
Oat and barley β-glucans were shown to acutely reduce energy intake and increase satiety 
in rodents and humans (Vitaglione et al., 2009, Beck et al., 2009, Lin et al., 2013) although 
one study showed no effect possibly because of the relatively small amount given (Peters et 
al., 2009). Over the long-term, cereal-based β-glucans contribute to the maintenance of 
normal blood cholesterol concentrations according to the European Food Safety Authority. 
However, their long-term effect on body weight and metabolism following supplementation 
remains to be confirmed (Beck et al., 2010).  
1.6.2 Protein and appetite regulation 
Dietary protein supplements have long been used by athletes to increase muscle mass and 
improve physical performance and high-protein diets have gained a great popularity over the 
last few decades. Indeed, of the three macronutrients, protein is recognised as the most 
potent appetite suppressor both in rodents and humans (Bensaid et al., 2002, Poppitt et al., 
1998). Research in the last two decades has shown that protein-rich loads increase satiety 
and lead to decreased energy intake acutely although there are still discrepancies in the 
results (Stubbs et al., 1996, Poppitt et al., 1998, Lejeune et al., 2006). Over the long-term, 
protein supplementation has been shown to increase weight loss and limit both FFM loss 
and decreased energy expenditure which normally occurs during weight loss by energy 
restriction (Wycherley et al., 2012, Krieger et al., 2006, Leidy et al., 2007). This is of great 
importance as lean mass is the main determinant of resting energy expenditure. 
The mechanism by which dietary protein induces satiety and reduces food intake remains to 
be fully elucidated. Some studies have shown that dietary protein modifies the secretion of 
GI hormones such as ghrelin, CCK and PYY; however others have failed to reproduce this, 
so further work is needed to confirm whether or not there is a link between dietary protein 
and appetite signalling (Batterham et al., 2006, Lejeune et al., 2006). In rodents switched 
from a normal-protein diet to a high-protein diet, c-fos expression changes in several areas 
of the CNS including the brainstem (Darcel et al., 2005). Furthermore, rodents fed a high-
protein diet show inhibition of NPY and stimulation of POMC expression (Ropelle et al., 
2008). This implies that dietary protein could act by a complex mechanism involving both the 
appetite centres and the reward pathways in the CNS. Over the long-term, the effect of 
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dietary protein on body weight might be explained by sustained reduction in appetite as well 
as increase in diet-induced thermogenesis leading to greater energy expenditure (Lejeune et 
al., 2006). These effects are dose-dependent and appear to differ depending on the source 
of protein and the amino-acid profile of the meal (Bensaid et al., 2002). For example, whey 
protein appears to be a particularly potent appetite suppressor which has been shown to 
increase GLP-1 concentrations (Hall et al., 2003). It is thought that specific amino acids are 
able to reduce appetite further than others. Leucine, for example, has been shown to limit 
weight gain when supplemented to rodents fed on a high-fat diet (Zhang et al., 2007, 
Ropelle et al., 2008).  
In conclusion, both protein and dietary fibre may be important in the prevention of weight 
gain by modulating both satiety and energy intake. Evidence on high protein high fibre diet is 
scarce. One 10-week study investigating the effect of a high protein high fibre unrestricted 
diet showed increased weight loss compared with a standard diet (Morenga et al., 2010). 
However, the control diet was a standard diet and therefore a comparison with a high fibre or 
high protein diet was not carried out. It is unclear whether foods containing a combination of 
high protein and high fibre have a synergistic effect on energy intake and contribute to 
greater satiety and weight maintenance over the long term.  
1.7 Mycoprotein, effects on energy intake and metabolism 
1.7.1 Mycoprotein, a complex structural ingredient 
Mycoprotein is a food stuff produced by fermentation of a carbohydrate substrate by 
Fusarium venenatum. Mycoprotein is the main ingredient of QuornTM products. It was 
discovered upon the search for alternatives to animal protein in the fear of a global protein 
shortage in the 1970s (Miller SA, 1999, Rodger, 2001). The novel food ingredient was 
commercialised by Marlow Foods in 1985. Its nutritional composition and its original 
structure were the basis of numerous research projects investigating the effect of 
mycoprotein on health in humans. To date, these studies have shown beneficial effects of 
mycoprotein compared with meat on blood lipid profiles (Turnbull et al., 1990, Turnbull et al., 
1992), glucose homeostasis (Turnbull and Ward, 1995) and appetite (Turnbull et al., 1993, 
Burley et al., 1993, Williamson et al., 2006).  
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1.7.1.1 Discovery and development of mycoprotein 
The fungus Fusarium venenatum was discovered in 1972 in Buckinghamshire and 
developed by the Rank Hovis McDougall group of companies (Rodger, 2001). To produce 
the mycoprotein, the fungus is grown by continuous flow fermentation using a glucose 
solution and other nutrients. The cells grow by filaments called hyphae, in the form of a 
mycelium, and are harvested every 5 to 6 hours and made into the food product after being 
heat processed to reduce the ribonucleic acid content and render the organism non-viable. 
The product is then centrifuged to suppress the water and obtain a dry paste. Egg albumen 
is used to bind the paste and vegetable flavourings are added. The paste is then steam-
cooked, chilled and cut into pieces or minced depending on the final product. A final freeze 
creates ice-crystals which help to give the product its meat-like texture. A full description of 
the production and processing has been previously published (Miller SA, 1999, Miller and 
Dwyer, 2001). In 1984, Rank Hovis McDougall and Imperial Chemical Industries formed a 
partnership named Marlow Foods. They launched their first Quorn™ product, a pie, in the 
UK, in 1985 after mycoprotein was approved by the Ministry of Agriculture, Fisheries and 
Food as being suitable for food use. This was followed by the launch of Quorn pieces in 
1990. 
1.7.1.2 Mycoprotein on the market 
Quorn™ products are mainly consumed by vegetarians and meat-avoiders but also by 
people who are concerned about their health or the environment as it represents a good 
source of non-animal protein (12g/100g). The popularity of Quorn™ products has risen in the 
past few decades with healthy eating becoming a major concern for the population.  Quorn 
products represent around 60% of the meat-free protein market at the present time (Marlow 
Foods Limited, 2013b). The United Kingdom remains the main market with over 500,000 
meals eaten daily although the product has developed considerably in several European 
countries, the US and, more recently, Australia and New Zealand (Marlow Foods Limited, 
2013b).  
1.7.1.3 Composition of mycoprotein  
Mycoprotein paste contains approximately 75% water and 25% dry product. The beneficial 
effects of mycoprotein on health have been attributed to its unique composition and 
structure. More specifically, previous studies suggested that the dietary fibre of mycoprotein 
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may be a key factor in its mechanism of action. Table 1.2 presents the nutritional 
composition of mycoprotein paste. Due to its water and fibre content, mycoprotein is 
relatively low in energy density (85kcal/100g raw weight) compared with lean meat cuts and 
poultry (100-150kcal/100g raw weight). 
Table 1.2: Nutritional composition of mycoprotein paste (Miller SA, 1999) 
Composition Per 100g 
Energy (kcal) 85 
Protein (g) 12.1 
Available carbohydrate (g) 
         of which  sugars (g) 
1.7 
0.8 
Total fat (g) 
        of which   saturated fatty acids (g) 
                        monounsaturated fatty acids (g) 
                        polyunsaturated fatty acids (g) 
                        other (g) 
3.4 
0.5 
0.3 
1.5 
1.1 
Dietary fibre (g) 6.8 
Mycoprotein has relatively low energy density and contains approximately 12g of protein and 7g of 
fibre per 100g of paste.  
1.7.1.3.1 Fibre content 
The dietary fibre content of mycoprotein is attributed mainly to the cell wall which represents 
about 25% of the cell‟s dry weight. Mycoprotein paste contains 7g of fibre per 100g. The cell 
wall is mainly composed of 2/3 original β-glucans (β-1:3 and β-1:6 glucosidic linkages, 65%) 
and 1/3 chitin (poly N-acetylglucosamine, 35%) as seen in figure 1.8 (Miller SA, 1999).  
β-glucans are polymers of D-glucose which are found in the cell wall of fungi, yeast and 
some cereals such as barley and oats. Barley and oat β-glucans have been thoroughly 
studied in previous research: They have unbranched 1:3 and 1:4 linkages with high water 
solubility whereas fungal and yeast β-glucans are branched and mainly insoluble (Ahmad et 
al., 2012, Kumar et al., 2012). Chitin is a polyaminosaccharide commonly found in the 
exoskeleton of crustaceans. The chitin molecules bind to the β-glucans forming a strong 
chitin-glucan matrix with low water solubility (88% insoluble) (Miller SA, 1999). 
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Figure 1.8: Nutritional composition of mycoprotein 
Percentages represent the composition of mycoprotein on a dry basis (mycoprotein paste has 75% 
water and 25% dry matter approximately). Nutritional composition of the mycoprotein paste is given in 
grams: Mycoprotein contains between 11 and 16g of protein per 100g and 7g of fibre per 100g. 
The complex structure and composition of this matrix is unique to mycoprotein and not 
normally found in the human diet. The fibre content of mycoprotein differentiates the product 
from meat, which contains little or no fibre therefore most research studies have attributed 
the beneficial effects of mycoprotein to its dietary fibre composition and content. 
1.7.1.3.2 Protein content 
The protein content of the dry cell stands between 42% and 50% which is about 11 to 16g 
per 100g of mycoprotein paste, depending on the water content of the final product. Table 
1.3 presents the protein content of various vegetarian and animal dietary sources of protein. 
Mycoprotein has similar protein content to chicken eggs. 
Table 1.3: Protein content of mycoprotein and other protein sources 
 
Protein content (g/100g) PDCAAS 
Mince Beef 25 0.92 
Cod 23 0.96 
Chicken breast 22 1 
Chicken eggs 12 1 
Mycoprotein 12 0.99 
Tofu 8 0.94 
Mycoprotein has similar protein content to egg and contains high quality protein as assessed by 
PDCAAS 
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The Protein Digestibility-Corrected Amino Acid Score (PDCAAS) of mycoprotein is 0.91, 
which is similar to that of minced beef as shown on table 1.2. The PDCAAS is a method of 
evaluation of protein quality based on the amino acid requirements for human and their 
digestibility. It was adopted by the FAO/WHO to evaluate protein quality in human nutrition in 
1991 (FAO, 2011). Furthermore, mycoprotein contains all nine essential amino acids and 
compares to egg in terms of amino acid composition. 
1.7.1.3.3 Other nutrients 
The lipid content of dry mycoprotein stands at around 13%, which is 3g per 100g in 
mycoprotein paste (table 1.2). In comparison, ground beef contains 20g per 100g of lipids 
(United States Department of Agriculture Nutrient Database).  Mycoprotein contains a high 
proportion of mono- and poly-unsaturated fatty acids (81% of total fatty acids) and low 
amounts of saturated fatty acids (19% of total fatty acids) (Miller SA, 1999). The fatty acid 
profile of mycoprotein is therefore more comparable to vegetable oil than meat. Furthermore, 
mycoprotein contains no cholesterol, but contains low amounts of ergosterol. Ergosterol is a 
component of yeast and fungal cell membranes and serves the same function cholesterol 
serves in animal cells. 
1.7.1.4 Structure of mycoprotein 
Mycoprotein hyphae (filaments) have a similar structure to animal muscle cells and therefore 
give mycoprotein paste a meat-like texture as seen in figure 1.9.  
 
Figure 1.9: The filamentous structure of mycoprotein 
A: The complex structural matrix of filaments give mycoprotein a meat-like texture B: Imaging of 
individual mycoprotein filaments with visible branching. Each filament measures between 400 and 
700µm and has a diameter ranging between 3 and 5µm. The branch frequency is 1 per 250 or 300 
µm (Miller SA, 1999). Pictures provided by Marlow Foods. 
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1.7.1.5 Physico-chemical properties of mycoprotein 
Mycoprotein powder is produced from milled freeze-dried mycoprotein paste and therefore 
has shorter filaments by around 85% (Marks LI, 2005). The filament length has been 
suggested to affect gastric emptying in previous research (Marks LI, 2004). Similarly, 
wholegrain cereals have been shown to promote better health benefits then refined cereals 
(O'Dea et al., 1980, Heaton et al., 1988). The unique glucan-chitin complex is specific to 
fungal mycelium and not usually present in human food. It may hold specific chemico-
physical properties. 
Viscosity is of special importance in the modulation of postprandial glycaemia by dietary 
fibres (Jenkins et al., 1978). Viscous fibres are thought to act on glycaemia through the 
formation of a gel due to their water-holding capacity and by delaying the rate of gastric 
emptying (Holt et al., 1979, Wursch and Pi-Sunyer, 1997). However, although cereals 
containing β-glucans such as oat and barley usually present a highly soluble fibre profile, the 
fibrous chitin-glucan matrix in mycoprotein has low water solubility (Miller SA, 1999). 
Consequently the role viscosity plays in glycaemic response to mycoprotein may be limited.  
1.7.2 Effects of mycoprotein on appetite and metabolism, previous findings 
Mycoprotein has been studied extensively, first to assess its suitability as a food ingredient, 
then its safety, finally its effect on health in clinical trials. This section will summarise findings 
from previous studies investigating the effect of mycoprotein on lipid profile, glucose 
homeostasis and energy intake. Initial studies were performed in rodents and later in 
humans.  
1.7.2.1 Effect of mycoprotein on blood lipid concentrations 
Early work on rodents suggested that mycoprotein reduced cholesterol and plasma 
triglycerides in a dose-dependent fashion (Owen et al., 1975, Owen et al., 1976a). Further 
studies carried out in humans showed that mycoprotein reduced total cholesterol, low-
density lipoprotein (LDL) and increased HDL in comparison with an isoenergetic meat 
control diet over 3 weeks (Turnbull et al., 1990). Similarly, mycoprotein supplementation in 
free-living subjects over 8 weeks reduced total cholesterol and LDL cholesterol compared 
with a soy-based isoenergetic supplementation (Turnbull et al., 1992). The authors 
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suggested that the dietary fibres from mycoprotein could bind to cholesterol and bile acids 
thereby reducing their concentration. 
1.7.2.2 Effect of mycoprotein on appetite and energy intake 
The acute effect of mycoprotein on hunger, satiety and energy intake has been investigated 
in 3 clinical trials (Burley et al., 1993, Turnbull et al., 1993, Williamson et al., 2006). In Burley 
et al.‟s study, 18 lean volunteers consumed an isocaloric mycoprotein or a chicken meal 
prior to an ad-libitum meal 4 ½ hours later and kept a food diary for the following 24 hours 
(Burley et al., 1993). There was a significant 18% reduction in energy intake at the ad-libitum 
meal following the consumption of the mycoprotein meal compared with the chicken meal. 
No significant differences in appetite sensations and 24-hour energy intake were found.  
In Turnbull et al.‟s study, 13 lean females consumed nutrient balanced meals containing 
mycoprotein or chicken and completed visual analogue scales (VAS) to assess appetite at 
regular intervals for 3 hours (Turnbull et al., 1993). Significant differences in prospective food 
intake and desire to eat but not in hunger and fullness were observed 3 hours after the 
consumption of mycoprotein compared with chicken. Energy intake, assessed by 48-hour 
food diary, was significantly reduced by 236 kcal at 24 hours and 288 kcal at 48 hours 
following the consumption of mycoprotein compared with chicken. Although the results of 
this study suggest that mycoprotein could have a long-lasting effect on appetite, there are 
several limitations to the design of the protocol. Firstly, the energy intake following the meal 
was assessed by weighed food diaries only rather than an ad-libitum meal. The author did 
not report any evaluation of the food diary quality and did not assess for under- or over-
reporting. Secondly, the type of meal (mycoprotein or chicken) was not blinded to the 
participants.  
In a study by Williamson et al., 42 overweight female participants consumed mycoprotein, 
chicken, or tofu followed by an ad-libitum lunch 20 minutes later and an ad-libitum dinner 4 
hours after lunch (Williamson et al., 2006). Energy intake at lunch was significantly reduced 
following the consumption of mycoprotein compared with chicken. No differences in appetite 
VAS or in energy intake at the ad-libitum dinner were found.  
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1.7.2.3 Effect of mycoprotein on glucose homeostasis  
To date, only one study has investigated the effects of mycoprotein on insulin and glucose 
profiles as a main outcome. In a randomised cross-over trial, 19 subjects consumed 
isoenergetic milkshakes containing either mycoprotein or a soy-based control (Turnbull and 
Ward, 1995). The study showed that mycoprotein significantly reduced glucose and insulin 
concentrations in comparison with the control milkshake. The authors suggested that the 
non-soluble fibres contained in mycoprotein (chitin and β-glucans) could delay gastric 
emptying, reduce glucose absorption, and bind to negatively charged lipids thereby lowering 
their GI uptake. They also suggested that the response could be due to the amino acid 
content of the two meals, particularly arginine which is a potent insulin secretatogue. 
In a 3 week supplementation study, Turnbull et al. did not find any significant changes in 
glucose homeostasis using an oral glucose tolerance test (OGTT) (Turnbull et al., 1990).  
1.7.2.4 Effect of mycoprotein on gastric emptying 
Marks investigated the effect of mycoprotein filaments length on glycaemic response, gastric 
emptying and satiety in 12 young healthy lean volunteers (Marks LI, 2005). Drinks containing 
short-filament (SF) and long-filament (LF) mycoprotein were compared. Gastric emptying 
was assessed by the paracetamol method. VAS and blood samples were collected at 
regular intervals for 2 hours. The study showed no difference in glycaemia between the 
drinks. The LF mycoprotein significantly reduced paracetamol concentrations compared with 
the SF mycoprotein suggesting that filament length may play a role in the delay of gastric 
emptying.  
In a second study, 14 healthy lean volunteers were asked to consume a bread roll with 
mycoprotein paste, or ham. Gastric emptying was assessed by the paracetamol method. 
GLP-1 concentrations were significantly higher following mycoprotein compared with ham at 
120 minutes but this was not associated with differences in appetite. Paracetamol 
concentrations were not significantly different compared with the ham.  
1.7.3 Summary of the literature and limitations of previous studies 
Table 1.4 summarises the results of previous work on mycoprotein.  
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Table 1.4: Summary of previous work investigating the effect of mycoprotein on appetite and metabolism in humans 
Reference Subject Dose Design Control Results 
     Lipids Glucose homeostasis Appetite and energy intake 
Turnbull  
(1990) 
n=17  
M+F 
Raised 
cholesterol 
191g P 
(eq 48g D) 
3 weeks 
parallel 
meat 
 13% TC 
 9% LDL 
 11% HDL 
No changes on OGTT No change in body weight 
Turnbull  
(1992) 
n=21 
M+F 
Raised 
cholesterol 
27g D 
(eq 130g P) 
8 weeks 
parallel 
Mycoprotein- 
free 
 16% TC 
 21% LDL 
Not investigated No change in body weight 
Turnbull  
(1993) 
n=13 
F 
lean 
healthy 
130g P 
(eq 32.5g D) 
Acute 
Cross-over 
Non-blinded 
chicken 
Not 
investigated 
Not investigated 
 desire-to-eat 
 prospective food intake 
No changes in hunger 
No changes in fullness 
 236kcal (24%) at 3 hours 
Burley  
(1993) 
n=18 
M+F 
lean 
healthy 
150g P + ?D 
(eq 37.5+ 
?D) 
Acute 
Cross-over 
Blinded 
chicken 
Not 
investigated 
Not investigated 
No changes in VAS 
 329kcal (males) at 4 ½ hours 
 121kcal (females) at 4 ½ hours 
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Table showing a summary of the available literature on mycoprotein. The results column shows the effect of mycoprotein compared with the control. Key: M, 
males; F, females; P, mycoprotein paste; D, mycoprotein dry powder, TC, total cholesterol; HDL, high-density lipoprotein; LDL, low-density lipoprotein; 
OGTT, oral glucose tolerance test, VAS, visual analogue scales, LF, long filaments; SF, short filaments; GLP-1, glucagon like peptide-1. 
Turnbull  
(1995) 
n=19 
M+F 
lean 
healthy 
20g D 
(eq 80g P) 
Acute 
Cross-over 
soy 
Not 
investigated 
 glucose  
(13% 60min) 
 
 insulin 
(19% 30min) 
(36% 60min 
Not investigated 
Williamson 
(2006) 
n=42 
overweight 
44.3g P 
(eq 10g D) 
Acute 
Cross-over 
tofu 
chicken 
Not 
investigated 
Not investigated 
No changes in VAS 
 40kcal (20min) 
Marks 
(2004) 
n=12 
M+F 
lean 
healthy 
90g P 
(eq 20g D) 
Acute  
Cross-over 
Blinded 
Mycoprotein 
LF vs SF 
Not 
investigated 
Glucose: no changes   
 
delayed gastric 
emptying 
at 30min and 60min 
following LF  
 
No changes in VAS 
Marks 
(2004) 
n=14 
M+F 
lean 
healthy 
50g P 
(eq 11g D) 
Acute 
Cross over 
Not blinded 
ham 
Not 
investigated 
Glucose: no changes 
 
 insulin at 90min 
 
No difference in gastric 
emptying 
 
 GLP-1 at 120 min  
 
No differences in VAS between 
ham and mycoprotein 
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The variety of studies and the differences in protocol including the amount of mycoprotein 
given, the type of participants (males or females, overweight or lean, healthy or unhealthy), 
the time allowed between test meals and ad-libitum meals as well as the environmental 
conditions surrounding the participants render the comparison difficult.  
There are major discrepancies in the appetite results especially in the assessment of 
appetite using VAS. Results on energy intake seem relatively consistent apart from the study 
by Williamson et al. which did not find any effect of mycoprotein on energy intake at 4 hours 
but at 20 min (Williamson et al., 2006). The amount of mycoprotein in this study was, 
however, relatively low. Although previous studies used different designs, the results 
suggest a potential dose-effect on energy intake. Intake of 44.3g, 130g and 150g of 
mycoprotein reduced energy intake at the next meal by 40, 236 and 329/121kcal 
(Males/Females) respectively. No study has investigated the effect of mycoprotein dose on 
energy intake and appetite. Furthermore, only one study investigated the effect of 
mycoprotein on energy intake in overweight volunteers (Williamson et al., 2006). It would be 
more relevant to involve overweight subjects because they would benefit most from appetite 
control. As overweight volunteers often show altered hunger and appetite profiles compared 
with lean volunteers, it is possible that overweight volunteers may respond differently to 
mycoprotein compared with lean volunteers. Further studies therefore need to be carried out 
in overweight volunteers in order to confirm previous findings in lean volunteers. 
The effect of mycoprotein on glycaemia requires further clarification as some studies found 
that mycoprotein reduces post-prandial glucose concentration whilst others found no effect. 
Most studies examining the effect of mycoprotein on insulin profiles seem consistent and 
show that mycoprotein acutely reduces serum insulin concentrations. It is however not 
known whether the effect on insulin is dose-dependent. Some studies suggest that high 
glycaemic index diets may be associated with altered substrate oxidation due to increased 
post-prandial glucose and insulin concentrations; although the effect seems inconsistent 
across studies (Brand-Miller et al., 2002, Diaz et al., 2005, Ritz et al., 1991). As mycoprotein 
contains fibre, substrate oxidation may be altered by the consumption of mycoprotein.  
The study by Marks is the only study which investigated potential mechanisms of action of 
mycoprotein. Marks found that mycoprotein with long filaments delayed gastric compared 
with mycoprotein with short filaments (Marks LI, 2005). However, no effect on GLP-1 
concentrations was noted. In the following study, comparing mycoprotein and ham, 
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mycoprotein showed no significant effect on gastric emptying but increased GLP-1 
concentrations at 120min compared with ham. Unfortunately, meals were not matched for 
macronutrient content which limits the interpretation of the results. No study has investigated 
the effect of mycoprotein on appetite hormones using an isocaloric macronutrient-matched 
meal approach.  
In conclusion, previous studies have shown that mycoprotein acutely reduces energy intake 
and improves glucose homeostasis and lipid profile in lean individuals (Burley et al., 1993, 
Turnbull et al., 1992, Turnbull and Ward, 1995). The effect in overweight volunteers remains 
to be clarified. Although previous studies have used different amounts of mycoprotein; to 
date, no study has investigated whether mycoprotein exerts a dose-dependent effect on 
energy intake. Furthermore, the mechanism of action remains unclear. Previous work 
suggested that mycoprotein may affect gastric emptying or GLP-1 concentrations (Marks LI, 
2004). Confirmation of whether the reduction in energy intake induced by mycoprotein is 
associated with changes in appetite hormones in needed. 
1.8 Conclusion 
Obesity is a pandemic that shows no sign of abatement. Obesity is a complex disorder which 
increases the risk of developing serious co-morbidities and affects life quality. In obese 
subjects, a number of modifications in the homeostatic and non-homeostatic appetite 
regulation systems as well as the gut microbiota and the glucose homeostasis system result 
in altered metabolism and, over the long term, impairment of several organs and 
development of serious co-morbidities. At the present time, metabolic surgery is the gold-
standard treatment for obesity. RYGB induces sustained weight loss by energy restriction 
and changes in metabolism. However, optimisation is still required to reduce the risk of 
complications. A pre-operative diet is required before the procedure; there is however no 
consensus on the optimal diet at the present time. The first part of this thesis therefore 
investigated the effect of different pre-operative diets followed by RYGB on body 
composition, surgery outcomes, and appetite regulation in morbidly obese patients 
undergoing RYGB. 
As the success of metabolic surgery resides partly in the alteration of appetite signals, there 
has been a rising interest in finding food components capable of mimicking these effects 
especially in the overweight population, where dietary changes remain the first-line choice of 
77 
 
treatment.  Dietary fibre and protein are both thought to reduce appetite by modifying satiety 
signals. Mycoprotein (Quorn), a fibre- and protein-rich fungal product, was shown to 
decrease energy intake in previous research. This thesis intends to clarify the mechanisms 
of action by which mycoprotein reduces appetite compared with other sources of protein 
using an acute feeding clinical trial in healthy overweight volunteers. 
1.9 Aims and hypotheses of this thesis 
1.9.1 Changes in liver fat and body composition following diet- and surgically-
induced weight loss in obese individuals 
1.9.1.1 Aims 
The aim of this study was to compare the effect of a 2-week vs 6-week pre-operative liquid 
formula LCD with a conventional low-carbohydrate/high-protein diet prior to RYGB surgery 
on intra-hepatocellular lipid content (IHCL), body composition and surgical outcomes in 
morbidly obese patients. 
1.9.1.2 Hypothesis 
Based on the available literature, I hypothesised that a 6-week pre-operative liquid formula 
LCD prior to RYGB would reduce IHCL content compared with a standard low-
carbohydrate/high protein conventional food diet and a 2-week LCD.  
1.9.2 Effect of mycoprotein on acute energy intake in overweight individuals 
1.9.2.1 Aims 
The aim of this study was to compare the effect of three doses of mycoprotein with 
macronutrient-matched meals containing a control protein on acute energy intake and satiety 
signals in overweight individuals. 
1.9.2.2 Hypothesis 
I hypothesised that mycoprotein consumption will reduce energy intake acutely compared 
with a control protein and that the reduction in energy intake will be associated with changes 
in satiety signals. 
78 
 
 
 
 
 
 
 
 
Chapter 2 
Materials and methods 
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2.1 Introduction 
This chapter will present the materials and methods used in the present research project for 
the assessment of body composition, the evaluation of energy intake and appetite, the 
measurement of energy expenditure and substrate oxidation, the collection and analysis of 
blood samples and the analysis of metabolomics. For each part, the methodologies will be 
described in detail and a critical evaluation of the methodology will be undertaken. 
Subsequent chapters will refer to materials and methods in this chapter but, in summary, 
table 2.1 shows which methods were used in each study. 
Table 2.1: List of materials and methods used in each study 
 MYCOPROTEIN STUDY WEIGHT LOSS STUDY 
Body composition:   
     Weight/BMI   
     Anthropometrics   
     Bioelectrical impedance analysis   
     MRI   
Energy intake and appetite:   
     Ad-libitum meal   
     Visual Analogue scales   
     Unweighed food diary   
Energy expenditure and 
substrate oxidation: 
  
     Indirect calorimetry   
Blood sample analysis:   
     Glucose   
     Insulin   
     Paracetamol   
     Leptin   
     GLP-1 and PYY   
     Lipids   
Metabonomics   
     1H NMR   
Key: BMI: body mass index, MRI: magnetic resonance imaging, GLP-1: glucagon-like peptide-1, PYY: 
peptide tyrosine-tyrosine, 
1
H NMR: proton nuclear magnetic resonance 
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2.2 Evaluation of body composition 
Body composition is of great importance in the study of obesity. In the overweight and obese 
population, increased BMI is associated with increased risk of co-morbidities. However, BMI 
alone was shown to be a limited reflection of health status and therefore more specific 
evaluation of body composition may be needed to assess health risks (Huxley et al., 2010, 
Hubbard, 2000). Several studies show that adipose tissue depots in the abdominal area are 
greatly correlated with increased risks of metabolic disorders (Yusuf et al., 2005). Visceral 
adipose tissue (VAT) especially, has been associated with increased risk of type-2 diabetes 
mellitus (T2DM) and cardiovascular disease (CVD) (Kuk et al., 2006). Conversely, lean 
tissue was shown to be a great predictor of weight loss following gastric bypass surgery and 
may therefore be of importance in the assessment of weight loss during energy restriction 
(Robert et al., 2013). A large number of methods can be used to determine body 
composition in humans. The methods for these measurements are described in the following 
sections. The methods used for each study were chosen based on the outcomes needed as 
well as the practicality, the cost and the feasibility considering the study cohort.  
2.2.1 Weight and BMI 
2.2.1.1 Method of measurement 
Body Mass Index (BMI) is calculated by dividing body mass (kg) by squared height (m2). 
Body mass was acquired using a Seca scale (Vogel & Halke Hamburg, Germany). Height 
was recorded using a stadiometer (Invicta Plastics Ltd., Leicester, UK). Both height and 
weight were measured in the morning following an overnight fast in the weight loss study 
(Chapter 3). For the purpose of both the mycoprotein and weight loss studies, BMI was used 
as a selection criterion in order to recruit a homogeneous cohort. 
2.2.1.2 Use and limitations of the BMI 
The BMI is the most common non-invasive method currently used to estimate whether a 
person is the correct weight for their height. The BMI is a useful, reproducible and 
inexpensive tool which can easily be used for epidemiological studies, retrospective studies 
and long-term studies (Whitlock et al., 2009). It is also commonly used in population 
assessment and perspective studies by governments and health agencies such as the World 
Health Organization (WHO). Although largely used because of its simplicity and practicality, 
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the BMI cannot distinguish between lean and adipose tissue and only correlates modestly 
with whole body fat levels (Romero-Corral et al., 2008). Furthermore, the BMI does not 
provide any information on adipose tissue distribution, especially on abdominal adipose 
tissue and is therefore of limited use for the assessment of metabolic risk (Huxley et al., 
2010). However, some studies have shown that the BMI predicts the risk of CVD and T2DM 
to a similar extent to waist circumference or wait-hip ratio (Taylor et al., 2010).  
2.2.2 Additional anthropometric measurements 
2.2.2.1 Methods of measurements 
Anthropometric measurements can be used as a complement to the BMI. For the purpose of 
the weight loss study (Chapter 3), anthropometrics measurements were taken with a flexible 
tape-measure as illustrated in figure 2.1: 
 
Figure 2.1: Anthropometric measurements sites in female (A) and male (B) participants 
Measurements correspond to the following: 1: waist at the mid-point between lower margin of the last 
palpable rib and the top of iliac crest, 2: hip circumference, 3: neck circumference 
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 Waist circumference at the midpoint between the lower margin of the last palpable rib 
and the top of the iliac crest (on top of panniculus where applicable) (measurement 1 
in figure 2.1) 
 Hip circumference at the widest part of the buttocks (underneath panniculus where 
applicable) (measurement 2 in figure 2.1) 
 Neck circumference below the laryngeal prominence for men and in the midway of 
the neck for women (measurement 3 in figure 2.1) 
Anthropometric measurements were taken by a single trained researcher to avoid any 
variations in the measurements. During measurements, participants were wearing loose 
cotton scrubs to avoid clothing constriction. 
2.2.2.2 Use and limitations of the waist and hip circumference 
Waist and hip circumferences are thought to be a better predictor of body fat distribution and 
are considered of great importance in the study of obesity (WHO, 2008b). The waist-hip 
ratio, especially, used by many as a proxy measurement of abdominal fat, was shown to be 
a better predictor of CVD risk than the BMI (Huxley et al., 2010). The WHO STEPwise 
approach to Surveillance provides clarification regarding the measurement of waist and hip 
circumferences. According to this protocol, the waist circumference should be measured 
directly over the skin “at the midpoint between the lower margin of the last palpable rib and 
the top of the iliac crest” (WHO, 2008a). Other protocols indicate that the measurement 
should be made at the top of the iliac crest (NHI, 2000), at the level of the umbilicus (MESA, 
2002), or at the point of minimal waist (Yusuf et al., 2005). The site of the measurement, 
however, seems to have only minimal impact on the association between waist-hip ratio and 
risks of cardiovascular disease (Ross et al., 2008). All protocols previously mentioned advise 
that the hip measurement should be taken at the widest part of the buttocks (NHI, 2000, 
WHO, 2008a). The measurement of the waist circumference requires the palpation of the rib 
and the iliac crest. In severely obese patients, the palpation of the bone structure is 
challenging as well as occasionally uncomfortable or painful. Furthermore, the potential 
presence of a panniculus, a layer of subcutaneous adipose tissue lying underlying the 
corium, makes the measurement sometimes difficult and highly variable in some patients. 
Similarly, measurement of hip circumference in obese patients can be challenging. 
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2.2.2.3 Use and limitations of additional measurements 
Additional anthropometric measurements were taken in order to assess changes in body 
shape and metabolic risks. Previous studies suggested that increased neck circumference 
contributes to the risk of metabolic syndrome independently of waist measurement (Onat et 
al., 2009). Upper-body fat distribution has been associated with increased risk of CVD and 
neck circumference has been suggested as an independent screening tool to identify 
patients at risk (Sjostrom et al., 1995). Furthermore obese patients suffering from obstructive 
sleep apnoea (OSA) were shown to have greater neck circumference than obese subjects 
with similar waist measurement (Hoffstein and Mateika, 1992). OSA is an under-diagnosed 
condition characterised by recurrent obstruction of the upper airway during sleep which 
causes excessive sleepiness and fatigue during the day and was shown to be associated 
with increased risk of coronary heart disease and metabolic syndrome (Drager et al., 2013, 
Nieto et al., 2000, Peppard et al., 2000). For the purpose of this study, neck circumference 
was recorded just below the laryngeal prominence for men and in the midway of the neck for 
women as previously performed (Onat et al., 2009). Neck circumference is relatively easy to 
measure in obese patients and could therefore result in less variability than waist 
circumference measurement in this study.  
2.2.3 Bioelectrical impedance analysis 
2.2.3.1 Acquisition of body composition by BIA 
Volunteers were asked to stand barefoot on a Tanita BC-418 segmental body composition 
analyser composed of 8 polar electrodes (Tanita Corporation, Japan). The BIA scale uses a 
constant current source with high frequency current (50 kHz, 500mA). The Tanita BIA scale 
predicts fat-free mass (FFM) based on data acquired by repeated regression analysis of 
Dual Energy X-ray Absorptiometry (DEXA) results in Japanese and Western populations 
(Tanita).  
BIA measurements were taken during screening visits of investigation 3 of the mycoprotein 
study (see Chapter 4 section 4.6.2). Volunteers were therefore not fasted and 
measurements were taken at any time of the day. 
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2.2.3.2 Principles of BIA 
Bioelectrical Impedance Analysis (BIA) is a common method used for the estimation of total 
body composition and segmental body composition. It is based on the conduction of an 
applied electric current throughout the intra- and extra-cellular fluids. The impedance, the 
degree to which a medium slows (reactance) or stops (resistance) an applied current, 
depends on the tissue characteristics: water has lower impedance than fat. Lean tissue, 
which contains more water than adipose tissue, therefore has lower impedance. The 
measured impedance is used to estimate the volume of Total Body Water (TBW) which 
provides an estimation of FFM (Lukaski et al., 1986). However, several other factors 
influence impedance in humans such as age, sex, or hydration (Lukaski and Bolonchuk, 
1988). The equations from Lukaski were then adapted from the regression of DXA studies 
by Tanita Corporation (Tanita).  
The estimation of body water is highly influenced by hydration status. Many factors can 
induce variations in hydration in humans such as illness, exercise, and food and alcohol 
intake. It is therefore necessary to take measurements under uniform conditions. 
The use of BIA to assess body composition has been thoroughly discussed in previous 
studies. Although fat mass measured by BIA has been shown to correlate relatively well with 
MRI and DEXA in previous studies using normal weight individuals, some studies showed 
that it may underestimate or overestimate total body fat and trunk fat in overweight and 
obese individuals with increased adiposity (Neovius et al., 2006, Lloret Linares et al., 2011, 
Verdich et al., 2011, Savastano et al., 2010, Shafer et al., 2009).  
2.2.4 Magnetic resonance imaging and spectroscopy 
As discussed previously, the accurate measurement of fat compartment within the body is of 
great importance in the assessment of the metabolic risks. At the present time, only two 
techniques are able to distinct and quantify all fat compartments within the body, Computed 
Tomography (CT) and Magnetic Resonance Imaging (MRI). Although CT scanning has been 
shown to be a robust and accurate technique to measure intra-abdominal adipose tissue 
content (Borkan et al., 1982, Baumgartner et al., 1988), the radiation doses that it delivers 
greatly limits its application in research. In clinical trials, MRI is therefore seen as the ideal 
replacement as it does not involve the use of ionising radiation. MRI is considered one of the 
gold standard methods to produce high quality images of internal body structures as it allows 
the scanning of any part of the body without moving the subject and gives superior contrast 
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between different tissues including soft tissues such as the muscle or the adipose tissue 
(Thomas et al., 2013). MRI therefore allows the accurate quantification of adipose tissue 
within body compartments and is of particular interest in the assessment of the metabolic 
risk. However, MRI is an expensive technique, which is therefore not applicable for large 
cohort studies. Furthermore, MRI may not be suited to all patient populations. For example, 
severely obese individuals with a body mass above 150kg require the use of a special MRI 
scanner as standard ones will not accommodate a weight of 150kg or more. Despite the 
restrictions on participant‟s body mass (<150kg), MRI was used in the weight loss and body 
composition study (chapter 3) to investigate changes in body composition and fat distribution 
during acute weight loss.  
2.2.4.1 Preparation for the MRI 
For the purpose of the weight loss study, participants were invited to attend the Robert 
Steiner MRI research facility at Hammersmith Hospital. Before each MRI, participants were 
asked to fill in a metal safety questionnaire (appendix 1). Purposely designed cotton scrubs 
were provided to all participants who were also required to wear a long-sleeve cotton tee-
shirt underneath the scrubs in order to prevent direct contact of the skin with the surface of 
the scanner. 
2.2.4.2 Acquisition of MR images and spectra 
The acquisition of images and spectra was performed by trained radiographers and 
members of the imaging team using a 1.5T multinuclear Philips Achiva Scanner (Philips 
Medical Systems, Best, Holland). Subjects were positioned lying either supine or prone 
depending on the part of the body being scanned and were automatically moved through the 
scanner. During scanning, volunteers had access to a buzzer, in case of emergency, and 
were able to hear and respond to instructions from the scanning console. Images and 
spectra were acquired in two parts corresponding to the following measurements. 
2.2.4.2.1 Hepatic and pancreatic lipid content 
For the measurement of intra-hepatocellular lipid (IHCL) content, 1H MR single voxel spectra 
were acquired from the right lobe of the liver using a Point-Resolved Spectroscopy (PRESS) 
sequence without water saturation and with 128 signal averages. Transverse images of the 
liver were used to ensure accurate positioning of the voxel in the liver, avoiding blood 
vessels, the gall bladder, and fatty tissue. Spectra were analysed in the time domain using 
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the AMARES (advanced method for accurate, robust, and efficient spectral fitting) algorithm 
included in the MRUI software package for quantitation of in vivo and medical magnetic 
resonance spectroscopy signals (Vanhamme et al., 1997). Peak areas for all resonances 
were obtained and lipid resonances were quantified with reference to water resonance, after 
correcting for T1 and T2. Analyses were performed by Dr E. L. Thomas. 
Pancreatic lipid content was measured using multi-echo imaging analysed in Matlab 
(MathWorks Inc, USA). Respiratory motion was controlled by acquiring images on a single 
breath-hold on expiration following hyperventilation. Analyses were performed by J 
Fitzpatrick.  
The measurement of ectopic fat in the pancreas by MRS is technically challenging because 
the small size of the organ makes the measurement susceptible to contamination by 
surrounding adipose tissue. Pancreatic fat is therefore commonly assessed by MRI-based 
techniques which allow for assessment of regional fat deposition in opposition to MRS where 
a single voxel is analysed. In brief, multi-echo is an MRI-based technique, which generates 
images where fat and water signals are in phase or out of phase. From the images, a decay 
curve can be generated which shows significant oscillations if high levels of fat are present. 
Multi-echo was shown to be a validated tool to quantify liver and pancreatic fat, more 
accurate and robust than Dixon-based techniques (Thomas et al., 2013, O'Regan et al., 
2008).  
2.2.4.2.2 Whole body adipose tissue distribution 
Whole body MR images were acquired on a Philips Achieva 1.5T system (Philips Medical 
Systems, Best, Holland) using a rapid T1-weighted spin echo sequence. Volunteers were 
scanned from their fingertips to their toes by acquisition of 10 mm thick transverse images 
with 10 mm gaps between slices through the body.  
Images were analysed by Vardis (Vardis Group, London, United Kingdom), an independent 
company blinded to the treatment of the participants, using SliceOmatic (Tomovision, 
Montreal, Canada) a semi-automated software program that employs knowledge-based 
image processing to label pixels as fat or non-fat components. In brief, voxels in each image, 
are codded into fat or non-fat. The size of the voxel is calculated from the matrix. The 
number of „fat‟ voxels is then multiplied by the volume of each voxel and converted from cm3 
to litres. Total and regional adipose tissue volumes were calculated from the scans and lean 
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tissue mass was calculated by difference. All data was sent at the end of the study. The 
compartments are described in figure 2.2.  
 
Figure 2.2: Description of fat compartments calculated from the MRI scans.  
Total adipose tissue (shown in white in the coronal image) was divided into subcutaneous adipose 
tissue (SAT, green) and internal adipose tissue (IAT, pink). SAT is divided between peripheral 
adipose tissue and subcutaneous abdominal adipose tissue (shown in green on the transversal 
abdominal slice). IAT is divided between intra-abdominal (or visceral) adipose tissue (shown in pink in 
the transversal abdominal slice) and non-abdominal IAT. Subcutaneous abdominal and visceral 
adipose tissues represent trunk adipose tissue. 
2.2.4.3 Principles of magnetic resonance imaging and spectroscopy 
Magnetic resonance imaging is a medical imaging technique enabling the distinction of 
internal tissues and organs. In summary, MRI uses the magnetic properties of the nuclei of 
hydrogen inside the human body. An external magnet is used to align the magnetisation of 
each hydrogen nuclei in the body and radio frequency pulses are applied to alter the 
alignment of this magnetisation. When the nuclei re-align with the external magnetic field, 
the energy is retransmitted and detected by the scanner. This re-alignment is characterised 
by T1, the spin-lattice relaxation time, and T2, the spin-spin relaxation time. T1 and T2 are 
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characteristics of each tissue. The difference in behaviour between tissues is the basis of 
contrast in MRI. However, because of inhomogeneities in the environment causing 
dephasing of the nuclei, different pulse sequences are applied to rephase the signal. The 
most common sequences are spin echo and gradient echo. In spectroscopy, a spectra 
depicting signal intensity versus frequency is acquired instead of an image. Indeed, the 
electrons surrounding the nuclei confer a different environment to the protons. The chemical 
shift is then used to provide information regarding the molecular group carrying the hydrogen 
nuclei. Each peak on the spectra corresponds to the concentration of the corresponding 
molecule while water is used as a reference.  
2.3 Evaluation of energy intake and appetite 
There are several methods available to determine energy intake and appetite in an 
individual. An ad-libitum meal can be used as a quantitative measure of appetite while visual 
analogue scales can be used to follow appetite sensations at regular intervals during a time 
course. Finally, food diaries are mainly used for the assessment of baseline energy intake or 
for the assessment of food intake in free-living subjects.  
2.3.1 Determination of energy intake by ad-libitum meal 
At the end of each visit, an ad-libitum meal was used as a quantitative measure of appetite. 
During the screening visit, participants were given a choice of three ad-libitum meals, which 
were similar in energy content and composition, and asked to choose their favourite. 
Participants were offered a meal in excess at the end of the blood sample collection and 
asked to eat until they felt “comfortably full”. The meal was weighed before and after and 
energy intake was calculated from the manufacturer‟s nutritional information. This also 
allowed for the calculation of macronutrient consumption by the individual (Hill et al., 1995). 
The test meal conditions were standardised by using the same rooms with constant light and 
controlled temperature. The room was kept free of odours, and other disturbing factors which 
could have affected appetite especially in restrained eaters (Fedoroff et al., 1997). Subjects 
were kept in separate rooms during the whole study visit to prevent the effect of social 
interaction on food intake (Bellisle et al., 2009). Subjects were allowed to watch television or 
read throughout the study mornings; they were however asked to refrain from watching any 
food programmes to avoid food cues. During the consumption of the meal, subjects were 
required to turn off the television or stop reading as food intake was shown to be affected by 
external sources of distraction (Bellisle et al., 2009). Subjects were left on their own in order 
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to prevent any impact of public attention (Polivy et al., 1986). Ad-libitum meals as a physical 
measure of appetite have been used extensively in previous appetite studies. The food 
intake consumed at an ad-libitum meal was shown to be highly reproducible within 
individuals (Lara et al., 2010). 
2.3.2 Determination of appetite by Visual Analogue Scales 
2.3.2.1 Definition of appetite terms  
Appetite is defined as the sum of all processes influencing eating. Hunger is the 
physiological drive to eat, a conscious sensation, which can be traced to changes in physical 
sensations in different part of the body. Fullness refers to the sensation of repletion, a 
conscious sensation, normally focused on the stomach. Satiation controls meal termination 
(meal size) and results from signalling from the stomach and the upper-intestine but also 
taste and reward. Finally, satiety is the inhibition of eating and hunger in the post-prandial 
period (Blundell and Halford, 1994). 
2.3.2.2 Acquisition of VAS scores  
Visual Analogue Scales (VAS) were used to assess appetite sensations during the visits. 
VAS consisted of five 100mm scales assessing feelings of: 
 hunger („how hungry do you feel right now?‟) 
 nausea („how sick do you feel right now?‟) 
 desire to eat („how pleasant would it be to eat right now?‟) 
 prospective food intake („how much do you think you could eat right now?‟) 
 fullness („how full do you feel right now?‟)  
A composite score was then calculated as the weighted mean of the four appetite scores 
(hunger, desire-to-eat, prospective food intake and fullness) as previously described by 
Anderson et al. and Abou-Samra et al. (Anderson et al., 2002, Abou-Samra et al., 2011). 
Following the consumption of a meal, other questions relating to the palatability of the meal 
were asked such as: 
 pleasantness („how pleasant was this meal?‟) 
 taste („how tasty was this meal?‟) 
 sweetness („how sweet did this meal taste ?‟) 
The left extremity of the scale was labelled with “not at all/nothing” and the right extremity of 
the scale with “extremely/a large amount”. Participants were asked to draw a vertical line to 
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assess their feelings at each time point. For each question of the VAS questionnaire, the 
distance between the extremity and the mark was measured at each time point and plotted 
to create a time profile. The two baseline scores were averaged.  
For each VAS, a Corrected Area Under the Curve (cAUC) was calculated to account for 
variability at baseline between study visits. First, the score of the first time point was set to a 
virtual baseline score set at 100 (or 0 for the fullness profile). All subsequent scores were 
subsequently represented as change from baseline. Then, the cAUC was calculated for this 
corrected profile using the trapezoidal rule.  
VAS have been widely used in previous studies and have been shown to be a valid measure 
of appetite (Flint et al., 2000). A previous study reviewed the reliability and validity of VAS in 
terms of their ability to predict feeding behaviour, their sensitivity to experimental 
manipulations and their reproducibility (Stubbs et al., 2000). The authors suggested that 
VAS correlate with, but do not reliably predict energy intake to the extent that they could be 
used as a proxy for energy intake. Despite subjects being told that the extremities of the 
scales represent extreme feelings, they still tend to often mark their feelings as 0 or 100 on 
the scales (Hill et al., 1995).  
2.3.3 Food diaries analysis 
2.3.3.1 Completion and analysis of the diaries  
Volunteers were asked to complete a detailed unweighed food diary to limit respondent 
burden. This involved recording every food item and drink they consumed over a specific 
period of time in a detailed manner using household measures. Volunteers were asked to 
provide details regarding the method of cooking, the quantities using measurements such as 
cups or tablespoons, the detail of the brands, and specific details about the food (packaging 
for commercial meals). Instructions and examples were provided to the participants. Any 
unclear recording was further clarified with the participant. The food questionnaires were 
analysed using DietPlan 6.50 by an independent researcher trained in nutritional analysis. 
Food portion sizes were estimated using Food Standards Agency Portion sizes references 
(FSA, 2002).  
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2.3.3.2 Assessment of under-reporting 
Assessing dietary intake using unweighed food diaries has many limitations. Firstly, the use 
of household measures to estimate quantities induces imprecision both from the respondent 
and the person analysing. Secondly, it is generally acknowledged that dietary intake is often 
under-reported especially in the overweight and obese populations (Goris et al., 2000, Price 
et al., 1997, Hill and Davies, 2001). Invalid dietary intake can result either from intentional or 
unintentional under-reporting (food eaten but not reported) or intentional alteration of diet 
(food intake reduced or certain types of food avoided) (Macdiarmid and Blundell, 1998). 
Several methods exist to assess under-reporting in nutritional analysis, the most common 
accepted one being the Goldberg method which lies on the principle that energy intake  
should equal energy requirements (Goldberg et al., 1991). Unfortunately, the method has 
poor sensitivity and specificity at individual level and is therefore of limited use for small 
interventional clinical trials (Livingstone and Black, 2003). Furthermore, the equations were 
derived from a population of lean individuals mainly and may therefore not be applicable in 
overweight and obese subjects with altered body composition. In large population studies, it 
is possible to improve the sensitivity of the equation by taking into account the physical 
activity level (PAL) and the number of recorded days (Black, 2000). However, on an 
individual basis, the ability of the Goldberg cut-off to detect under-reporting, even after 
correction, remains limited (Black, 2000). For the purpose of this work, under-reporting was 
estimated using the traditional Goldberg method with group corrections for activity level and 
number of recorded days d: 
Weight loss study:   (PAL = 1.55, d = 3)  1.00 < EI/RMR < 2.40 
Mycoprotein study:   (PAL = 1.55, d = 1)   0.87 < EI/RMR < 2.75 
Where PAL is the physical activity level (evaluated as light in both studies), EI is the energy 
intake and RMR the resting metabolic rate or resting energy expenditure. Harris-Benedict 
and Schofield equations have been shown to overestimate energy expenditure in both 
overweight and obese individuals (Mifflin et al., 1990, Ullah et al., 2012). For the mycoprotein 
investigation involving overweight volunteers, RMR was therefore estimated using the Mifflin 
St Jeor equations (Mifflin et al., 1990, Ruiz et al., 2011). Established equations, including the 
Mifflin St Jeor equations, poorly predict resting energy expenditure in obese individuals 
(Wilms et al., 2010, Alves et al., 2009, Horie et al., 2011, Weijs, 2008, de Oliveira et al., 
2011). Very few studies have developed new equations to estimate resting energy 
expenditure in the morbidly obese specifically. The Horie-Waitzberg and Gonzalez equation 
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was developed and validated in severely obese individuals planning to undergo bariatric 
surgery; it was therefore considered the most appropriate equation to use in the weight loss 
investigation (Horie et al., 2011).  
The EI/RMR ratio was calculated for participants in each study and compared with the 
Goldberg cut-off. 
2.3.4 Compliance during the pre-operative diet 
2.3.4.1 Review visits 
Compliance during the LCD was assessed by weekly reviews, during which motivation levels 
were evaluated, potential side-effects discussed and compliance assessed orally. 
Anthropometric measurements were taken to assess weight loss. Dietary intake during the 
LCD was recorded by 7-day weighed food diaries and discussed with the participants during 
the review visit. Participants following the LCD were provided with their weekly intake of LCD 
meal replacements of their choice. Participants following the standard low-carbohydrate 
high-protein diet also attended weekly review visits during which the diet was discussed and 
any questions answered. A urine sample was provided at each review visit for the 
measurement of ketone bodies: A Siemens Multistix 10 SG urine dip stick (Siemens 
Healthcare Diagnostics Inc., UK) was quickly immersed into the urine sample and levels of 
ketone bodies were assessed automatically on a Siemens Clinitek Status® Analyser 
(Siemens Healthcare Diagnostics Inc., UK). Ketone bodies are produced mainly in the 
mitochondria of the liver cells in response to glucose unavailability. Therefore, ketone bodies 
levels are high during energy restriction. The measurement of ketone bodies was an 
inexpensive and rapid method to assess compliance to the LCD.  
2.3.4.2 Difference between predicted and observed weight loss 
Daily required energy intake (REI) to maintain body weight was calculated as REI=REE*1.55 
with daily REE estimated by the Horie-Waitzberg Gonzalez equations based on body mass 
and FFM. FFM was calculated by difference between body mass and total adipose tissue 
mass measured by MRI. Daily energy deficit (ED) was calculated as ED= REI - EI during the 
pre-operative diet (810kcal for the 2-week and 6-week Cambridge low-calorie diets, 
1000kcal for the control diet).  From daily ED, daily minimal and maximal predicted weight 
loss were calculated as ED:9 and ED:4 to account for differences between lipid and 
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carbohydrate or protein oxidation. Weekly observed weight loss was compared with weekly 
minimal and maximal predicted weight loss. 
2.4 Evaluation of energy expenditure and substrate oxidation 
To determine energy expenditure and substrate oxidation, indirect calorimetry was used. 
Indirect calorimetry is an accurate method for estimating energy expenditure from the 
consumption of oxygen and the production of carbon dioxide during rest or steady state 
exercise. Continuous values of pulmonary gas exchange are measured in an open or closed 
circuit (Simonson and DeFronzo, 1990).  
2.4.1 Acquisition of data 
Upon arrival in the morning, fasting participants were asked to empty their bladder and to 
subsequently collect all their urine into a container throughout the visit and at the end of the 
visit for the measurement of urinary nitrogen excretion from urea. The total time of urine 
collection was recorded. REE was measured at baseline and every hour for 3 hours by 
open-circuit indirect calorimetry (Gas Exchange Monitor, GEM Nutrition, Daresbury, 
Cheshire, UK). Before each measurement, the calorimeter was calibrated with „zero‟ (0.00% 
O2, 0.00% CO2) and „span‟ (20.00% O2, 1.00% CO2) gases (BOC Gases, Surrey, UK).  The 
volunteers were asked to lie in a semi-recumbent position under the canopy and were 
allowed to watch television, read or listen to music. The measurements were first allowed to 
stabilise for 10 to 15 minutes following which the VO2 and VCO2 were recorded every minute 
for 15 minutes. The mean of the last 10 VO2 and VCO2 measurements was calculated; any 
value exceeding mean ± 2SD was excluded.   
2.4.2 Estimation of energy expenditure 
REE was estimated from oxygen consumption and carbon dioxide production in a given time 
using the following equation by Weir (Weir, 1949): 
REE = (3.94 * VO2) + (1.11 * VCO2) – (2.17 * N) 
Where REE is in kcal per minute, VO2 is the volume of oxygen consumed in litres per 
minute, VCO2 is the volume of carbon dioxide produced in litres per minute, and N is the 
urinary nitrogen is in grams per minute.  
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2.4.3 Estimation of substrate oxidation 
Macronutrients are metabolised in the presence of O2 to produce CO2, H2O and heat. The 
ratio of CO2 produced to O2 consumed (VCO2/VO2), called the respiratory exchange ratio 
(RER) gives an accurate estimate of the proportions of carbohydrate and fat being oxidized:  
When 100% of carbohydrate is oxidized, the RER is 1.0 and when 100% fat is oxidized, the 
RER is 0.7. Measurements of O2 consumption and CO2 production were used to quantify 
substrate oxidation in the body (Frayn, 1983): 
CHO oxidation = (4.55 * VCO2) – (3.21 * VO2) – (2.87 * N) 
Fat oxidation = (1.67 * VO2) – (1.67 * VCO2) – (1.92 * N) 
Where CHO oxidation and fat oxidation are in grams per minute, VCO2 and VO2 in litres per 
minute and N in grams per minutes. 
2.5 Analysis of blood samples 
2.5.1 Collection of samples 
Sample collection was carried out by specific methods depending on the analysis. For each 
analysis, various additives were added before or after the collection of the sample and 
sample were centrifuged immediately or after clotting as shown on table 2.2.  
Table 2.2: Methodology for the collection and processing of samples 
Analysis 
Sample type and 
collection tube 
Additive Processing 
Glucose 
Plasma  
Gray vacutainer 
Potassium oxalate/ 
Sodium fluoride 
Immediate 
centrifugation 
Paracetamol 
Serum  
SST vacutainer 
Clot activator  
Gel for separating 
Clotting for 30 min at 
room temperature 
before centrifugation 
Insulin 
Serum 
SST vacutainer 
Clot activator  
Gel for separating 
Clotting for 15 min at 
room temperature 
before centrifugation 
Leptin 
Plasma 
Lithium heparin tube 
Lithium heparin 
Aprotinin
1
 
Immediate 
centrifugation 
GLP-1/PYY 
Plasma 
Lithium heparin tube 
Lithium heparin 
Aprotinin
1
 
Immediate 
centrifugation 
 
1
Aprotinin (Trasylol, Nordic Pharma): pancreatic trypsin inhibitor, [Trasylol]=20µL/ml of whole blood 
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Samples were centrifuged at 4000rpm (eq 2550 rcf, radius 145mm) for 10 min at 4°C and 
separated into aliquots before storage at -80°C until analysis. 
2.5.2 Glucose analysis  
The glucose analysis was performed in the department of biochemistry at Hammersmith 
hospital using an Abbott ci8200 analyzer (Abbott Diagnostics, USA). The method is 
enzymatic, using hexokinase and Glucose‐6‐phosphate dehydrogenase. In summary, 
glucose is phosphorylated by hexokinase. One micromole of NADH is produced for each 
micromole of glucose consumed. The NADH produced absorbs light at 340 nm and can be 
detected by spectrophotometry as an increased absorbance. The analyser gives back direct 
readings of glucose levels. The limit of detection is 0.139mmol/L.  
2.5.3 Paracetamol analysis 
Paracetamol analysis was used to estimate gastric emptying rate. Paracetamol is not 
absorbed in the stomach but rapidly absorbed once it reaches the small intestine. Upon 
absorption in the small intestine, paracetamol can be measured in the plasma and the peak 
paracetamol concentration can therefore be used to estimate gastric emptying. The 
acetaminophen (paracetamol) analysis was performed in the department of biochemistry at 
Hammersmith hospital using an Abbott Architect ci8200 analyzer (Abbott Diagnostics, USA). 
The enzyme, aryl acylamidase, cleaves the amide bond of the acetaminophen molecule to 
form p-aminophenol and acetate. p-aminophenol reacts with 8-hydroxyquinoline-5-sulfonic 
acid in the presence of manganese ions to form a coloured compound. The analyser reads 
the absorbance at 615nm which is directly proportional to the concentration of 
acetaminophen in the sample. The reportable range of the assay is 3 to 377µg/mL.  
The paracetamol method has been widely used to estimate gastric emptying in clinical trials. 
Studies have shown that paracetamol can be used as an inexpensive alternative to more 
invasive methods such as scintigraphy and polyethylene glycol dilution (Naslund et al., 2000, 
Glerup et al., 2007).  
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2.5.4 Radioimmunoassays 
2.5.4.1 Principles of radioimmunoassay 
Radioimmunoassays (RIA) were performed in the department of Medicine at Imperial 
College London with the assistance of other members of the research team and under the 
guidance of Prof M. Ghatei and A Hogben. Samples were assayed in duplicate to increase 
the accuracy of the results. A fixed concentration of labelled tracer (labelled antigen) was 
incubated with a constant dilution of antiserum. The concentration of antigen binding sites on 
the antibody was therefore limited and when unlabeled antigen was added, there was 
competition between the labelled tracer and the unlabelled antigen for the limited and 
constant antibody sites. The amount of tracer bound to antibody therefore decreased as the 
concentration of unlabelled antigen increased. After centrifugation, the amount of 
radioactivity was counted both in the supernatant containing the free tracer and the pellet 
containing the antibody bound tracer. The amount of unlabelled antigen in the sample was 
calculated from a standard curve made with increasing concentrations of standard 
unlabelled antigen.  
2.5.4.2 Insulin  
The insulin RIA was carried out using a Millipore Human Insulin Specific RIA Kit (Millipore 
Corporation, Billerica, USA) according to the manufacturer‟s specified protocol. The assay 
did not cross‐react with proinsulin; therefore true levels of insulin were measured. The assay 
was performed in a total volume of 700μl. The assay was incubated for 20 hours at room 
temperature before separation of the free from antibody bound label by secondary antibody. 
The limit of detection was 2.715µU/mL. Intra- and inter-assay variation was 3.2 % and 3.9 % 
respectively. 
2.5.4.3 Leptin  
The leptin RIA was carried out using a Millipore Human Leptin Specific RIA Kit (Millipore 
Corporation, Billerica, USA) according to the manufacturer‟s specified protocol. The assay 
was performed in a total volume of 700μl and incubated for 20 hours at room temperature 
before separation of the free from antibody bound label by secondary antibody. The limit of 
detection was 0.437ng/mL. Intra- and inter-assay variation was 5% and 4.5% respectively. 
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2.5.4.4 GLP-1 analysis  
GLP-1 concentrations were measured by a specific and sensitive in-house RIA (Kreymann 
et al., 1987). The antibody cross-reacted 100% with all amidated forms of GLP-1, but did not 
cross react with glycine extended forms [GLP1-37 and GLP7-37] or any other known pancreatic 
or gastro-intestinal peptide. The assay was performed in a total volume of 700μl and 
incubated for three days at 4ºC before separation of the free from antibody bound label by 
charcoal adsorption. The limit of detection was 7.5 pmol/l. The reported in-house intra- and 
inter-assay variation is 5.4% and 11.5% respectively. 
2.5.4.5 PYY analysis  
PYY concentrations were measured using a specific and sensitive RIA (Adrian et al., 1985). 
The assay measured the hormone fragment, PYY3-36, and the full length hormone, PYY1-36, 
both of which are biologically active. The antibody cross-reacted fully with the biologically 
active circulating forms of PYY but not with PP or other known gastro-intestinal hormones. 
The assay was performed in total volume of 700μl and incubated for three days at 4ºC 
before separation of the free from antibody bound label by secondary antibody. The 
detection limit of the assay was 2.5 pmol/l. The reported in-house intra- and inter-assay 
variation is 5.8% and 9.8% respectively. 
2.5.5 Estimation of insulin sensitivity and beta-cell function 
Numerous simple indices are available from the literature to estimate insulin sensitivity and 
beta-cell function. Four indices were used in this project in order to investigate changes in 
insulin resistance over the long-term (weight loss and body composition study) and compare 
insulin sensitivity and beta-cell output in response to a test meal (weight loss and body 
composition and mycoprotein studies) 
In the weight loss and body composition study, changes in hepatic insulin resistance were 
assessed using the Homeostatic model assessment (HOMA-IR). The HOMA-IR is an 
absolute measure of hepatic insulin resistance which is based on fasting measurement of 
glucose and insulin (Matthews 1985): 
HOMA-IR = (fasting glucose x fasting insulin) / 22.5 
Fasting insulin is in mU/L and fasting glucose in mmol/L. The estimate of insulin resistance 
obtained by the HOMA-IR correlates (r=0.88, p<0.0001) with estimates obtained by the 
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euglycaemic clamp method (Matthews et al., 1985) and has been validated as a simple test 
to measure insulin resistance in both normal volunteers and patients with impaired glucose 
tolerance or T2DM (Hermans et al., 1999).  
In the mycoprotein and weight loss and body composition studies, changes in post-prandial 
insulin sensitivity during a meal tolerance test were assessed by the Matsuda Index which 
is calculated by the following formula:  
Matsuda-SI = 10,000 / (square root [fasting glucose x fasting insulin x mean tolerance test 
glucose x mean tolerance test insulin]) 
Fasting and meal tolerance test glucose are in mmol/L and fasting insulin and meal 
tolerance test insulin are in mU/L. Participants completed a meal tolerance test at each visit. 
The Matsuda Index was shown to correlate (r=0.73, p<0.0001) with the rate of whole-body 
glucose disposal during an euglycaemic insulin clamp (Matsuda and DeFronzo, 1999). 
In both studies, beta-cell output was estimated using the insulinogenic index (IGI) which is 
calculated by the following formula (Seltzer et al., 1967):  
IGI = increment in insulin at 30 min / increment in glucose at 30 min 
Insulin is in mU/L, glucose in mmol/L and increments are calculated from basal values. The 
IGI is a ratio representing the increase in insulin release to the magnitude of the 
corresponding glycaemic stimulus. In non-diabetic subjects, the increase in insulin in 
response to oral ingestion of glucose is associated with a fast clearance of blood glucose. In 
mildly diabetic volunteers, the same glucose test results in delayed hyperinsulinemia 
associated with prolonged hyperglycaemia while in moderately diabetic subjects, the insulin 
release remains low despite greater hyperglycaemia. The IGI has been validated against 
estimates by both hyperinsulinemic euglycaemic clamp and intra-venous glucose tolerance 
test techniques (Tura et al., 2006, Hanson et al., 2000).  
In both studies, beta-cell function was estimated using the oral disposition index (Bergman 
et al., 1981). In healthy individuals with normal glucose tolerance, a reduction in insulin 
sensitivity is normally compensated by an increase in first-phase insulin secretion so that the 
product of both, named disposition index is a constant. In both studies, disposition index was 
calculated as: 
Disposition Index = Matsuda-SI x IGI 
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The oral disposition index was shown to be predictive of the development of T2DM in 
several studies (Utzschneider et al., 2009, Lorenzo et al., 2010).  
2.5.6 Biochemistry analysis 
Other analysis performed, including total cholesterol, HDL, LDL, triglycerides and glycated 
haemoglobin (HBA1C) were performed by the department of Biochemistry at Hammersmith 
Hospital. 
2.6 Methods for metabonomics  
Metabolic fingerprinting is a non-targeted method aiming to classify samples through pattern 
recognition. The method does not intend to identify differences in specific metabolites but 
rather take a „snapshot‟ of the whole profile of metabolites in a sample, aiming to compare 
patterns in response to environmental, genetic or nutritional alterations for example.  
2.6.1 Definitions and principles 
A metabolite is the product of a metabolic reaction. The dynamic collection of metabolites, 
which are intermediates and end products of regulatory cellular processes, is called the 
metabolome (Fiehn, 2002). Metabolomics is defined as a comprehensive analysis based on 
the non-biased identification and quantification of all the metabolites in a biological system 
(Fiehn, 2002). Metabolomics has been successfully used in research to study metabolic 
changes of living organisms in many areas of sciences such as pharmacology, toxicology, 
and more recently nutrition and medicine among others (Nicholson et al., 2002, Gibney et 
al., 2005, Matsubara et al., 2012, Floegel et al., 2013, Walsh et al., 2013). 
Metabonomics has been previously described as „the quantitative measurement of the 
dynamic multi-parametric metabolic response of a living system to pathophysiological stimuli 
or genetic modification‟ (Nicholson et al., 1999). As such, metabonomics aims to „detect, 
identify and quantify the history of time-related metabolic changes in an integrated biological 
system‟ (Nicholson et al., 1999).  
1H NMR is considered the gold-standard method for metabolomics because it combines 
relatively minimal sample preparation with high reproducibility and robustness (Fan et al., 
1997). Therefore, metabolic fingerprinting using 1H NMR (principles previously described in 
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Chapter 2 section 2.2.5.3) was used in urine and plasma samples in order to clarify the 
effects of mycoprotein compared with chicken on the metabolome.  
2.6.2 Preparation of samples and treatment of the data 
Sample collection was performed at Imperial College London Hammersmith Hospital 
research centre during mycoprotein investigations 2 and 3. Preparation of the samples was 
carried out at the University of Reading, Department of Food and Nutritional Sciences. 1H 
NMR analysis was carried out by Dr J Swann. I then manually pre-processed the NMR 
spectra including the phasing, baseline correction and calibration. Data treatment by 
Principal components analysis (PCA) and Orthogonal Partial least Square Discriminant 
Analysis (OPLS-DA) was carried out by Dr J Swann. Metabolites were identified with the 
help of Dr J Swann and Dr Isabel Garcia Perez. 
From the total of plasma samples from investigation 2, three plasma samples were retained 
for the purpose of the analysis: One fasting (-15min) and two post-prandial (30 min, 180 
min). Urine samples from investigation 3, collected over 3 hours following the consumption 
of mycoprotein and chicken (as described in Chapter 4 section 4.6.1) were retained for the 
analysis. 
Figure 2.3 illustrates the sequence of events followed during the metabonomics analysis.  
 
Figure 2.3: Sequence of events for the metabonomics analysis  
Key: 
1
H NMR: proton spectroscopy, PCA: principal component analysis, OPLS-DA: Orthogonal Partial 
Least Square Discriminant Analysis 
2.6.2.1 1H NMR Spectroscopy analysis and treatment of urine samples 
For each sample, 400μL urine was mixed with 200μL of pH 7.4 phosphate buffer before 
being prepared for the NMR spectroscopic analysis following the protocol described 
elsewhere by Beckonert et al. (Beckonert et al., 2007). 1H NMR spectroscopy was 
performed at 300 K on a Bruker 700 MHz spectrometer (Bruker Biospin, Karlsruhe, 
101 
 
Germany) using the following standard one-dimensional pulse sequence with saturation of 
the water resonance: relaxation delay (RD)-90°-t1-90°-tm-90°-acquire free induction decay 
(FID), where 90° represents the applied 90° radio frequency pulse, t1 is an interpulse delay 
set to a fixed interval of 3 ms, RD was 2 s and tm (mixing time) was 100 ms. Water 
suppression was achieved through irradiation of the water signal during RD and tm. Each 
urine spectrum was acquired using 8 dummy scans, 128 scans, 64K time domain points with 
a spectral width of 20 000 Hz. Prior to Fourier transformation, the FIDs were multiplied by an 
exponential function corresponding to a line broadening of 0.3 Hz. 
2.6.2.2 1H NMR  Spectroscopy analysis and treatment of serum samples 
For each sample, 200 µL serum was added to 400 µL of 0.9% saline. The serum samples 
were then prepared according to the method described previously (Beckonert et al., 2007).  
1H NMR spectra were recorded on the same Bruker 700 MHz spectrometer with a probe 
temperature of 300 K. Spectra were acquired from all samples using the one-dimensional 
pulse sequence with saturation of the water peak as with the urine samples. Each serum 
spectrum was acquired using 8 dummy scans, 128 scans, 64K time domain points with a 
spectral width of 20,000 Hz. Standard 1H NMR spectra yield information on both low and 
high molecular weight molecules.  
2.6.2.3 Pre-processing of NMR spectra 
The 1H NMR spectra were manually phased and baseline-corrected in Topspin software 
version 3.2 (Bruker Corporation, USA). Urine spectra were manually referenced to 
trimethylsilyl propionate (TSP) at δ 0.0, whereas serum spectra were referenced manually to 
the lactate at δ 1.33.  1H NMR spectra were then imported into Matlab and urine spectral 
regions occupied by water and urea (δ 4.45−6.95) were excluded. Serum spectral regions 
from δ 4.44 to 5.00 were also excluded. Finally, spectra were aligned and normalized to the 
sum (Dieterle et al., 2006) using a Matlab script developed in-house (Swann et al., 2011).  
2.6.2.4 Data treatment 
Pattern recognition techniques aim to compare fingerprints, find differences between classes 
(or groups of samples) and classify samples. All analyses were performed using SIMCA P. 
The following techniques were applied. 
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2.6.2.4.1 Principal Components Analysis (PCA) 
PCA is an 'unsupervised' technique to analyse metabolomics data. It is termed unsupervised 
because the class (group) of the sample is not included in the model. The principal 
components are linear combinations of the original descriptors, such that they are 
uncorrelated, and describe decreasing amounts of data variance (PC1>PC2>PC3) 
(Nicholson et al., 2002). However, due to the large variation in the data, a supervised 
method is usually applied afterwards as PCA is often able to show a trend of separation 
between classes but interpretation is eased by the use of supervised models. 
2.6.2.4.2 Orthogonal Partial Least Squares-Discriminant Analysis (OPLS-DA) 
An OPLS-DA algorithm was applied to the data sets. The OPLS model has been described 
elsewhere (Whelehan et al., 2006, Garcia-Perez et al., 2010, Bylesjo et al., 2006). In brief, 
the OPLS-DA method separates the variations in the data into orthogonal components, 
which represent variation unrelated to the objective, and correlated components or predictive 
variation, which are related to the objective. The orthogonal variation is the systematic 
variation which is not linearly related to the differences in class such as experimental 
variations which originate from instrumental, procedural, or biological variations. The OPLS 
method rotates the model so that the first OPLS component is purely related to the between-
class difference. The first component therefore is the „„predictive‟‟ component while the 
second, third, and subsequent components, termed „orthogonal‟, reflect within-class 
differences. Separating out the purely predictive variation into the first component does not 
change the accuracy of the model or its ability to predict new data but leads to much clearer 
interpretation using the „„pure‟‟ loadings of the first component, which are directly related to 
the class differences. 
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Chapter 3 
Changes in liver fat and body composition 
following diet- and surgically-induced weight 
loss in obese patients undergoing Roux-en-Y 
gastric bypass 
 
104 
 
Abstract 
Roux-en-Y gastric bypass (RYGB) is currently considered the gold-standard treatment for 
morbid obesity. Weight loss is recommended prior to RYGB to reduce liver size and risks of 
complications. However, there is no consensus on the optimal pre-operative diet type and 
duration.  This study aimed to compare the effect of a 2-week (2W) and a 6-week (6W) pre-
operative liquid formula low-calorie diet (LCD) with a low-carbohydrate, high-protein (C) pre-
operative diet prescribed routinely in bariatric clinics on intra-hepato cellular lipid content 
(IHCL), body composition and surgical outcomes in obese patients undergoing RYGB.  
Morbidly obese participants (n=29, 125.8±3.6kg) were randomised into one of the 3 pre-
operative diets (C, 2W LCD, 6W LCD). Participants attended a baseline (visit 1), post-diet 
(visit 2), 1-month post-RYGB (visit 3) and 6-month post-RYGB (visit 4) visit. Body 
composition and IHCL were assessed by magnetic resonance imaging (MRI) and 
spectroscopy (MRS). Fasting and post-prandial blood samples were collected for the 
measurement of glucose and insulin profiles. Surgical outcomes were assessed by a single 
surgeon blinded to the groups. Fasting and post-prandial appetite sensations and acute food 
intake during an ad-libitum meal were recorded. 
Weight loss in the C, 2W LCD and 6W LCD was 1.8%, 4.7% and 10.7% respectively. The 
weight loss closely matched predicted weight loss in the 2W LCD and 6W LCD group but 
was lower than predicted in the C group. IHCL was reduced by 40% in the 2W LCD 
compared with the control with no significant additional reduction in the 6W LCD group. 
Interestingly, IHCL did not reduce at 1 month post-RYGB in the 2W and 6W LCD groups. No 
differences in surgical outcomes were observed between groups. Significant reductions in all 
fat compartments and improvements in insulin sensitivity were induced by weight loss 
following RYGB. Participants experienced a decrease in appetite, which was associated with 
a reduction in food intake by 80% at 1-month and 61% at 6-month post-RYGB.  
The results suggest that a pre-operative LCD may be of great benefit to reduce IHCL prior to 
RYGB. Although these changes did not significantly improve surgical outcome in this cohort, 
the results may be of clinical relevance in the treatment of super obese patients or patients 
with increased abdominal adiposity prior to RYGB. Importantly, the results suggest that the 
conventional low-carbohydrate high-protein diet may not be strictly followed by patients and 
therefore does not induce significant changes in IHCL prior to surgery. 
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3.1 Introduction 
Obesity is associated with an increase in adipose tissue depots within the body. Fat 
distribution is of great importance in the risk of developing metabolic disease. Abdominal and 
especially visceral adipose tissue are strongly associated with increased risk of CVD and 
T2DM. Among the intervention strategies developed to reduce the incidence of obesity, 
metabolic surgery is currently the most effective at providing significant sustained weight 
loss. Laparoscopic Roux-en-Y gastric bypass (RYGB), one of the most common procedures 
performed, induces an average weight loss of 30% over 24 months and significant 
reductions in subcutaneous and visceral abdominal fat (Buchwald et al., 2009, Weiss et al., 
2009). The weight loss is attributed to a combination of effects including energy restriction, 
rearrangement of the gastro-intestinal (GI) tract, and modification of GI hormone and bile 
acids secretion (Pournaras et al., 2012, Ionut et al., 2013). Although weight loss cannot be 
predicted following the procedure, several factors have been associated with greater weight 
loss including male sex, younger age and pre-operative lean mass independently of age and 
sex (Robert et al., 2013). Despite its success, the procedure carries significant risks of peri-
operative and post-operative complications including wound or chest infection, bleeding, 
leakage, and thrombo-embolism (Flum et al., 2009).  
Most clinics currently require patients undergoing metabolic surgery to follow a pre-operative 
diet prior to the procedure in order to improve the surgical field-of-view and limit the risk of 
liver laceration. Patients are currently advised to use low energy diets varying from low 
carbohydrate-high protein diet, yogurt or milk diet, to low-calorie meal replacements while 
the duration of the diet varies between 4 days and 4 weeks. Low-calorie diets (LCDs), 
providing 800-1200kcal per day, have been widely used to induce acute weight loss over a 
short time. LCDs were shown to induce significant reductions in liver fat and metabolism in 
previous research and may therefore be of great use as a preparation for metabolic surgery. 
The present investigation will aim to investigate the effect of 3 different pre-operative weight 
loss diets on liver fat and body composition and their impact on surgical outcomes.  
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3.2 Purpose of the study 
3.2.1 Aim of the study 
The aim of this randomised controlled study was to investigate the effect of a 2-week and a 
6-week liquid formula 800kcal/day low-calorie diet compared with a low-carbohydrate high-
protein 1000kcal/day conventional food diet advised as a standard of care at Imperial Weight 
Centre on hepatic and pancreatic lipid content, body composition, and surgery outcomes in 
obese human adults undergoing gastric bypass surgery.  
3.2.2 Hypotheses 
Based on the available literature, it was hypothesised that the 6-week LCD would result in 
greater reduction in hepatic fat than the 2-week LCD and 2-week control diet. 
3.2.3 Outcomes 
The primary outcome of this study was the change in intra-hepatocellular lipid (IHCL) 
measured by 1H MRS between baseline and after the pre-operative diet before surgery 
between the 6-week LCD, 2-week LCD and 2-week control groups. 
The following secondary outcomes were investigated: 
 Changes in body weight, waist, hip, and neck circumference between the 3 
groups following the pre-operative diet and at 1 month and 6 months post-RYGB 
 Changes in body composition including total abdominal adipose tissue, visceral 
adipose tissue and fat free mass between the 3 groups following the pre-
operative diet and at 1 month and 6 months post-RYGB 
 Changes in pancreatic lipid content between the 3 groups following the pre-
operative diet and at 1 month and 6 months post-RYGB 
 Changes in glucose homeostasis and lipid profiles between the groups following 
the pre-operative diet and at 1 month and 6 months post-RYGB 
 Changes in appetite and food intake between the groups following the pre-
operative diet and at 1 month and 6 months post-RYGB 
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3.3 Methods 
3.3.1 Recruitment 
For the purpose of the study, participants were recruited from the Imperial Weight Centre 
waiting list for Roux-en-Y gastric bypass. I approached potential participants during normal 
bariatric clinic times and explained the purpose of the study. Potential participants were 
given the Participant Information Sheet (appendix 2). Participants who expressed their 
interest in the study were invited to attend a screening visit at Hammersmith hospital 
Imperial College clinical research facility to assess their eligibility for the study and give 
written, informed consent (appendix 3). The screening also involved answering questions 
about their medical history, including current medical problems, past and current 
medications, weight history, and psychological history. Participants were asked to fill in a 
variety of questionnaires including: 
 The MRI safety metal checklist (appendix 1) 
 The Three Factor Eating Questionnaire (TFEQ) (Stunkard and Messick, 1985)  
 The Dutch Eating Behaviour Questionnaire (DEBQ) (Van Strien, 1986)  
 The Barratt Impulsiveness Scale (Patton et al., 1995)  
 The Behavioural Approach System and Behavioural Inhibition System (BIS/BAS 
scale) (Carver and White, 1994)  
 The Positive and Negative Affect Schedule (PANAS) (Watson et al., 1988)  
 The Beck Depression Inventory-II (BDI-II) (Beck et al., 1996)  
Following this, a health screening was performed during which anthropometric 
measurements were taken. Females were asked to provide a urine sample for pregnancy 
test. At the end of the screening, eligible participants were randomised into one of the study 
groups. The eligibility was based on the criteria shown in figure 3.1. 
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Figure 3.1 : Eligibility criteria assessed during the screening visit 
Body shape was assessed visually and with a tape measure. In case of doubt, participants were 
invited to come for a scan „try‟ prior to the start of the study. History of depression was taken with the 
medical history and further confirmed by the Beck Depression Inventory II questionnaire. 
3.3.2 Randomisation 
Participants who were eligible to take part in the study were randomised into group 1, 2 and 
3. The randomisation was done by an independent member of the research team and was 
stratified by sex in order to prevent significant differences in sex ratio between groups.  
3.3.3 Sample size 
The present investigation was a pilot study therefore no power calculation was done. 
3.3.4 Design of the study  
Following randomisation, participants were invited to attend 4 main study visits as described 
in figure 3.2: 
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Figure 3.2: Design of the study over 6 months 
Participants were asked to attend 4 main visits:   
- VISIT 1: baseline visit 
- VISIT 2: pre-operative (post-diet) visit 
- VISIT 3: Post-operative short term visit (1 month post-surgery) 
- VISIT 4: Post-operative long-term follow-up visit (6 months post-surgery) 
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Between visit 1 and 2, participants were asked to strictly follow the diet that they had been 
allocated to. Compliance to the diet was assessed by short weekly review visits during the 
diet as described in Chapter 3 section 3.3.4.3. Group 1 followed an 810kcal LCD for 2 weeks 
prior to RYGB surgery. Group 2 followed an 810kcal LCD for 6 weeks prior to RYGB 
surgery. Group 3 followed a low-carbohydrate high-protein diet described in the next section.  
3.3.4.1 Sequence of events during the study visits 
3.3.4.1.1 Preparation for the study day 
Participants were asked to refrain from drinking alcohol and doing strenuous exercise for 24 
hours, and fast for 12 hours prior to their visit. Participants were asked to fill in a 3-day food 
diary before they attended a visit in order to assess baseline, diet, short-term and long-term 
post-operative energy and macronutrient intake. 
3.3.4.1.2 MRI and anthropometric measurements 
Participants arrived in the morning following a 12-hour fast. After signing the MRI metal 
checklist (appendix 1), participants were asked to change into provided scrubs. 
Anthropometric measurements were taken (as described in Chapter 2 section 2.2.1 and 
Chapter 2 section 2.2.2) including body weight, waist, hip, and neck circumference. 
Participants were taken into the MRI unit and invited to take position into the MRI scanner.  
Whole body composition including fat distribution, intra-hepatocellular (IHCL) and pancreatic 
lipid content were assessed by MRI, MRS and multi-echo imaging techniques as described 
in Chapter 2 section 2.2.5. 
3.3.4.1.3 Gut hormone profile 
Following the MRI, participants were taken to the Wellcome Trust NIHR Imperial College 
clinical research facility which will be further referred to as the research unit. Participants 
were first asked to provide a urine sample. Participants were then taken to a single room and 
invited to either sit or lie down on a bed according to their preference. A catheter was 
inserted by a trained research nurse, following which participants were given 30 minutes to 
relax. Two fasting baseline blood samples were taken at -15 and 0 minutes, following which 
participants were provided with a 380kcal milkshake (Complan, and 200mL of whole milk, 
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see appendix 4). Milkshake flavour was chosen during the screening visit and remained the 
same throughout the study for each participant. Participants were asked to consume the 
milkshake slowly over 15 minutes. Further blood samples were taken at 15, 30, 45, 60, 90, 
120, 150 and 180 minutes. At each time point, appetite scores were collected using VAS as 
shown in figure 3.3: 
 
Figure 3.3: Sequence of events during each study visit  
Participants arrive fasted in the morning and have their measurements taken prior to the MRI (60min). 
Following the MRI, participants are taken to the research unit for the blood sampling. Two baseline 
samples are taken at -15 and 0 min. Participants are then asked to consume a 380 kcal milkshake 
within 15 minutes. Further blood samples are taken at regular intervals. At the end of the visit, 
participants are offered an ad-libitum ice-cream meal. Visual Analogue Scores (VAS) of appetite and 
nausea are collected at every time point. 
At the end of the 3-hour post-prandial period, the catheter was removed by the nurse and 
participants were offered a large bowl of ice cream of their choice (Häagen-Dazs, see 
appendix 5) which they were asked to eat until they felt comfortably full for the assessment 
of ad-libitum energy intake as described in Chapter 2 section 2.3.1. The ice-cream was the 
same at each visit for a single participant. Participants filled in one last VAS to assess 
appetite before leaving the unit. Following both the milkshake and the ice-cream, three extra 
questions were added on the VAS on the tastiness, pleasantness, and sweetness of the 
meal. Similarly to other VAS, the scores ranged from „not at all‟ to „extremely‟. 
3.3.4.2 Low-calorie diet and control diet 
3.3.4.2.1 Control group  
Participants in the control group were advised to bring their pre-operative diet booklet 
provided by the bariatric dietitian (see appendix 6). The conventional low-carbohydrate high-
protein diet is designed to provide 800-1000kcal daily. I ensured that the participant had a 
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good understanding of the requirements of the diet by asking them to provide examples of 
meals that they would be having.  
3.3.4.2.2 Low-calorie diet 
Participants following the LCD diets were all given similar instructions on their pre-operative 
diet at the end of the first study visit. The LCD was explained orally and in an instruction 
sheet which was given to the participant (appendix 7). The LCD (Cambridge Weight Plan) 
included a range of shakes and soups ranging from 137 to 146kcal (appendix 8). 
Participants were advised to consume one meal replacement 4 times a day with a total 
allowance of 750mL of skimmed milk throughout the day, mixed into shakes or consumed 
fresh. Therefore, the diet provided a total energy content of 788 to 824 kcal per day. 
Participants chose their meals according to their preference for 7 days before coming back 
to the unit for their review visit and getting the meal replacements for the following 7 days.  
3.3.4.3 Review visits  
During the pre-operative diet, all participants attended review visits once per week (both 
LCD and control diet).  Participants in the 2-week LCD group and the 2-week control group 
attended 1 review visit and participants in the 6-week LCD group attended 5 review visits. 
The review visits consisted of a one-to-one interview during which various aspects of the diet 
were discussed such as compliance, difficulty, side-effects, and motivation. Motivational 
interviewing, encouragements and other communication techniques were used to improve 
motivation and future compliance. The visit was based on a non-critical approach which 
enabled participants to share the difficulties met during the diet as well as report any extra 
meals they may have had. Participants on the 2-week and 6-week LCD were also given their 
meal replacements for the next seven days. This enabled participants to change menus 
weekly to their liking. A urine sample was collected to check for ketone bodies. All 
participants were told that a urine sample would be collected at the review visit in order to 
assess their compliance to the diet. 
3.3.4.4 Pre-operative visit 
The pre-operative visit followed the same sequence of events as the first visit. The visit took 
place on the day before their surgery. Participants were asked to fill in an unweighed 3-day 
113 
 
food diary completed on the last 3 days of the pre-operative diet in order to assess diet 
compliance.  
3.3.4.5 Evaluation of the Roux-en-Y gastric bypass procedure  
Each surgical procedure was assessed retrospectively by the surgeon at the end of the 
surgery. To prevent variability in the results, it was decided that a single surgeon would 
operate on the research participants. The surgeon was experienced enough to perform the 
procedure on a patient of average BMI (40-50) with minimal stress and difficulty. However, 
due to unforeseen circumstances, the surgeon was replaced by another consultant who had 
similar surgical technique and experience on 3 occasions. Surgeons and assistant surgeons 
were blinded to the type of pre-operative diet that the subjects had been following. 
The surgery was assessed by a multi-part questionnaire which was based on questionnaires 
previously published by Anders Thorell‟s and David Edholm‟s groups (Edholm et al., 2011, 
Van Nieuwenhove et al., 2011). The questionnaire (appendix 9) consisted of 4 parts: part A 
included the participant‟s details and medical conditions, part B included the main outcomes 
of the procedure such as operating time, estimated blood loss, general difficulty of the 
procedure and liver laceration score, part C included anatomic details regarding the liver and 
the abdominal cavity as well as details of the surgery on 7 variables, and part D included 
complication ratings over the short and long terms. 
The scores for part B were combined into two overall scores: the anatomy of the liver (size 
and sharpness of the liver edge) and exposure of the hiatal region, were combined into a 
surgical field of view score; and the exposure, bleeding, difficulty in dissection, difficulty in 
reconstruction, surgical judgment, technical demand and psychological stress were 
combined into a complexity of surgery score. 
3.3.4.6 Post-operative diet 
No specific instructions were given to the participants as part of the study. Participants 
received advice from the Imperial Weight loss centre from the bariatric dietitian and had 
access to a booklet with instructions to follow on the post-operative diet. In summary, the 
booklet advises the following: 
 Liquid diet (day 1 – day 10): diluted fruit juices, smooth soup, high protein liquid 
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 Puree diet (day 11 – day 35): porridge, yogurt, scrambled eggs, pureed meat or 
fish, cream soup, blended vegetables 
 Soft diet (day 36 – day 48): soft vegetables and fruits, soft meat and fish, 
crackers and toasts 
3.3.4.7 Post-operative visit 
Participants returned to the research unit for their post-operative study visit 4 weeks post-
surgery. The sequence of events followed was similar to other visits to the exception that 
participants were offered up to 30 minutes to finish the milkshake. Participants were asked to 
fill in an unweighed 3-day food diary prior to the visit and to prepare in a similar way. No 
instructions on post-operative diet were given to the participants.  
3.3.4.8 Follow-up visit  
Participants returned to the research unit for their follow-up visit 24 weeks post-surgery. The 
sequence of events was similar to other visits. Participants were asked to fill in an 
unweighed 3-day food diary prior to their visit and to prepare in a similar way.  
3.3.5 Statistics 
The normality of the distribution of the data was tested by Kolmogorov-Smirnov normality 
test or assessed by Kurtosis and Skewness values (≤2.0 and ≥-2). Normally distributed data 
is presented as statistic mean with standard error of the mean. Non-normally distributed data 
is presented as geometric mean with 95% confidence interval.  
Differences within groups were assessed by repeated-measurement one way ANOVA 
followed by post-tests with Bonferroni corrections for normally distributed data or Friedman 
test followed by Dunns post-tests for non-normally distributed repeated data.  
Differences between groups were assessed by calculating percentage changes between 
visits in order to correct for baseline differences. Differences were compared using one-way 
ANOVA followed by post-test with Bonferroni corrections for normally distributed data or by 
Kruskal-Wallis test for unpaired non parametric data followed by Dunns post-test.  
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Differences in surgical analysis (difficulty of procedures, complexity of surgery and duration 
of procedure) were analysed by Univariate procedure to correct for the effect of age, sex, 
and pre-operative weight.  
All results were analysed on SPSS version 21 (IBM Corporation). Graphics were prepared 
using GraphPad Prism version 5.01 (GraphPad Software, Inc). 
3.4 Results 
3.4.1 Recruitment   
For the purpose of this report, analysis of the results was carried out on a sub-population of 
participants who had completed the study. Recruitment is on-going to complete the required 
sample size of 10 participants per group. Figure 3.4 shows the flow chart of the recruitment 
process from the initial contact to the completion of the study.   
Main reasons for ineligibility included size not permitting scanner fitting, significant condition 
which would affect the results or time commitment issues. Main reasons for withdrawal 
included time commitment, dislike of the meals or dislike of the procedures (MRI or blood 
sampling). Each analysis included the number of participant based on the recruitment flow 
chart. Comparison of baseline visit and pre-operative visit included 20 participants, 
comparison of baseline visit and 1-month post-operative visit included 19 participants and 
comparison of baseline visit and 6-month post-operative visit included 14 participants. 
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Figure 3.4: Flow chart representation of the recruitment  
Following recruitment, participants are randomised into one of the three pre-operative groups: Control 
(conventional low-carbohydrate high-protein diet prior to RYGB), 2W LDC (2-week low-calorie diet 
prior to RYGB), 6W LCD (6-week low-calorie diet prior to RYGB).  
117 
 
3.4.2 Baseline characteristics of the participants 
The baseline characteristics of participants who entered and completed the study are 
presented in table 3.1. The average BMI of the participants was 46.1±0.7 kg/m2. There were 
no significant difference between groups in baseline age, weight, BMI, hip and waist 
circumferences. 
Table 3.1: Baseline characteristics of participants who started and completed the study 
 CONTROL 2-WEEK LCD 6-WEEK LCD p-value 
All participants who completed VISIT 1 
N 7 9 8  
Sex ratio M:F 2:5 1:8 2:6  
Age (years) 40 (28-56) 40 (30-53) 46 (36-60) 0.57 
Weight (kg) 125.7 ± 7.6 126.9 ± 4.0 126.3 ± 5.1 0.99 
BMI (kg/m2) 45.2 ± 2.0 46.5 ± 1.0 46.3 ± 0.8 0.74 
Waist cir (cm) 132 ± 3 134 ± 3 130 ± 3 0.65 
Hip cir (cm) 132 ± 5 137 ± 2 136 ± 2 0.45 
Ethnic origin 
- White 
- Black  
- Other 
 
3 
0 
4 
 
8 
1 
0 
 
4 
1 
3 
 
All participants who completed VISIT 4 
N 6 4 6  
Sex ratio M:F 2:4 0:4 2:4  
Age (years) 40 (28-56) 36 (16-83) 51 (44-58) 0.37 
Weight (kg) 
124.5  
(106.3-145.8) 
125.6 
(112.0-140.8) 
125.2 
(111.2-141.0) 
0.99 
BMI (kg/m2) 44.9 (39.9-50.6) 47.2 (42.2-52.8) 46.5 (44.4-48.7) 0.74 
Waist cir (cm) 131 (124-139) 134 (122-148) 130 (120-140) 0.87 
Hip cir (cm) 132 (121-144) 137 (127-148) 136 (129-142) 0.83 
Ethnic origin 
- White 
- Black  
- Other 
 
2 
0 
4 
 
5 
1 
0 
 
4 
1 
2 
 
Data presented as mean ± SEM for all variables apart from age (geometric mean with 95% 
confidence interval of the geometric mean) 
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3.4.3 Body composition  
3.4.3.1 Changes in body mass  
3.4.3.1.1 Changes in body mass within groups 
Figure 3.5 shows the mean change in body mass for each group during the course of the 
study.  
 
Figure 3.5: Average body mass throughout the study 
Bar charts represent mean body mass with standard errors. **p<0.01 compared with baseline, 
***p<0.001 compared with baseline. Bar charts represent different n numbers. Analysis done on 
matched data. 
Changes in body mass following the pre-operative diet 
During the pre-operative diet, participants on the control diet lost an average of 2.3±0.5 kg (-
1.8%) (p=0.008 compared with baseline), participants on the 2-week LCD lost an average of 
6.0±0.5 kg (-4.7%) (p<0.0001 compared with baseline) and participants on the 6-week LCD 
lost an average of 13.6±1.0 kg (-10.7%) (p<0.0001 compared with baseline) as seen in 
figure 3.5. 
Changes in body mass at 1-month post-surgery 
At 1-month post-surgery, participants on the control diet lost an average of 12.5±3.5 kg (-
9.9%) from baseline (p=0.0003), participants on the 2-week LCD lost an average of 14.9±2.2 
kg (-12.0%) from baseline (p<0.0001) and participants on the 6-week LCD lost an average of 
21.1±1.6 kg (-16.6%) from baseline (p<0.0001) as seen in figure 3.5. 
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Changes in body mass at 6-month post-surgery 
At 6-month post-surgery, one participant (2W LCD group) was excluded from the analysis 
due to significant complications at 3 months, excessive weight loss (45kg), multiple 
admission to hospital, and planned re-operation in the following few months. Therefore only 
13 subjects were included in the analysis of body composition at 6-months. At 6-month post-
surgery, participants on the control diet had lost an average of 29.6±1.2 kg (-23.5%) from 
baseline (p<0.0001), participants on the 2-week LCD had lost an average of 33.4±0.6 kg (-
27.0%) from baseline (p<0.0001), participants on the 6-week LCD had lost an average of 
33.7±3.3 kg (-26.7%) from baseline (p=0.0002) as seen in figure 3.5. 
3.4.3.1.2 Comparison of body mass loss between groups 
Figure 3.6 shows the percentage body mass loss between visit 1 and 2 (during the pre-
operative diet), visit 2 and 3 (following RYGB), between visit 1 and 3 (from baseline to 1-
month post-surgery), and between visit 1 and 4 (from baseline to 6-month post-surgery). 
 
Figure 3.6: Comparison of percentage body mass loss between groups 
Comparison between: baseline and post-diet (A), post-diet and 1-month post-surgery (B), baseline 
and 1-month post-surgery (C) and baseline and 6-month post-surgery (D). Bar charts represent mean 
percentage body mass loss with standard errors. *** p<0.001, **p<0.01. Figures have different n 
numbers as specified in figure 3.4. 
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Comparison of the effect of the pre-operative diet between groups 
During the pre-operative diet, there was a significant effect of the diet on body mass 
percentage change (p<0.0001) as seen in figure 3.6 A. Participants in the 6-week LCD 
group lost significantly more weight than participants in the 2-week LCD group and 
participants in the control. Participants in the 2-week LCD group also significantly lost more 
weight than participants in the control group. 
The rate of the weight loss was similar in both 2-week LCD and 6-week LCD: At the end of 
the 2-week LCD, the 2-week LCD group had lost an average of 6.0 kg (-4.7%). After 2 
weeks of LCD (out of 6 weeks), the 6-week LCD group had lost an average of 5.7kg (-4.5%). 
The 6-week LCD group lost an average of 2.27 kg per week.  
Comparison of the effect of RYGB between groups 
There was no significant difference in percentage weight loss between the post-diet visit and 
the 1-month post-surgery diet (figure 3.6 B). However, between the post-diet visit and the 1-
month post-surgery visit, participants in the 6-week LCD group lost 7.5±0.8kg (-6.7%), 
participants in the 2-week LCD group lost 9.2±0.6kg (-7.8%) whilst participants in the control 
group lost 10.2±1.4kg (-8.3%). Although these differences were not significant they suggest 
that pre-operative weight loss may limit post-operative weight loss.  
Comparison of weight loss at 1-month post-surgery between groups 
The mean percentage body mass loss for each group between baseline and 1-month post-
surgery is shown in figure 3.6 C. The effect of the pre-operative diet remained significant at 
1-month post-surgery (p=0.0005) as seen in figure 3.6 C. Overall, the 6-week LCD group 
had lost significantly more weight than the 2-week LCD and control groups at one month 
post-surgery as seen in figure 3.6 C.  
Comparison of weight loss at 6-month post-surgery between groups 
There was no effect of the pre-operative diet 6-months post-operatively; the overall weight 
loss was similar for all groups. This confirms the results from 1-month post-surgery showing 
that pre-operative weight loss may be compensated for by reduced post-operative weight 
loss. However, only 13 participants were included in the analysis at 6 months therefore 
results should be interpreted with caution.  
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3.4.3.1.3 Overall weight loss for all groups combined 
Combining data from all completed participants showed that they lost an average of 
32.8±1.7kg which represents a 26.0±1.1% weight loss. The completed participants 
decreased their body weight from 125.8±3.6kg to 93.0±2.9kg (p<0.0001). 
3.4.3.2 Changes in anthropometric measurements 
3.4.3.2.1 Changes in waist circumference at the midpoint 
Changes in mean waist circumference measured at the midpoint for each group throughout 
the study are shown in figure 3.7. 
 
Figure 3.7: Waist circumference throughout the study 
Bar charts represent mean waist circumference with standard errors. *p<0.05 compared with 
baseline, **p<0.01 compared with baseline, ***p<0.001 compared with baseline. Bar charts represent 
different n numbers. Analysis done on matched data. 
Changes in waist circumference following the pre-operative diet 
At the end of the pre-operative diet, the control group had a non-significant reduction of 
0.4±1.5 cm (-0.2%) in their waist circumference from baseline (NS), the 2-week group had 
reduced their waist circumference by 6.9±1.6 cm (-5.3%) from baseline (p=0.0026) and the 
6-week LCD group had reduced their waist circumference by 7.9±1.3 cm (-6.0%) from 
baseline (p=0.001) as seen in figure 3.7. 
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Changes in waist circumference at 1-month post-surgery 
At 1-month post-surgery, the control group had reduced their waist circumference by 6.1±1.7 
cm (-4.7%) from baseline (p=0.015), the 2-week LCD group had reduced their waist 
circumference by 13.4±1.7 cm (-10.2%) from baseline (p=0.0003) and the 6-week LCD 
group had reduced their waist circumference by 14.1± 1.4 cm (-10.9%) from baseline 
(p<0.0001) as seen in figure 3.7. 
Changes in waist circumference at 6-month post-surgery 
At 6-month post-surgery, the control group had reduced their waist circumference by 
20.7±1.6 cm (-15.7%) from baseline (p<0.0001), the 2-week LCD group by 28.5±3.4 cm (-
21.4%) from baseline (p=0.0039) and the 6-week LCD group by 25.7±4.4 cm (-19.5%) from 
baseline (p<0.0001) as seen in figure 3.7. The aforementioned participant with significant 
complications was excluded from the analysis. 
Comparisons of changes in waist circumference between groups 
Figure 3.8 shows the difference in percentage reduction in waist circumference between 
groups. 
During the pre-operative diet, there was a significant difference in waist circumference 
percentage change between the 3 groups as seen in figure 3.8 A (p=0.0092): The 2-week 
and 6-week LCD groups had reduced their waist circumference significantly more compared 
with the control group with no significant differences between the 2-week and 6-week LCD 
groups. 
Following RYGB, no significant differences in waist circumference percentage change were 
observed between groups between the post-diet visit and the 1-month post-surgery visit as 
seen in figure 3.8 B. 
Between baseline and 1-month post-surgery, the percentage change in waist circumference 
remained significantly greater following the 2-week and 6-week LCD groups compared with 
the control group with no significant differences between the 2-week and 6-week LCD 
groups (p=0.0046) as seen in figure 3.8 C. 
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Between baseline and 6-month post-surgery, no significant differences in percentage waist 
reductions were observed between the 3 groups at 6-months post-surgery in line with results 
from weight loss as seen in figure 3.8 D. 
 
 
Figure 3.8: Comparison of percentage change in waist circumference between groups 
Comparison between: baseline and post-diet (A), post-diet and 1-month post-surgery (B), baseline 
and 1-month post-surgery (C), and baseline and 6-month post-surgery (D) Bar charts represent mean 
percentage change in waist circumference with standard error *** p<0.001. Figures have different n 
numbers as specified in figure 3.4. 
3.4.3.2.2 Changes in hip circumference 
At the end of the pre-operative diet, the control group had reduced their hip circumference by 
3.7±0.9 cm (-2.8%) from baseline (p<0.01), the 2-week group had reduced their hip 
circumference by 3.6±0.7 cm (-2.6%) from baseline (p<0.001) and the 6-week LCD group 
had reduced their hip measurement by 10.0±2.1 cm (-7.4%) from baseline (p<0.01).  
There was a significant difference in hip circumference percentage change between the 3 
groups between baseline and the post-diet visit (p=0.02): the 6-week LCD group had 
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significantly greater percentage reduction in hip circumference compared with the control 
group and the 2-week LCD group with no significant differences between the 2-week LCD 
and the control groups. 
At 1-month post-surgery, the control group had reduced their hip circumference by 7.5±1.0 
cm (-5.7%) from baseline (p<0.001), the 2-week LCD group had reduced their hip 
circumference by 9.6±0.8 cm (-7.0%) from baseline (p<0.001) and the 6-week LCD group 
had reduced their hip circumference by 15.7±2.1 cm (-11.6%) from baseline (p<0.001) 
The percentage change in hip circumference remained significantly greater in the 6-week 
LCD group compared with the control group, with the 2-week LCD group showing 
intermediate results (p=0.017). 
At 6-month post-surgery, the control group had reduced their hip circumference by 19.4±2.7 
cm (-14.5%) from baseline (p<0.001), the 2-week LCD group had reduced their hip 
circumference by 27.4±3.8 cm (-19.8%) from baseline (p<0.001) and the 6-week LCD group 
had reduced their hip circumference by 25.5±2.7 cm (-18.8%) from baseline (p<0.001). 
No significant differences in hip circumference reductions were observed between the 3 
groups at 6-months post-surgery. 
3.4.3.2.3 Changes in neck circumference during the pre-operative diet 
The percentage change in neck circumference during the pre-operative diet is shown in 
figure 3.9. 
 
Figure 3.9: Comparison of change in neck circumference (cm) during the pre-operative diet  
Bar charts represent mean change in neck circumference with standard error ** p<0.01 
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At the end of the pre-operative diet, there was a significantly higher reduction in neck 
circumference in the 6-week LCD group (-2.2±0.2 cm (-5.3%)) compared with the control 
group (-0.3±0.5 cm (-0.8%)) with the 2-week LCD group showing intermediate reduction (-
1.1±0.3 cm (-2.6%)) (p=0.0052) as seen in figure 3.9. 
3.4.3.3 Changes in body composition and fat distribution assessed by MRI 
3.4.3.3.1 Total adipose tissue 
Changes in total adipose tissue content throughout the study are shown in figure 3.10. There 
were no significant differences between groups in baseline total adipose tissue content (6W 
LCD: 69.5±2.7L, 2W LCD: 72.7±2.3L, Control: 71.0±5.6L). 
 
Figure 3.10: Total adipose tissue content throughout the study 
Data presented as mean with standard error. *p<0.05, **p<0.01, ***p<0.001 compared with baseline. 
Bar charts represent different n numbers. Analysis done on matched data. 
Changes in total adipose tissue following the pre-operative diet 
During the pre-operative diet, the control group lost 0.9±1.3L (-1.2%, NS) of total adipose 
tissue, the 2-week LCD group lost 3.6±1.0L (-5.2%, p<0.05) of total adipose tissue and the 
6-week LCD group lost 7.7±0.9L (-11.1%, p<0.001) of total adipose tissue as seen in figure 
3.10. 
Changes in total adipose tissue between baseline and 1-month post-surgery 
At 1-month post-surgery, the control group had lost 5.4±1.0 L of total adipose tissue (-7.3%, 
p<0.01), the 2-week LCD group had lost 9.1±1.7 L of total adipose tissue (-12.5%, p<0.001) 
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and the 6-week LCD group had lost 12.2±0.6 L of total adipose tissue (-17.6%, p<0.001) as 
seen in figure 3.10. 
Changes in total adipose tissue between baseline and 6-month post-surgery 
At 6-month post-surgery, the control group had lost 19.9±2.5 L of total adipose tissue (-
30.6%, p<0.05), the 2-week LCD group had lost 28.5±4.1 L of total adipose tissue (-37.3%, 
N too small to perform analysis) and the 6-week LCD group had lost 23.7±1.0 L of total 
adipose tissue (-34.1%, p<0.01).  
Comparisons of changes in total adipose tissue between groups 
Figure 3.11 shows the difference in percentage reduction in total adipose tissue content 
between groups. 
 
Figure 3.11: Comparison of percentage change in total adipose tissue content between groups 
Comparison between: baseline and post-diet (A), post-diet and 1-month post-surgery (B), baseline 
and 1-month post-surgery (C), and baseline and 6-month post-surgery (D) Bar charts represent mean 
percentage change in total adipose tissue content with standard error *p<0.05, **p<0.01. Figures 
have different n numbers as specified in figure 3.4. 
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During the pre-operative diet, the reduction in whole body fat was significantly higher in the 
6-week LCD group compared with the 2-week LCD group and the control group (p=0.0022) 
as seen in figure 3.11 A. 
Between the post-diet visit and the 1-month post-surgery visit, changes in adipose tissue 
content were not significantly different between groups as seen in figure 3.11 B. 
Between baseline and the 1-month post-surgery visit, the difference in whole body fat loss 
remained significant between the 6-week LCD group and the control group with the 2-week 
LCD group showing intermediate results as seen in figure 3.12 C.  
Between baseline and the 6-month post-surgery visit, changes in adipose tissue content 
were not significantly different between the control and the 6-week LCD group as seen in 
figure 3.11 D. No comparison could be made with the 2-week group due to the limited 
number of participants with 6-month data in this group.  
Total loss of adipose tissue 
Overall, participants in the study lost 22.9L (-33.1%) of adipose tissue from 69.1 L to 46.3 L. 
3.4.3.3.2 Fat-free mass loss during the pre-operative diet and following RYGB 
During the pre-operative diet, fat loss represented 54% of the weight loss for the 2-week 
LCD group and 51% of the weight loss for the 6-week LCD. 
At 6-month post-surgery, the mean total weight loss for all participants was 30.7±2.3 kg. Of 
this, adipose tissue loss represented 66.4% (20.0±1.1 kg or 22.2L) and FFM (by difference) 
represented 33.6%. FFM loss represented 32.4% in the 6-week LCD group and 34.4% in the 
control group and 35.2% in the 2-week LCD group (NS). 
3.4.3.3.3 Changes in subcutaneous and internal adipose tissue 
For the definition of fat compartments, please refer to Chapter 2 section 2.2.5.2. Total 
adipose tissue is composed of the sum of subcutaneous adipose tissue (SAT) and internal 
adipose tissue (IAT). Changes in SAT and IAT throughout the study for each group are 
shown in figure 3.12. 
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Figure 3.12: Subcutaneous (A) and internal (B) adipose tissue content throughout the study 
Data presented as mean with standard error. *p<0.05, **p<0.01, ***p<0.001 compared with baseline. 
Bar charts represent different n numbers. Analysis done on matched data. 
Changes in SAT and IAT following the pre-operative diet 
The pre-operative diet induced significant reductions in SAT content in the 6-week LCD 
group (baseline: 59.4±3.1L, post-diet: 52.4±2.9L, -11.7%, p<0.0001) and the 2-week LCD 
(baseline: 61.8±4.1L, post-diet: 58.7±4.2L, -5.2%, p<0.05) but not in the control group 
(baseline: 59.6±6.6L, post-diet: 58.8±6.4, -1.4%, NS) as seen in figure 3.12. During the pre-
operative diet, only the 6-week LCD group had a significant reduction in IAT (-0.76L, -7.7%, 
p<0.05) as seen in figure 3.12. 
Changes in SAT and IAT between baseline and 1-month post-surgery  
At 1-month post-surgery, the control group had lost 5.2±0.7L of SAT (-8.7%, p<0.001), the 2-
week LCD group had lost 8.4±1.1L of SAT (-13.1%, p<0.001) and the 6-week LCD group 
had lost 11.2±0.7L of SAT (-19.0%, p<0.001) compared with baseline as seen in figure 3.12. 
At 1-month post-surgery, again, only the 6-week group had a significant change in IAT 
content (-0.95±0.3L, -8.5%, p<0.05) compared with baseline as seen in figure 3.12. 
Changes in SAT and IAT between baseline and 6-month post-surgery 
At 6-month post-surgery, the control group had lost 17.3±2.1L of SAT (-32.3%, p<0.001), the 
2-week LCD group had lost 26.4±3.7L of SAT (-39.1%, N too small to perform analysis) and 
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the 6-week LCD group had lost 20.8±1.0 L of SAT (-35.6%, p<0.001) compared with 
baseline as seen in figure 3.12. 
At 6-month post-surgery, the control group had lost 2.6±0.4L of IAT (-23.5%, p<0.05), the 2-
week LCD group had lost 2.2±0.3L of IAT (-20.9%, N too small to perform analysis) and the 
6-week LCD group had lost 2.9±0.6L of IAT (-25.9%, p<0.001) compared with baseline as 
seen in figure 3.12. 
Comparison of changes in SAT between groups 
Figure 3.13 shows the percentage change in SAT content during the pre-operative diet and 
between baseline and 1-month after RYGB.  
 
Figure 3.13:  Comparison of percentage change in subcutaneous adipose tissue content 
between groups 
Comparison between: baseline and post-diet (A), post-diet and 1-month post-surgery (B), baseline 
and 1-month post-surgery (C), and baseline and 6-month post-surgery (D) Bar charts represent mean 
with standard error *p<0.05, **p<0.01, *** p<0.001. Figures have different n numbers as specified in 
figure 3.4. 
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There were significant differences in SAT content reduction between the 3 groups during the 
pre-operative diet (p=0.0001) (figure 3.13 A). There were no significant differences in SAT 
loss following RYGB (figure 3.13 B). Therefore, differences in SAT loss between groups 
were maintained at 1-month post-surgery (p=0.0002) (figure 3.13 C). No significant 
differences in SAT loss were found between the control and the 6-week LCD group at 6 
months post-surgery. The 2-week group could not be compared at 6 months due to the 
limited number of data in this group.  
Comparison of changes in IAT between groups 
Figure 3.14 shows the percentage change in IAT content during the pre-operative diet and 
between baseline and 1-month after RYGB. Graphs are represented as scatter plot because 
the variability of the data was large.  
 
Figure 3.14: Comparison of percentage change in internal adipose tissue content between 
groups 
Comparison between: baseline and post-diet (A), post-diet and 1-month post-surgery (B), baseline 
and 1-month post-surgery (C), and baseline and 6-month post-surgery (D) Bar charts represent mean 
with standard error. Figures have different n numbers as specified in figure 3.4 
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No significant differences in IAT content reduction were noted between groups during the 
pre-operative diet (figure 3.14 A), between post-diet and 1-month post-surgery (figure 3.14 
B), between baseline and 1-month post-surgery (figure 3.14 C), and between baseline and 
6-month post-surgery (figure 3.14 D). 
Total loss of SAT and IAT 
By 6-month post-surgery, overall, participants had lost an average of 20.6±1.4L of SAT (-
35%) and 2.62L (-25%) of IAT from baseline. 
3.4.3.3.4 Changes in abdominal adipose tissue content 
Abdominal adipose tissue is composed of the sum of abdominal SAT and VAT (Chapter 2 
section 2.2.5.2). Figure 3.15 shows an example of time-related changes in transverse 
abdominal images acquired by MRI in one participant. 
 
Figure 3.15: Transversal images of the abdomen acquired by MRI 
Images were acquired on a male participant approximately at the same level of the abdomen 
(assessed subjectively). Differences in subcutaneous abdominal and visceral adipose tissue can be 
seen between baseline (A) and post-diet (B), between post-diet (B) and 1-month post-surgery (C), 
and between 1-month-post surgery (C) and 6-month post-surgery (D). 
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Figure 3.16 A shows the changes in abdominal adipose tissue content in each group 
throughout the study. Abdominal adipose tissue content was divided into subcutaneous 
abdominal and visceral adipose tissue content shown in figure 3.16 B and 3.16 C. 
 
Figure 3.16: Abdominal (A), subcutaneous abdominal (B) and visceral (C) adipose tissue 
content throughout the study  
Data presented as mean with standard error, *p<0.05, **p<0.01, ***p<0.001 compared with baseline. 
Bar charts represent different n numbers. Analysis done on matched data. 
Changes in abdominal SAT and VAT following the pre-operative diet 
Following the pre-operative diet, abdominal SAT was reduced by 2.7±0.3L (-13.4%, 
p<0.001) in the 6-week LCD group, by 0.9±0.3L (-4.7%, NS) in the 2-week LCD group, and 
0.4±0.3L (-1.8%, NS) in the control group.  
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Following the pre-operative diet, VAT was reduced by 0.8±0.2L (-13.7%, p<0.05) in the 6-
week LCD group. Reductions in VAT following the pre-operative diet compared with baseline 
in the 2-week LCD group (0.3L, -5.5%, NS) and the control group (0.04L, 0.7%, NS) were 
not significant.  
Changes in abdominal SAT and VAT between baseline and 1-month post-surgery 
At 1-month post-surgery, abdominal SAT was reduced by 4.2±0.4L (-20.7%, p<0.001) in the 
6-week LCD group, by 2.4±0.3L (-10.8%, p<0.01) in the 2-week LCD group, and 1.6±0.2L (-
8.0%, p<0.001) in the control group compared with baseline as shown in figure 3.16. 
At 1-month post-surgery, VAT was significantly reduced in the 6-week LCD group (-15.7%, 
p<0.01) compared with baseline while differences were not significant in the 2-week LCD 
and the control group as shown in figure 3.16.  
Changes in abdominal SAT and VAT between baseline and 6-month post-surgery 
At 6-month post-surgery, abdominal SAT was reduced by 7.9±0.9L (-38.9%, p<0.001) in the 
6-week LCD group, by 8.4±1.3L (-40.5%, N too small to perform analysis) in the 2-week LCD 
group, and by 6.2±0.5L (-34.3%, p<0.05) in the control group, compared with baseline as 
shown in figure 3.16. 
VAT was reduced by 2.4±0.5L (-36.5%, p<0.001) in the 6-week LCD group, by 1.0±0.1L (-
23.3%, N too small to perform analysis) in the 2-week LCD group, and by 1.8±0.3L (-29.8%, 
p<0.01) in the control group, between baseline and the 6-month post-surgery visit as shown 
in figure 3.16. 
Comparison of changes in abdominal SAT and VAT between groups following the pre-
operative diet 
Figure 3.17 shows the percentage change in abdominal SAT and VAT content during the 
pre-operative diet. There was a significant difference in the change in abdominal SAT 
between groups: The 6-week LCD group lost significantly more abdominal SAT than the 
control and 2-week LCD groups (p=0.0002).  
Although differences in VAT loss were observed between groups during the pre-operative 
diet, these did not reach significance (p=0.22). 
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Figure 3.17: Comparison of percentage change in subcutaneous abdominal (A) and visceral 
(B) adipose tissue content during the pre-operative diet between groups 
Data presented as mean with standard error, **p<0.01, ***p<0.001 
3.4.3.3.5 Changes in adipose tissue distribution following RYGB 
Figure 3.18 shows the abdominal on peripheral, internal on subcutaneous and visceral on 
subcutaneous abdominal adipose tissue ratios at baseline, following the pre-operative diet, 
at 1-month post-surgery and at 6-month post-surgery. 
 
Figure 3.18: Fat distribution assessed by ratios throughout the study 
A: Abdominal:peripheral, B: internal:subcutaneous, C: visceral:subcutaenous abdominal. Data 
presented as mean with standard error, *p<0.05,**p<0.01, ***p<0.001 compared with baseline. Bar 
charts represent different n numbers. Analysis done on matched data. 
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Figure 3.18 A shows that the abdominal:periphery adipose tissue ratio was slightly 
decreased at 6-month post-surgery compared with baseline. However, the amplitude of the 
change was limited showing that abdominal and peripheral adipose tissue content decrease 
almost to the same extent. Figure 3.18 B and 3.18 C show that both internal:subcutaneous 
adipose tissue and visceral:subcutaneous abdominal adipose tissue ratios significantly 
increased following RYGB, showing that the proportion of the reduction in peripheral adipose 
tissue content is greater than the proportion of the reduction in IAT content both on the 
whole body scale and on the abdominal scale. 
3.4.3.4 Changes in hepatic and pancreatic fat content 
3.4.3.4.1 Intra-hepato cellular lipid content (IHCL) by MRS 
Figure 3.19 shows IHCL levels at each visit in the 3 groups. 
 
Figure 3.19: IHCL content throughout the study 
Data presented as mean with standard error. *p<0.05 compared with baseline,**p<0.01 compared 
with baseline, ***p<0.001 compared with baseline. Bar charts represent different n numbers. Analysis 
done on matched data. 
Baseline 
There were significant differences in baseline IHCL between groups (p<0.05) as seen in 
figure 3.19. Participants in the 6-week LCD group had significantly lower baseline IHCL 
(3.6% (2.1-6.4)) compared with participants in the control group (23.5% (8.0-68.9)).  
Participants in the 2-week LCD group had intermediate levels (8.4% (2.4-28.9)).  
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Baseline IHCL levels (log transformed) did not correlate with baseline body weight but 
correlated with baseline VAT content (r=0.54, p=0.014) and waist circumference (midpoint) 
(r=0.48, p=0.02).  
The variability in the data in the control group was due to two participants with high IHCL 
content (73.4% and 60.5%). 
Changes in IHCL during the pre-operative diet 
All participants had decreased IHCL content at the second visit apart from 3 in the control 
group. The percentage change in IHCL during the pre-operative diet was 0.1±8.3% in the 
control group (NS), -40±7.1% in the 2-week LCD group (p<0.01), and -67.4±9.1% in the 6-
week LCD group (p<0.01) as seen in figure 3.19.  
The percentage change in IHCL following the pre-operative diet was strongly positively 
correlated with the percentage change in body weight (r=0.72, p=0.0002). 
Changes in IHCL between baseline and 1-month post-surgery 
At 1-month post-surgery, the percentage change in IHCL from baseline was -26.4±15.1% in 
the control group (NS), -31.8±13.4% in the 2-week LCD group (NS), and -57.8±11.9% in the 
6-week LCD group (p<0.01) as seen in figure 3.19. 
Changes in IHCL between baseline and 6-month post-surgery 
At 6-month post-surgery, the percentage change in IHCL from baseline was -83.0±8.3% in 
the control group (p<0.01), -69.8±16.5% in the 2-week LCD group (p<0.05), and -88.1±3.5% 
in the 6-week LCD group (p<0.001) as seen in figure 3.19. 
Comparison of changes in IHCL between groups  
Figure 3.20 shows the percentage change in IHCL content during the pre-operative diet and 
between baseline and 1-month after RYGB. 
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Figure 3.20: Comparison of percentage change in IHCL content between groups 
Comparison between: baseline and post-diet (A), post-diet and 1-month post-surgery (B), baseline 
and 1-month post-surgery (C), and baseline and 6-month post-surgery (D) Bar charts represent mean 
with standard error *** p<0.001. Figures have different n numbers as specified in figure 3.4. 
Following the pre-operative diet, there was a significant difference in the percentage 
decrease in IHCL between the 3 groups (p=0.0001): Participants in the 2-week LCD group 
and 6-week LCD group had significantly greater percentage reduction in IHCL compared 
with participants in the control group (p<0.01 and p<0.001 respectively) as seen in figure 
3.20 A. There was no significant difference in percentage reduction between the 2-week 
LCD group and the 6-week LCD group.  
There were no significant differences in the percentage reduction in IHCL between groups at 
1-month (figure 3.20 C) and 6-month (figure 3.20 D) following RYGB. 
Interestingly, between the post-diet visit and the 1-month post-surgery visit, there was a non-
significant increase in IHCL in the 2-week and 6-week LCD group while IHCL decreased in 
the control group as seen in figure 3.20 B.  
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To illustrate this, images and corresponding spectra showing the time-related change in 
IHCL content in one participant in the 2-week LCD group are shown in figure 3.21. Images 
on the left show the position of the voxel in which IHCL was measured by spectroscopy. 
Graphics on the right show typical spectra acquired by 1H NMR spectroscopy. The first 
signal on the left arises from water and the signal on the right arises from lipid. The IHCL 
content, calculated as the proportion of the area under the lipid peak divided by the area 
under the water peak, is expressed as a percentage. In this participant, elevated baseline 
IHCL greatly reduced from 12% to 4% following the pre-operative 2-week LCD. However, 
IHCL content was increased to 8% at 1-month after surgery. At 6-month post-surgery, IHCL 
content was reduced again to 1%.  
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Figure 3.21: MR images and spectra showing IHCL in a participant throughout the study 
Images show the position of the voxel where spectroscopy-acquired IHCL was measured. The 
spectra on the right show signals arising from water and fat. The IHCL content is calculated as the 
proportion of the area under the lipid peak divided by the area under the water peak and expressed 
as a percentage. The participant was in the 2-week LCD group. 
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3.4.3.4.2 Pancreatic lipid content by multi-echo 
At 6-month post-surgery, results were only available for 3 participants in the 2-week LCD 
group. Results were available for 6 participants in the control group and 5 in the 6-week LCD 
group. Therefore, pancreatic lipid results are shown until visit 3 only (involving 7 participants 
in the 6-week LCD group, 6 participants in the control group and 4 participants in the 2-week 
LCD group) as seen in figure 3.22. 
 
Figure 3.22: Pancreatic fat levels throughout the study  
Data presented as mean with standard error.  
There were no significant changes in pancreatic lipid content throughout the study. The 2-
week and 6-week LCD did not affect pancreatic lipid content content. The minimum 
pancreatic lipid content observed at baseline was 0.51% and the maximum 38.6% showing 
great differences in pancreatic lipid content between participants at baseline. At baseline, no 
significant correlation was found between pancreatic lipid content (log transformed) and VAT 
or between pancreatic lipid content (log transformed) and HOMA-IR.  Changes in pancreatic 
lipid content during the pre-operative diet did not correlate with changes in body weight or in 
VAT content.  
Furthermore, no correlation was found between pancreatic lipid content (log transformed) 
and IHCL (log transformed) at baseline. This suggests that high levels of IHCL were not 
necessarily associated with high levels of pancreatic lipid content. Figure 3.23 shows 
transversal abdominal images acquired by MRI and corresponding multi-echo for 3 
volunteers with various levels of pancreatic and liver lipid content.  Volunteer 1 (figure 3.23 A 
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and 3.23 D) has high levels of liver fat and high levels of pancreatic lipid content. Volunteer 2 
(figure 3.23 B and 3.23 E) has high levels of IHCL and low levels of pancreatic lipid content. 
Volunteer 3 (figure 3.23 C and 3.23 F) has low levels of IHCL and low levels of pancreatic 
lipid content. This illustrates that liver and pancreatic lipid content do not follow a linear 
relationship.  
 
Figure 3.23: Magnetic resonance images with corresponding multi-echo images showing 
different liver and pancreatic lipid content 
A, B, and C are T1-weighted magnetic resonance images. D, E, F are corresponding multi-echo 
images showing volunteer with high liver fat and high pancreatic fat (D), high liver fat and low 
pancreatic fat (E) and low liver fat and low pancreatic fat (F). Fat levels are shown by colour scale 
(legend on the right) with high levels represented in yellow, orange, and red and low levels 
represented in blue 
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3.4.4 Lipid profiles 
Significant differences in lipid profile were observed between groups during the pre-operative 
diet as seen in figure 3.24. As expected from the weight loss, the 6-week LCD induced 
significantly greater percentage reductions in total cholesterol, triglycerides, and LDL 
compared with the control diet and significantly greater percentage reduction in total 
cholesterol and LDL compared with the 2-week LCD. However, the 6-week LCD diet also 
induced significantly greater percentage reductions in HDL. 
 
Figure 3.24: Comparison of percentage change in lipids profile during the pre-operative diet 
between groups 
Data presented as mean with standard error.  T Chol : Total Cholesterol, TriG : triglycerides, LDL : 
low-density lipoprotein, HDL : high-density lipoprotein. *p<0.05, **p<0.01, ***p<0.001 
At 1-month post-surgery, only differences in percentage total cholesterol change remained 
significant between the 6-week LCD group and the control group. 
To investigate the effect of surgery on serum lipids, the complete results for all groups were 
matched into one data set as seen in figure 3.25. Total cholesterol, triglycerides and LDL 
concentrations were significantly lower at 6-month following surgery compared with baseline 
whilst HDL concentrations were significantly lower at 1-month post-surgery compared with 
baseline but were back to baseline levels at 6-month post-surgery.  
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Figure 3.25: Serum lipid concentrations throughout the study in all participants 
A: total cholesterol, B: triglycerides, C: High-density lipoprotein (HDL), D: Low-density lipoprotein 
(LDL). All groups combined. Data presented as mean with standard error, *p<0.05, **p<0.01, 
***p<0.001. Data shown for completers only. 
3.4.5 Glucose and insulin profiles 
One participant from the 2-week LCD group was excluded from the glucose and insulin 
analysis because she could not finish the milkshake within 30 minutes at the 1-month post-
surgery visit. 
3.4.5.1 Plasma glucose concentrations 
Changes in plasma glucose concentrations following the pre-operative diet 
The effect of the pre-operative diet on plasma glucose concentrations in each group is 
shown in figure 3.26.  
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Figure 3.26: Plasma glucose concentrations and % change in AUC at baseline and post-diet  
A: control, B: 2-week LCD, C: 6-week LCD, D: % change in AUC. Data presented as mean with 
standard error 
The 6-week LCD induced a significant reduction in fasting plasma glucose concentrations 
(baseline: 5.9±0.3 mmol/L, post-diet: 4.8±0.2 mmol/L, p<0.05) and at 30min (baseline: 
6.9±0.3 mmol/L, post-diet: 5.5±0.3 mmol/L, p<0.05). Differences between baseline and post-
diet in the 2-week LCD and control group were not significant. No differences in glucose 
AUC following the pre-operative diet were noted in any of the groups.   
Changes in plasma glucose concentrations following RYGB 
Plasma glucose concentrations for the control group, 2-week LCD group and 6-week LCD 
group at each visit are shown in figure 3.27 
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Figure 3.27: Plasma glucose concentrations throughout the study  
A: control, B: 2-week LCD, C: 6-week LCD. Data presented as mean with standard error. *p<0.05, 
**p<0.01 compared with the baseline (Bonferroni corrections applied). Data shown for completers 
only. 
Plasma glucose concentrations were significantly changed following RYGB at 1-month and 
6-month post-surgery in all groups (significant interaction time*visit, p<0.0001 in the control 
group, p=0.03 in the 2-week LCD group, p<0.0001 in the 6-week LCD group).   
As shown in figure 3.27, following RYGB, glucose concentrations increased much faster and 
to a greater extent compared with baseline and the post-diet visits. Plasma glucose 
concentrations reached a peak at 30-45 min following RYGB while the peak was 
approximately between 45 and 90 min prior to surgery. Glucose concentrations decreased 
rapidly after peaking.  
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Changes in plasma glucose concentrations in all participants between baseline and 6-
month post-surgery 
Because the weight loss was equivalent in all groups at 6-month, the data was combined for 
all groups in one set. The results are shown in figure 3.28. 
 
Figure 3.28: Plasma glucose concentrations and AUC at baseline and 6-month following RYGB  
A: Plasma glucose concentrations, B: glucose AUC. All groups combined. Data presented as mean 
with standard error. *p<0.05,**p<0.01,***p<0.001 (Bonferroni corrections applied). Data shown for 
completers only. 
As described previously, following RYGB, plasma glucose concentrations increased rapidly 
following the ingestion of the test meal to reach a peak at 30 min and decrease thereafter as 
seen in figure 3.28 A. Plasma glucose concentrations were significantly lower at 90min and 
120 min compared with baseline. This was confirmed by the AUC as shown in figure 3.28 B, 
which was significantly decreased following RYGB (baseline: 1120±32mm2, 6-month post-
surgery: 1007±32mm2, p=0.002).  
Figure 3.29 shows changes in glycated haemoglobin (HbA1c) concentrations throughout the 
study. HbA1c levels were significantly lower at 6-month post-surgery compared with baseline 
(baseline: 44.3±1.7mmol/L, 6-month post-surgery: 37.1±1.3mmol/L, p=0.0006). 
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Figure 3.29: Fasting glycated hemoglobin concentrations at baseline and 6-month post-
surgery  
All groups combined. Data presented as mean with standard error. ***p<0.001 compared with 
baseline. HbA1c: Glycated hemoglobin. Data shown for completers only. 
3.4.5.2 Serum insulin concentrations 
Changes in serum insulin concentrations following the pre-operative diet 
Serum insulin concentrations at baseline and following the pre-operative diet in each group 
are shown in figure 3.30.  
The 6-week LCD induced a significant reduction in fasting serum insulin concentrations 
(baseline: 14.7 µU/L (8.2-26.1 µU/L), post-diet: 6.0µU/L (3.4-10.7 µU/L), p=0.031). 
Reductions in post-prandial insulin concentrations were also observed in the 2-week LCD 
and 6-week LCD group following the pre-operative diet but these were not significant. Both 
2-week and 6-week LCD induced significant reductions in insulin AUC compared with 
baseline.  No significant changes in fasting and post-prandial serum insulin concentrations, 
and insulin AUC were observed in the control group. 
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Figure 3.30: Serum insulin concentrations and % change in AUC at baseline and post-diet 
A: control, B: 2-week LCD, C: 6-week LCD, D: Percentage change in insulin AUC from baseline. Data 
presented as mean with standard error. *p<0.05, **p<0.01 
Changes in serum insulin concentrations following RYGB 
Serum insulin concentrations for the control group, 2-week LCD group and 6-week LCD 
group at each visit are shown in figure 3.31. 
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Figure 3.31: Serum insulin concentrations throughout the study  
A: control, B: 2-week LCD, C: 6-week LCD. Data presented as mean with standard error. *p<0.05, 
**p<0.01, ***p<0.0001 compared with baseline (B) or post-diet (PD) (Bonferroni corrections applied). 
Data shown for completers only. 
RYGB induced significant changes in serum insulin concentrations at 1-month and 6-month 
post-surgery in all groups as seen in figure 3.31 (significant interaction time*visit, p<0.0001 
in the control group, p=0.0006 in the 2-week LCD group, p<0.0001 in the 6-week LCD 
group).   
Insulin concentrations increased rapidly and to a greater extent following the test meal to 
reach a peak at 30-45 min. Consequently insulin concentrations following RYGB were higher 
at 15, 30 and 45 min. Insulin concentrations decreased rapidly after 45 min and were lower 
at 90 min following RYGB compared with baseline or post-diet. 
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Changes in serum insulin concentrations in all participants between baseline and 6-
month post-surgery 
Because the weight loss was equivalent in all groups at 6-month, the data was combined for 
all groups in one set. The results are shown in figure 3.32. 
 
Figure 3.32: Serum insulin concentrations and AUC at baseline and 6-month following RYGB  
A: Serum insulin concentrations, B: insulin AUC. All groups combined. Data presented as mean with 
standard error. *p<0.05,**p<0.01,***p<0.001 (Bonferroni corrections applied). Data shown for 
completers only. 
As described previously, following RYGB, serum insulin concentrations increased rapidly 
following the ingestion of the test meal to reach a peak at 30-45 min and decrease rapidly 
thereafter as seen in figure 3.32 A. Serum insulin concentrations were significantly higher at 
15, 30 and 45 min compared with baseline. This was confirmed by the AUC as shown in 
figure 3.32 B, which was significantly decreased following RYGB (baseline: 
15508±2423mm2, 6-month post-surgery: 10245±1059mm2, p=0.007). 
3.4.5.3 Markers of insulin sensitivity 
Changes in insulin sensitivity markers following the pre-operative diet 
Figure 3.33 shows the percentage change in Matsuda and HOMA-IR indices between 
baseline and after the pre-operative diet. Although differences did not reach significance, 
combined with the glucose and insulin data, they suggest that weight loss induced by LCD 
improves insulin sensitivity and reduces insulin resistance.  
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Figure 3.33: Comparison of percentage change in insulin sensitivity following the pre-
operative diet between groups 
A: Matsuda Index, B: HOMA-IR. Data presented as mean with standard error 
Changes in insulin sensitivity markers following RYGB 
Results were combined for all groups to investigate the effect of RYGB on markers of insulin 
sensitivity and insulin resistance. Figure 3.34 shows the changes in Matsuda, Insulinogenic, 
and Disposition indices as well as the HOMA-IR between baseline and 6-month post-
surgery.  
 
Figure 3.34: Insulin sensitivity and beta-cell function throughout the study 
A: Matsuda Index, B: Insulinogenic Index, C: Disposition index, D: HOMA-IR. Data presented as 
mean with standard error. All participants combined. *p<0.05, ***p<0.001. Data shown for completers 
only. 
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Following RYGB, there was a significant increase in Matsuda Index (baseline: 46.7 CI: 30.9-
70.5, 6-month post-surgery: 88.4 CI: 70.0-111.5, p=0.0004 for log transformed Matsuda) and 
a significant decrease in HOMA-IR (baseline: 2.9 CI: 1.8-4.6, 6-month post-surgery: 1.0 CI: 
0.7-1.3, p<0.0001 for log transformed HOMA-IR), suggesting significantly improved insulin 
sensitivity and reduced insulin hepatic resistance as seen in figure 3.34. There was a 
significant increase in Insulinogenic Index (baseline: 13.6 CI: 8.6-21.4, 6-month post-
surgery: 26.7 CI: 16.8-42.3, p=0.010 for log transformed Insulinogenic Index) and 
Disposition Index (baseline: 634 CI:463-868, 6-month post-surgery: 2358 CI: 1516-3668, 
p<0.0001 for log transformed Disposition Index), suggesting improved β-cell function 6-
month following RYGB. 
3.4.6 Leptin levels 
Fasting plasma leptin concentrations are shown in figure 3.35. 
 
Figure 3.35: Plasma leptin concentrations throughout the study 
Data presented as mean with standard error, *p<0.05, ***p<0.001 compared with corresponding 
baseline concentration. Bar charts represent different n numbers. Analysis done on matched data. 
Leptin concentrations at baseline 
There was no difference in leptin levels at baseline between the three groups as seen in 
figure 3.35. Baseline leptin concentrations were significantly correlated with total adipose 
tissue content (r=0.55, p=0.012) and strongly correlated with subcutaneous adipose tissue 
content (r=0.61, p=0.004). 
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Change in leptin concentrations following the pre-operative diet 
During the pre-operative diet, leptin levels significantly decreased by 31% in the 2-week LCD 
group (baseline: 60.9±10.2ng/mL, post-diet: 42.1±8.3ng/mL, p<0.001) and by 49% in the 6-
week LCD group (baseline: 51.2±7.2ng/mL, post-diet: 26.3±4.2ng/mL, p<0.001) but did not 
change significantly in the control group as seen in figure 3.35.  
Changes in leptin concentrations following the pre-operative diet were significantly correlated 
with changes in total adipose tissue (r=0.66, p=0.004) and more strongly correlated with 
changes in subcutaneous adipose tissue (r=0.69, p=0.002). 
Comparison of change in leptin concentrations following the pre-operative diet 
between groups 
Figure 3.36 shows the percentage change in leptin concentrations following the pre-
operative diet between the 3 groups. 
 
Figure 3.36: Comparison of percentage change in leptin following the pre-operative diet 
between groups 
Data presented as mean with standard error, ***p<0.001 
The percentage decrease in leptin concentrations was significantly greater in the 6-week 
LCD than in the control (p<0.001) with the 2-week LCD having an intermediate effect as 
shown in figure 3.36.  
Change in leptin concentrations following RYGB 
At 1-month post-surgery, the difference in percentage decrease from baseline between the 
6-week LCD (-61±4%) and control group (-31±5%) remained significant (p=0.007) in line 
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with previous findings on total and subcutaneous adipose tissue results. No significant 
differences in leptin concentrations between groups were noted at 6 months. 
3.4.7 Surgery outcomes 
3.4.7.1 Subjective assessment of the surgical outcomes 
3.4.7.1.1 Surgical field of view 
Mean size of the liver left lobe, sharpness of the liver edge and exposure of the hiatal region 
as well as the combined surgical field of view score are presented in figure 3.37. 
 
Figure 3.37: Subjective assessment of the liver size and surgical field of view between groups 
Surgical scores assessing the size of the liver, the sharpness of the liver edge and the exposure of 
the hiatal region (A) which are combined into one score showing the surgical field of view (B). Data 
presented as mean with standard error. For all scores, smaller scores represent better operating 
conditions 
Although the results suggest that differences were observed between the groups, these did 
not reach significance. For all group, the average surgical field of view score was less than 
6, which represents normal operating conditions (normal liver size, normal sharpness of the 
liver edge and normal exposure of the hiatal region). 
3.4.7.1.2 Surgery complexity 
Difficulty of surgery and complexity of surgery scores are shown in figure 3.38.  
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Figure 3.38: Subjective assessment of surgery difficulty and complexity of the procedure  
Surgery difficulty (A) was assessed by visual analogue scale score and complexity of surgery (B) was 
assessed by combination of 7 surgical factors. Data presented as mean with standard error.  
No significant differences between groups were observed even after correcting for body 
weight at operation. Furthermore, average scores for both difficulty of surgery and 
complexity of surgery were below the 50% limit showing that they were perceived by the 
surgeon as relatively straightforward procedures. There was a trend towards significant 
correlation between perceived difficulty and IHCL content at the time of surgery (r=0.43, 
p=0.06). 
3.4.7.2 Operative time 
The duration of procedures was averaged for each group and showed no significant 
differences between groups as seen in figure 3.39.  
 
Figure 3.39: Mean operative time between groups. 
Data presented as mean with standard error. 
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3.4.7.3 Complications rate 
In the first 4 weeks following RYGB, there were no complications in the 6-week LCD group. 
In the 2-week LCD group, one participant developed pneumonia at week 2. In the control 
group, one participant developed hypoxia due to lung atelectasis and was admitted to 
intensive care for 14 hours following surgery and one participant was admitted to accident 
and emergency twice for pain of unknown origin.  
Between week 4 and week 6, one participant in the 6-week LCD group had recurrent 
abdominal pain and was later (9-month post-surgery) treated for gallstones. One participant 
in the 2-week LCD was admitted to hospital 7 times. The participant stayed in hospital for 
over 5 weeks in total due to inflamed small intestine and loose staples in the stomach pouch 
and was unable to tolerate normal food intake for around 5-10 weeks. The participant was 
fed by enteral nutrition for over 2 weeks. By 6 months post-surgery, the participant had lost 
over 45kg and was excluded from the analysis. 
3.4.8 Energy intake and appetite ratings 
3.4.8.1 Acute energy intake  
Although large differences in food intake at the ad-libitum ice-cream meal were observed 
between groups at baseline, these were not significant (Control:  281±39 g, 2-week LCD: 
360±42g, 6-week LCD: 273±48g). No differences in acute food intake between groups were 
noted at any visit.   
The data was therefore compiled into one set. Mean energy intake for all groups was 
calculated at baseline, at the post-diet, at 1-month post-surgery and at 6-month post-surgery 
as shown in figure 3.40. 
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Figure 3.40: Mean food intake for all participants at each visit 
Bar charts represent mean with standard error. **p<0.01 compared with baseline, ***p<0.001 
compared with baseline. Data shown for completers only. 
There was a significant effect of the visit on energy intake (p<0.0001). Energy intake at the 
second visit (post-diet pre-operative visit) was significantly reduced by 19% (p=0.004). 1-
month post-operatively, energy intake was significantly reduced by 80% compared with 
baseline (p<0.0001). 6-month after the procedure, the energy intake was increased 
compared with the energy intake at 1-month post-operatively after the procedure (p=0.07) 
but energy intake remained 61% lower than at baseline (p<0.0001).  
3.4.8.2 Appetite scores 
Hunger, nausea, desire-to-eat, prospective food intake, and fullness scores over time with 
corresponding AUC can be seen in figure 3.41 and 3.42. All participants were combined into 
one data set of data as no differences between groups were seen before and after RYGB. 
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Figure 3.41: Appetite scores and corresponding AUC for all participants throughout the study 
Visual analogue scores for hunger (A), nausea (C), and desire-to-eat (E) at each visit with 
corresponding area under the curve (AUC) for hunger (B), nausea (D) and desire-to-eat (F). Data 
presented as mean with standard error. ***p<0.001 and **p<0.01 compared with baseline. Data 
shown for completers only. 
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Figure 3.42: Appetite scores and corresponding AUC for all participants throughout the study  
Visual analogue scores for prospective food intake (G), and fullness (J) at each visit with 
corresponding area under the curve (AUC) for prospective food intake (H), and fullness (K). Data 
presented as mean with standard error. ***p<0.001, **p<0.01, and *p<0.05 compared with baseline. 
Data shown for completers only. 
3.4.8.2.1 Fasting appetite scores 
Fasting score were significantly altered by surgery: Fasting hunger was lower at 1-month 
post-surgery compared with baseline (baseline: 43±6, 1-month post-surgery: 31±6, 
p=0.015). Fasting desire-to-eat was lower at 1-month post-surgery compared with baseline 
(baseline: 55±6, 1-month post-surgery: 40±6, p=0.036). Similarly, fasting prospective food 
intake was lower at 1-month post-surgery compared with the post-diet visit (post-diet visit: 
48±6, 1-month post-surgery: 30±4, p=0.015). Fasting scores were significantly higher at 1-
month post-surgery compared with baseline for nausea (baseline: 6±2, 1-month post-
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surgery: 11±4, p=0.007) and fullness (baseline: 22±3, 1-month post-surgery: 39±7, p=0.025). 
Differences in fasting scores between baseline and 6-month post-surgery visits and between 
1-month post-surgery and 6-month post-surgery were not significantly different. 
3.4.8.2.2 Effect of RYGB on appetite scores 
There was a clear effect of the surgery on all appetite scores as well as nausea scores. The 
effect of the visit was strongly significant for all appetite scores (p=0.0001 for hunger, 
p=0.0001 for nausea, p<0.0001 for desire-to-eat, p<0.0001 for prospective food intake, 
p<0.0001 for fullness). The interaction between time and visit was also significant for all 
appetite scores (p=0.04 for hunger, nausea p<0.0001, p=0.0005 for desire-to-eat, p=0.0012 
for prospective food intake, p=0.0003 for fullness). This shows that appetite scores were 
decreased both throughout the whole study day and also in response to the test meal. 
Differences between baseline and the 1-month visit were significant at almost every time 
point and are therefore not represented in figure 3.41 and 3.42.  
Figure 3.41 B D F and 3.42 H K show that participants had significantly increased fullness 
overall throughout the whole visit, and significantly decreased hunger, desire-to-eat and 
prospective food intake at 1 and 6 months post-surgery. Average nausea scores were high 
following RYGB reaching almost 60 at the 1-month post-surgery visit. In line with the food 
intake, appetite feelings were partly restored at 6-month post-surgery.  
The difference between 1 month and 6 months post-surgery did not reach significance in the 
post-tests. There was a trend towards increased fullness and decreased hunger, desire-to-
eat and prospective food intake at the second visit but this was not significant after 
correction for multiple comparisons.   
3.4.8.3 Energy intake from the 3-day food diary 
The average energy intake for 24-hour calculated from the 3-day food diaries is shown in 
figure 3.43.  
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Figure 3.43: 24-hour energy intake throughout the study  
Calculated from 3-day food diaries completed before each visit. Data presented as mean with 
standard error. **p<0.01 compared with energy intake from 2W LCD and 6W LCD groups at visit 2. 
Bar charts represent different n numbers. Analysis done on matched data. 
3.4.8.3.1 Baseline reported energy intake 
Although large differences in energy intake at baseline were observed between the 3 
groups, this was not significant due to the great variability of the data. In order to verify if 
energy intake was adequate at baseline, the ratio of resting energy expenditure (REE) and 
energy intake (EI) at baseline was compared with the Goldberg cut-off. The results showed 
that 7 participants were under the cut-off and 1 was over. Upon confirmation, the participant 
reported large over-eating prior to the start of the study in prevision of the dietary restrictions 
required by the pre-operative diet and the surgery. 
3.4.8.3.2 Reported energy intake during the pre-operative diet 
During the pre-operative diet, all groups reported significantly decreased energy intake at the 
post-diet visit compared with baseline. The 2-week LCD and the 6-week LCD consumed 
significantly less energy at the post-diet visit (2W LCD: 755kcal per day CI: 681-838 kcal per 
day, 6W LCD: 706 kcal per day CI: 564-884 kcal per day) than the control group following 
the conventional low-carbohydrate high-protein diet (1160 kcal per day CI: 879-1531 kcal per 
day). 
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3.4.8.3.3 Reported energy intake at 1-month and 6-month following RYGB  
Energy intake at 1-month post-surgery did not significantly differ from that of the post-diet 
visit. Although differences in energy intake between 1 month post-surgery and 6 months 
post-surgery were observed, these did not reach significance.  
Combining all data into one set, energy intake decreased from 2510±375kcal, to 688±56kcal 
at 1-month after RYGB (-73%) and 1001±84kcal 6 months after RYGB (-40%). 
3.4.9 Assessment of compliance during the pre-operative diet 
Minimal and maximal predicted weekly weight loss were compared against observed weekly 
weight loss for each participant as described in Chapter 2 section 2.3.5. Figure 3.44 shows 
the average weight loss compared with the minimal and maximal predicted weight loss for 
each group separately.  
 
Figure 3.44: Comparison of observed weight loss versus predicted weight loss following the 
pre-operative diet  
Data presented as mean with standard error. 
All participants from the 2-week LCD group had observed weight loss within the predicted 
range of weight loss. All participants from the 6-week LCD group apart from 1 had observed 
weight loss within the predicted range. The aforementioned participant outside the predicted 
range was 80g below the minimal predicted weight loss. Of the participants in the control 
group, only two out of 6 were within the predicted range of weight loss. The other 4 
participants were below the predicted range. 
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3.5 Discussion 
3.5.1 Weight loss, anthropometrics, and body composition 
This investigation showed that a weight loss of 10.7% and 4.7% are achievable in morbidly 
obese individuals prior to RYGB using a 6-week LCD and 2-week LCD respectively. Both 
LCD diets induced significantly greater weight loss than a conventional low-carbohydrate 
high-protein diet. Indeed, patients following the conventional low-carbohydrate high-protein 
diet had lower weight loss than the minimal predicted weight loss based on the energy 
content of the diet. This shows that patients may not be accurately following the diet despite 
this being explained by a bariatric dietitian prior to the operation and precise guidelines being 
given as a booklet. It is possible that patients over-estimate portions advised in the booklet 
or that they disregard the guidelines because of increased hunger. The results highlighted 
the fact that better guidelines need to be given to pre-operative patients on a conventional 
diet or that regular visits should be put in place in order to maintain compliance and 
adherence to the diet. The results may also suggest that the restriction in food choices 
during the LCD diet or the intensity of the LCD treatment may help to achieve better 
compliance and therefore weight loss in the short-term. Importantly, it should be 
acknowledged that the intensity of the treatment in the 6-week LCD group was greater than 
in the 2-week LCD and control groups. Indeed, the total number of visits was 10 in the 6-
week LCD group compared with 6 in both 2-week groups. This may have significantly 
contributed to the difference in results between groups but was necessary for the purpose of 
the study. 
The weight loss during the LCD was equivalent to a 2.3kg weight loss per week which is in 
line with previous results showing a weight loss of 1.5 to 2.5 kg per week using VLCD or 
LCD (Edholm et al., 2011, Lewis et al., 2006, Van Nieuwenhove et al., 2011, Fris, 2004). 
However, in the present study, 46% and 49% of the weight loss was from fat-free mass loss 
for the 2-week and 6-week LCD respectively. These numbers are much higher than findings 
from the previous literature which reported a fat-free mass loss of 26 to 37% during VLCD or 
LCD (Chaston et al., 2007). It is unclear why the fat-free mass loss was higher in this cohort 
but it could be hypothesised that it may be linked to the age of the participants (mean age 40 
and 46 in the 2-week and 6-week LCD) or to the limited amount of physical activity of the 
participants in the study. Unfortunately, the physical activity questionnaire was not 
completed at baseline, but basic information on activity levels was collected and showed that 
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apart from a few isolated cases, all participants did not undertake any regular activity apart 
from walking short distances. Most of them reported that they were active at home. 
Furthermore, these measurements may be confounded by hydration status. Although body 
water has been shown to decrease as overweight increases, the relationship is less clear in 
morbidly obese individuals, as most are subject to water retention (Gundersen and Shen, 
1966). It is possible that water retention in some participants significantly decreased during 
weight loss therefore resulting in the over-estimation of fat-free mass reduction. 
Waist and hip circumferences are considered of great importance in the study of obesity 
because they give a better picture of body fat distribution than body weight and BMI alone 
(NHI, 2000, Despres and Lemieux, 2006, Yusuf et al., 2005). The weight loss in the 6-week 
and 2-week LCD groups was associated with significant reductions in waist and hip 
circumference. Anthropometric measurements can be challenging in obese patients and 
results should therefore always be interpreted with caution. Indeed, the measurement of the 
waist circumference requires the palpation of the rib and the iliac crest (WHO, 2008a). In 
these morbidly obese patients, the palpation of the bone structure was challenging as well 
as occasionally uncomfortable or painful. Furthermore, the presence of a panniculus, a layer 
of subcutaneous adipose tissue lying underlying the corium, made the measurement difficult 
and highly variable in some patients. For similar reasons, the measurement of the hip 
circumference was also challenging. The 6-week LCD also induced significant reductions in 
neck circumference. This may be of great importance as increased neck circumference is 
associated with obstructive sleep apnoea and both are significant predictors of difficult 
intubation during the procedure (Ezri et al., 2003, Gonzalez et al., 2008, Kim et al., 2011, 
Magalhaes et al., 2013). As the 6-week LCD was the only pre-operative diet to induce 
significant changes in neck circumference, it may be advisable in patients with increased 
neck circumference and predictable difficulties in intubation that this pre-operative dietary 
regimen be followed. 
Differences in weight loss during the pre-operative diet were associated with significantly 
different reductions in total adiposity between groups. The LCD induced greater reductions 
in subcutaneous, abdominal, and subcutaneous abdominal adipose tissue.  Although 
differences in internal and visceral adipose tissue loss were observed between the groups, 
the differences were not significant. This could possibly be due to the final sample size of the 
study not being achieved yet. Indeed internal and visceral adipose compartments are of 
relatively limited size compared with the subcutaneous and subcutaneous abdominal 
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compartments and therefore a larger number of participants might be needed to get 
significant results. There is limited data available in the literature investigating changes in 
whole body and separate adipose compartments during weight loss by LCD. Previous 
studies suggest that during short-term weight loss, there is a preferential loss of intra-
abdominal adipose tissue over subcutaneous adipose tissue (Kamel et al., 2000, Chaston 
and Dixon, 2008, Fujioka et al., 1991, Goodpaster et al., 1999). The results from the present 
study showed similar reductions in visceral versus subcutaneous abdominal adipose tissue 
(-13.7% and -13.4% in the 6-week LCD, -5.5% and -5.7% in the 2-week LCD, -1.7% and -
1.8% in the control group). Interestingly, subcutaneous and internal adipose compartments 
showed comparable reductions during the pre-operative weight loss in the 2-week LCD 
group (-5.2% and -5.2%) while in the 6-week LCD, subcutaneous adipose tissue was 
reduced by 11.7% and IAT by 7.7%. This may suggest that following preferential loss of IAT, 
longer-term weight loss prioritises the loss of subcutaneous adipose tissue. However, this 
was not confirmed at the level of the abdomen as this study showed similar reduction in 
visceral and subcutaneous abdominal adipose tissues in the 2-week LCD but also in the 6-
week LCD group. At 6-month post-surgery, ratios of internal versus peripheral and visceral 
versus subcutaneous abdominal fat distribution were significantly higher than at baseline, 
showing that the loss of adipose tissue was proportionally greater in subcutaneous adipose 
tissue than IAT. Although participants experience great total weight loss, most of them did 
not report increasing their activity levels at 6 months, which may explain partly these results. 
Although results should be taken with caution as the number of completed participants to the 
date of the analysis was 14 (-1 with severe complications), it shows an overall weight loss of 
32.8kg equivalent to 26%. The weight loss at 6 month was composed of 66.4% adipose 
tissue loss and 33.6% fat-free mass loss which is in line with previous findings showing that 
fat-free mass loss varied between 22 and 33% depending on the studies (Chaston et al., 
2007). Previous study have suggested that increased pre-operative weight loss by LCD 
might results in improved compliance to the post-operative diet and greater total weight loss 
(Kadeli et al., 2012, Livhits et al., 2009). At the present time, the results from this study do 
not confirm this hypothesis as total weight loss was similar for all groups. The results 
suggest that following RYGB, individuals with greater amount of pre-operative weight loss 
lose weight slower and to a lesser extent than individuals with limited pre-operative weight 
loss.  
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3.5.2 Hepatic and pancreatic lipid content 
Baseline IHCL content correlated with VAT and waist circumference confirming that visceral 
adiposity is associated with increased ectopic fat accumulation. This is in line with previous 
findings showing that obese individuals with increased abdominal adiposity are at higher risk 
of developing NAFLD (Vernon et al., 2011, Chalasani et al., 2012). The 4.7% weight loss 
and 10.7% weight loss in the 2-week and 6-week LCD groups were associated with a 40% 
and 67% reduction in IHCL respectively. This is in line with previous studies showing that 
IHCL was reduced by 72.5% in participants following a 6-week 450-800kcal per day VLCD 
and that a 4-week LCD of 800-1100kcal per day induced a 7.5kg weight loss and a 40% 
reduction in liver fat (Edholm et al., 2011, Lewis et al., 2006). Interestingly, Lewis et al.‟s 
study showed no significant reduction in IHCL in patients without steatosis while the present 
study shows that even patients with very low baseline IHCL can achieve significant 
reductions in IHCL with weight loss. The reduction in IHCL was correlated with the total body 
weight loss but not with changes in visceral adipose tissue suggesting that the reduction of 
ectopic fat may take place independently of the reduction in VAT during weight loss.  
Interestingly, IHCL was not reduced in the first month following RYGB in the 2-week and 6-
week LCD group who had experienced large IHCL reduction prior to the operation. Previous 
studies have shown a close relationship between IHCL and insulin resistance whereby 
weight loss improves insulin sensitivity and concomitantly reduces IHCL. In this study, this 
relation was observed following weight loss induced by the pre-operative diet and at 6-month 
post-surgery. At 1-month post-surgery, however, no reduction in IHCL was observed despite 
significant improvement in insulin sensitivity. Such findings have been reported in previous 
studies and suggest that the relationship between IHCL and insulin sensitivity in the early 
dynamic phase following RYGB may not be as straightforward and simply due to energy 
restriction as during standard weight loss by energy restriction (Johansson et al., 2008). 
Unfortunately, although it is likely that patients achieved pre-operative weight loss in their 
study, the pre-operative weight loss was not reported in the study by Johansson and 
colleagues. Therefore confirmation that the relationship between weight loss, IHCL reduction 
and improved insulin sensitivity is maintained if pre-operative weigh loss is not achieved is 
not possible. In the 2-week and 6-week LCD groups, energy restriction following RYGB may 
result in lipid mobilisation from the visceral and abdominal adipose tissue and increased free 
fatty acids flux to the liver, consequently leading to a rise in IHCL. It is unclear why similar 
mechanisms did not occur without pre-operative weight loss. Because the control group had 
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significantly higher IHCL at baseline, it is possible that energy restriction may be the 
predominant mechanism of liver fat loss in patients with fatty liver disease following RYGB. 
In the study from Johansson et al., only participants with no specific hepatic disease disorder 
resulting in fatty liver were recruited, and their baseline IHCL content was 14.4%. In my 
study, participants in the 2-week and 6-week had a baseline liver fat content of 8.4% and 
3.6% respectively, while participants in the control group had a mean baseline IHCL content 
of 23.5%. Particularly, two participants had increased baseline IHCL of 73.4% and 60.5%. 
Further research will be needed to compare the effect of RYGB on IHCL in patients with fatty 
liver or relatively low baseline IHCL content.  
Previous studies have indicated that liver volume was significantly correlated with IHCL 
content and that changes in liver volume could be predicted by changes in IHCL (Lewis et 
al., 2006, Edholm et al., 2011). Although liver volume was not measured in this study, this 
suggests that reductions in liver volume had occurred by the end of the LCD. Liver volume 
may be calculated as future work from multi-slice abdomen images by manually selecting 
the liver perimeter on each slice and multiplying it with the slice thickness.  In Colles et al’s 
study, investigating the effect of a 12-week VLCD (456-680kcal/day), 80% of the reduction in 
liver volume was achieved within the first 2 weeks (Colles et al., 2006). In the present study, 
the 2-week LCD induced a significant 40% reduction in IHCL while another 4-week of LCD 
only achieved a further 27% reduction in IHCL which did not reach significance. The results 
from my study are not as striking as these from Colles et al. possibly because of the higher 
energy content of the diet in my study, or because they investigated liver volume while this 
study looked at liver fat content (Colles et al., 2006). However, it does suggest similarly that 
a 2-week LCD is sufficient to achieve significant reductions IHCL and that further weight loss 
may only present limited additional benefit in terms of liver fat reduction.  
Pancreatic fat at baseline was not correlated with IHCL content and VAT, which contradicts 
findings from previous studies (Le et al., 2011). Furthermore, in this study, changes in 
pancreatic fat during the pre-operative diet were not correlated with changes in body weight 
or VAT. Changes in pancreatic fat throughout the study did also not seem to follow a similar 
pattern to changes in liver fat. This is in contradiction with previous studies showing that 
weight loss induces significant reductions in pancreatic fat (Lim et al., 2011, Rossi et al., 
2012). In Rossi et al‟s study, an 8.9% weight loss induced a 42.3% reduction in pancreatic 
fat and a 84.1% reduction in IHCL while in Lim et al‟s study, an 8-week VLCD induced a 
significant 22.5% reduction in pancreatic fat (Rossi et al., 2012, Lim et al., 2011). However, 
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despite not experiencing a reduction in pancreatic fat, participants showed improved insulin 
sensitivity and lipid profiles following weight loss, suggesting that the relationship between 
pancreatic fat and metabolic profile may not be straightforward. The results were unexpected 
and it is unclear why pancreatic fat did not decrease following such significant changes in 
body weight. The acquisition of the images was done in a standardised way by using a 
similar part of the pancreas during each visit. However, the pancreas is a small organ and 
data acquisition is therefore more subject to respiratory motion, especially in obese 
individuals. To overcome this, data was acquired using multi-echo images as opposed to 
magnetic resonance spectroscopy which produces more robust results for pancreatic fat 
(Thomas et al., 2012). The results suggest that pancreatic lipid metabolism and liver lipid 
metabolism may not follow the same mechanisms as the decrease in liver fat did not 
correlate with a decrease in pancreatic fat. The measurement of pancreatic fat during 
intervention studies is a relatively new area, and more research will be needed to examine 
the relationship between pancreatic fat and weight loss during weight loss induced by energy 
restriction or by metabolic surgery.  
3.5.3 Changes in glucose homeostasis, lipids profile and leptin 
This study showed that differential changes in glucose homeostasis can be induced by both 
LCD and RYGB. The 6-week LCD reduced baseline glucose levels. However, baseline 
glucose concentrations were significantly more elevated in the 6-week LCD group compared 
with the 2-week LCD and control groups. It is difficult to compare the changes in the 6-week 
LCD group with changes in the 2-week LCD and control groups who had normal fasting 
glucose levels. Glucose profiles were not significantly affected by the pre-operative diet. 
Both 2-week and 6-week LCD significantly decreased insulin concentrations while no 
changes in glucose AUC were observed. The results suggest that insulin sensitivity was 
improved following the LCD but differences were not significant with the number of 
participants recruited. This is in line with previous findings (Hofso et al., 2011, Wing et al., 
1994, Lim et al., 2011). Although results from previous studies suggest a decrease in 
glucose levels following significant weight loss by dietary energy restriction, most studies 
included diabetic patients or patients with impaired glucose tolerance whereas participants in 
this study had normal glucose levels (Wing et al., 1994, Jackness et al., 2013, Lim et al., 
2011). This may explain why there was no significant decrease in glucose levels following 
weight loss.  
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Following RYGB, participants experienced an early rise in glucose and insulin 
concentrations, to a significantly higher extent than at baseline or after the pre-operative diet. 
Both glucose and insulin levels quickly returned to baseline within 90 min and were then 
significantly lower than at baseline or after the pre-operative diet. The changes were 
associated with improved insulin sensitivity, decrease fasting insulin resistance and 
increased beta cell output and function. This „leftward‟ shift in glucose and insulin profiles as 
well as the changes in insulin sensitivity indices have been documented in several previous 
studies (Falken et al., 2011, Hofso et al., 2011, Plum et al., 2011, Camastra et al., 2013). 
The increase in 1st phase insulin response is thought to be associated with supra-
physiological levels of incretin hormone GLP-1 following RYGB (Falken et al., 2011, 
Laferrere et al., 2008).  
As expected from the weight loss, both LCD and RYGB were associated with significant 
changes in lipid profiles. Reductions in total cholesterol, triglycerides, and LDL were 
significantly greater in the 6-week LCD group than the control and the 2-week LCD to a 
certain extent. Baseline leptin concentrations correlated with total and subcutaneous adipose 
tissue. Leptin concentrations decreased during the pre-operative diet in the 2-week and 6-
week LCD groups and following RYGB. Changes in leptin concentrations correlated with 
changes in total and subcutaneous adipose tissue contents which in line with previous 
findings (Korner et al., 2009, Considine et al., 1996). 
3.5.4 Surgical outcomes 
This study did not show any significant differences in the subjective assessment of surgical 
field of view, difficulty of the procedure, and complexity of the procedure. It is possible that 
the amplitude of the weight loss in the different groups was not sufficient to induce significant 
differences. Furthermore, other factors may influence these parameters to a further extent. 
For example, the 2-week and 6-week LCD failed to induce significant differences in visceral 
fat which may be of greater importance in the evaluation of the procedure complexity. 
Although increased pre-operative weight and BMI have been shown to be extensively 
associated with increased risks at surgery, there is limited evidence on the effect of 
increased weight and BMI on the procedure difficulty (Van Nieuwenhove et al., 2011, Flum 
et al., 2009, Mason et al., 1992). Also, only participants who could fit the MRI scanner were 
able to be included in the study. Although this was necessary in order to answer the main 
hypothesis of the study, it restricted the eligibility to relatively small obese patients. A similar 
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study in individuals of BMI 50 to 60 kg/m2 may have produced different results. In the study 
by Nieuwenhove and colleagues, the difference in surgery difficulty was limited (35 vs 26) 
and rated as relatively easy even though the study involved 298 patients undergoing RYGB 
following a control or 2-week LCD pre-operative diet (Van Nieuwenhove et al., 2011), 
therefore it is possible that my study was under-powered to investigate differences in 
surgical outcomes. 
This study showed no differences in the duration of the procedure between groups. 
However, results from previous studies suggest that the study was under-powered to 
investigate this variable therefore no conclusions should be drawn (Alvarado et al., 2005, 
Alami et al., 2007). Furthermore, while pre-operative weight loss has been shown to 
decrease procedure perceived difficulty in a large study, this was not associated with 
changes in operative time between the groups (Van Nieuwenhove et al., 2011).  While some 
studies showed that pre-operative weight loss reduces operative time, others have shown 
that it makes no difference (Cassie et al., 2011). Results may therefore be more dependent 
on the surgeon‟s experience. In this study, a single surgeon was designated to operate on all 
participants. However, the surgeon was replaced by colleagues on three occasions due to 
unforeseen circumstances and teaching commitments. In order to maintain the integrity of 
the data, results from other surgeons were excluded from the analysis. The surgeon who 
operated in the present study was highly experienced and operated on a large number of 
cases per year, which may explain why pre-operative weight loss did not make a difference 
in operative time. As a limitation to the study, it is possible that operative time, assessed 
retrospectively by the surgeon, may have not been accurate. Other studies often have 
specific guidelines for time recording whereby start time may be defined as the time of first 
incision on skin and finish time as last contact of stapler on skin or removal of all 
laparoscopic material from the body.  
Finally, this study was a small pilot study without sufficient data to draw from on the rate of 
complications between groups. Out of 14 completed participants, 4 developed early or later 
complications including one serious complication. Some studies have shown that pre-
operative weight loss may decrease the risk of post-operative complications while others 
found no difference in complication rates between control and pre-operative weight loss 
groups (Benotti et al., 2009, Alvarado et al., 2005, Cassie et al., 2011). 
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3.5.5 Changes in appetite and energy intake  
At baseline, the assessment of the food diaries showed that some participants were either 
under-reporting or, restricting their energy intake in anticipation of their surgery even though 
participants were specifically asked not to start dieting prior to the start of the study. 
Although these results do not affect the different response to the pre-operative diet, they 
may have accounted for baseline differences. 
This study showed that RYGB decreased acute food intake at an ad-libitum meal by 80% 
compared with baseline at 1-month post-operatively and this was increased to 61% from 
baseline at 6-month post-surgery. Hunger, desire-to-eat and prospective food intake 
followed the same direction and were significantly decreased at 1-month and 6-month post-
surgery. Conversely, fullness was significantly increased following RYGB. Analysis of the 3-
day food diaries showed a 73% and 40% reduction in energy intake at home at 1-month and  
6-month after RYGB respectively. Changes in appetite and energy intake may result from 
the combination of restriction due to the limited size of the gastric pouch, changes in taste 
(as the ad-libitum meal was ice-cream), or increased satiating gut hormones. As discussed 
in the general introduction, obesity is associated with a dysfunction of the homeostatic and 
non-homeostatic appetite systems : Obese individuals were shown to have lower fasting and 
post-prandial levels of anorectic hormones PYY and GLP-1 and therefore experience 
blunted satiety feelings following food intake and early return of hunger (Ranganath et al., 
1996, Batterham et al., 2003, le Roux et al., 2006b). RYGB has been shown to restore and 
even increase further than lean control the levels of PYY and GLP-1 which may contribute to 
the maintenance of weight loss over the long-term (Beckman et al., 2011, le Roux et al., 
2007, Korner et al., 2005). To extend the work, it would be of interest to measure GI 
hormones in the study to investigate whether differences in pre-operative weight loss induce 
differential changes in GI hormones post-RYGB.  
This study does not suggest that LCD has an effect on appetite and acute energy intake 
which is in line with previous findings (Lips et al., 2013, Plum et al., 2011). However, energy 
intake was significantly decreased at the second visit in all 3 groups. One simple reason for 
this may be that the second visit was scheduled the day prior to RYGB and that participants 
may have felt significantly more anxious than at baseline. Although this was not recorded on 
a visual analogue score, several participants reported anxiety orally during the visit. 
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Visual analogue scores of nausea were largely elevated at 1-month post-surgery. Nausea 
was reduced at 6-month post-surgery but remained greatly elevated compared with 
baseline. This could be due to increased post-prandial GLP-1 and PYY levels following 
RYGB. Indeed, several studies have shown that RYGB induces a supra-physiological 
increase in GI hormones GLP-1 and PYY, compared with pre-operative obese individuals 
and to lean individuals  (Korner et al., 2005, le Roux et al., 2007). PYY, GLP-1 and GLP-1 
agonists have been previously associated with nausea and vomiting and increased 
concentrations of GLP-1 and PYY following RYGB may therefore be responsible for the 
post-prandial nausea (Garber, 2011, Degen et al., 2005, Naslund et al., 2004).  This could 
also be due to the carbohydrate content of the test-meal inducing „dumping syndrome‟ in 
most participants, especially at 1-month after surgery. The „dumping syndrome‟ is a 
condition where the undigested hypertonic content of the stomach empties rapidly into the 
small intestine creating a shift of fluid into the intestinal lumen, causing any or a combination 
of the following symptoms: nausea, vomiting, cramping, diarrhoea, dizziness, palpitations 
(Machella, 1949). Early „dumping syndrome‟ has been associated with the mechanical 
distension of the jejunum while late „dumping syndrome‟ is thought to be associated with 
hypoglycaemia following hyperinsulinemia (Machella, 1949). While „dumping syndrome‟ may 
have caused significant discomfort in some participants, feelings of nausea returned to 
baseline before the end of the visit and it is unlikely that they would have affected energy 
intake at the ad-libitum meal. Furthermore, previous studies show that dumping syndrome is 
not been associated with further weight loss post RYGB (Mallory et al., 1996). 
3.6 Conclusion 
This study showed significant reductions in most fat compartments, IHCL, lipids and insulin 
profile following a pre-operative 6-week LCD although differences in visceral and IAT were 
not significant. The results suggest that the weight loss induced by conventional low-
carbohydrate high-protein diet may not be sufficient to induce significant changes in 
abdominal adipose tissue and IHCL prior to surgery. Weight loss during a 2-week LCD was 
intermediate and induced significant changes in most parameters. In particular, the reduction 
in IHCL reached 40% in the 2-week group and 67.4% in the 6-week LCD but the difference 
between the two groups was not significant suggesting that a 2-week LCD might be 
sufficient to reduced IHCL prior to RYGB in most patients. However, liver volume was not 
measured in this study and may show significant differences between the two diets. Liver 
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volume will be measured in all participants as future work and correlations with surgical 
outcomes will be tested.  
Excessive amounts of adipose tissue and increased liver fat are thought to increase surgical 
risk during abdominal laparoscopic surgery. The results of this study therefore suggest that 
the use of LCD might be useful in the prevention of peri-operative complications during 
RYGB. However, the changes may not be of clinical relevance in this participant cohort as 
the 2-week and 6-week LCD did not significantly decrease the perceived surgery difficulty or 
the operative time. It is possible that the study may be underpowered to investigate changes 
in surgical outcomes. Nevertheless, the results may be of clinical relevance in the treatment 
of super obese patients or patients with increased abdominal adiposity prior to RYGB 
therefore a similar study should be carried out using larger patients. 
The study confirmed previous findings that RYGB induces significant reduction in hunger, 
desire to eat and prospective food intake and induces significant greater feelings of fullness. 
Food intake was reduced by 80% at 1-month post-surgery and maintained at 61% from 
baseline at 6-month post-surgery. RYGB induced a great shift in glucose and insulin 
concentrations. The latest may be due to increased GLP-1 concentrations and this will be 
investigated as a future work.  
The number of enrolled participants did not reach the recruitment target and only 14 
participants completed the 6-month visit, which, unfortunately, limits the conclusions that can 
be drawn from the study. However, the study showed that a pre-operative LCD results in 
greater reduction in liver fat than the routinely prescribed pre-operative diet. Therefore 
following a pre-operative LCD may be of great benefit in individuals with increased 
abdominal adiposity or extremely obese patients with increased risks of complications. 
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Chapter 4 
Effect of mycoprotein on acute energy intake  
in overweight volunteers 
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Abstract 
Previous studies have shown that mycoprotein reduces appetite and improves glycaemic 
control acutely in healthy lean volunteers. This set of 3 randomised studies aimed to 
investigate whether mycoprotein reduces energy intake in a dose-dependent manner 
compared with a control protein in overweight individuals and whether this is associated with 
changes in gastro-intestinal hormones, gastric emptying, and substrate oxidation.  
In a pilot study (investigation 1), the effect of 10g, 20g and 31g of mycoprotein powder on 
energy intake was compared with whey protein. 9 fasting overweight participants were given 
test meals pair-matched for energy and macronutrient content containing mycoprotein or 
whey protein at breakfast and an ad-libitum meal 3 hours later. Fasting and post-prandial 
perception of appetite and blood samples were collected at regular intervals. The results 
showed that mycoprotein did not reduce energy intake acutely compared with whey protein.  
In investigation 2, 44g, 88g and 132g of mycoprotein paste was given in a risotto test meal to 
36 overweight volunteers and compared with isocaloric and macronutrient pair-matched 
chicken meals. The same protocol was followed. The high level of mycoprotein paste 
significantly reduced appetite by 10% at the ad-libitum meal and by 9% during the following 
24 hours. This was not associated with changes in GI hormones GLP-1 and PYY. Insulin 
concentrations were reduced following the consumption of mycoprotein compared with 
chicken whilst there were no changes in glycaemia. A third investigation was designed to 
explore the effect of mycoprotein on gastric emptying and substrate oxidation. 
In investigation 3, 132g of mycoprotein paste was compared with chicken. Resting energy 
expenditure and substrate oxidation were measured at regular intervals by indirect 
calorimetry. Gastric emptying was assessed by the paracetamol method. The results 
showed no significant difference in gastric emptying and substrate oxidation following 
consumption of mycoprotein compared with chicken.  
This study showed that mycoprotein paste reduces energy intake in overweight volunteers. 
A minimal dose of 132g of mycoprotein paste was necessary to reduce energy intake by 
10%. This study also confirms that both mycoprotein powder and paste improve insulin 
sensitivity. The mechanism remains, however, unclear.  
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4.1 Introduction 
Mycoprotein is a novel fungal food stuff, which combines high levels of protein and fibre and 
a complex food matrix. As discussed in Chapter 1 section 1.7.2, previous studies have 
shown that mycoprotein acutely reduces energy intake and improves glucose homeostasis 
and lipid profiles in lean individuals (Burley et al., 1993, Turnbull et al., 1992, Turnbull and 
Ward, 1995). The effect in overweight volunteers remains to be clarified. Although previous 
studies have used different amounts of mycoprotein; to date, no study has investigated 
whether mycoprotein exerts a dose-dependent effect on energy intake.  
Furthermore, the mechanism of action remains unclear. Previous work suggested that 
mycoprotein may delay gastric emptying and induce higher plasma GLP-1 concentrations 
(Marks LI, 2004).  Confirmation of whether the reduction in energy intake induced by 
mycoprotein is associated with changes in appetite hormones in needed. 
4.2 Aims and hypotheses 
4.2.1 Aims 
The main aim of the mycoprotein study was: 
 To compare the effect of mycoprotein on energy intake to equivalent levels of control 
protein 
Secondary aims of the study were: 
 To define the minimal level of mycoprotein eaten at a single meal which suppresses 
appetite in overweight volunteers 
 To investigate whether mycoprotein exerts a dose-dependent effect on appetite and 
ad-libitum energy intake 
 To determine whether changes in appetite are associated with changes in gut 
hormone levels. 
 To compare the effect of mycoprotein on glucose and insulin concentrations to 
equivalent levels of control protein 
 To explore the effect of mycoprotein on gastric emptying, energy expenditure and 
substrate oxidation 
 To investigate changes in metabonomics following the intake of mycoprotein 
compared with chicken 
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To answer these questions, a randomised, single-blinded, controlled trial was designed. 
Healthy overweight volunteers consumed three levels of mycoprotein or a control protein in a 
randomised order on separate occasions.  
4.2.2 Hypotheses 
The primary hypothesis of the study was that mycoprotein would reduce energy intake and 
appetite feelings further than the control protein (1). 
Supporting hypotheses were as follows: 
2) Appetite reduction following the consumption of mycoprotein will be associated with 
increased post-prandial levels of gut hormones such as GLP-1 and PYY  
3) There will be a dose-dependent decrease in energy intake with increasing mycoprotein 
dose 
4) Mycoprotein will lower glucose and insulin concentrations further than the control protein 
5) Mycoprotein will delay gastric emptying and increase fat oxidation compared with a 
control protein 
6) Mycoprotein will induce significant changes in the metabolome compared with the control 
protein. 
4.2.3 Clarification of aims for investigation 1, 2, 3 and 4 
Investigation 1 aimed to confirm hypotheses 1, 2, 3 and 4. Overweight volunteers (n=9) 
consumed 10g, 20g, and 31g of freeze-dried mycoprotein powder or whey protein soups 
pair-matched for macronutrient and energy content.   
Investigation 2 aimed to confirm hypotheses 1, 2, 3 and 4. Overweight volunteers (n=36) 
consumed 44g, 88g and 132g of mycoprotein paste (Quorn™) or chicken in a risotto pair-
matched for macronutrient and energy content.  
Investigation 3 aimed to confirm hypotheses 1, 4 and 5. Overweight volunteers (n=14) 
consumed 132g of mycoprotein or chicken risotto matched for macronutrient and energy 
content.  
Investigation 4 aimed to confirm hypothesis 6. The investigation consisted of a finger-printing 
analysis of urine and plasma samples following the intake of mycoprotein and chicken using 
metabonomics.  
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4.3 Design of the study 
4.3.1 Recruitment  
Advertisements were placed at Imperial College London and Imperial College NHS Trust 
sites, and in newsletters. Advertisements were also placed on websites such as Gumtree 
and in newspapers (Metro, The Evening Standard). Invitations were also sent to participants 
who met the inclusion criteria in The Sir John McMichael Centre, Hammersmith Hospital, 
healthy volunteer database. All advertising was done in agreement with the protocol 
approved by the West London Research Ethic Committee on July 27, 2009 (REC reference 
number 09/H0707/51). The Participant Information Sheet (appendix 10) was sent to 
volunteers prior to the screening visit. 
 
Figure 4.1: Inclusion and exclusion criteria for recruitment 
Inclusion and exclusion criteria were checked during the screening visit. *Stable weight defined as no 
variation greater than 5% of the weight within the past 6 months. DEBQ: Dutch Eating Behaviour 
Questionnaire. 
Following a telephone screening to check basic eligibility criteria (age, BMI), volunteers were 
invited to attend a screening visit to assess their suitability for the study and to give written, 
informed consent (appendix 11). Inclusion and exclusion criteria were assessed as 
described in figure 4.1. 
179 
 
Participants were invited to taste three commercially available ready-meals with similar 
macronutrient composition and rate them on a likeness scale. They were offered their 
favourite option during the visits providing that they did not rate it as ‘extremely like it’ to 
prevent over-consumption during the visit. 
4.3.2 Randomisation 
Following the screening, eligible participants were enrolled in the study. The randomisation 
of the visits was carried out by computer programme (Random.org, Randomness and 
Integrity Services Limited, Ireland) by a member of the research team, independent of the 
research project. 
4.3.3 Sample size calculation 
The sample size calculation was based on the study by Burley et al. as the design of this 
study was the closest to the design used in this work (Burley et al., 1993). Following an 
isocaloric meal containing 27g of protein from mycoprotein or chicken, they reported a 
significant 18% difference (s) in energy intake (kcal) with a standard deviation of 16 (δ) 
(chicken: 1350kcal ±397 in males, 909kcal ±223 in females, mycoprotein: 1025kcal ±367 in 
males, 778kcal ±276 in females, main effect of meal type p<0.01, main effect of sex p<0.02). 
The sample size n needed for this cross-over trial was advised by Mr Joseph Eliahoo, 
statistical consultant at Statistical Advisory Service, using the following:  
n = f(α,β)* 2s2 / δ2 = f(0.05,0.1)* 2*182 / 162 = 27 
(where α is the level of statistical significance and β the probability of the type-2 error) 
A sample size of n=27 subjects was therefore needed. To account for a 30% drop out, a 
minimum of 35 participants were recruited to take part in this study. 
4.3.4 Design of the study visits 
4.3.4.1 Sequence of events 
Participants were asked to come in for a study visit once per week, preferably on the same 
day with a minimal wash-out period of 4 days between two study visits. The first visit, during 
which an identical protocol was followed, was a training visit in order to reduce the effect of 
stress-induced changes on appetite hormone levels and ad-libitum energy intake 
(Chandarana et al., 2009).  
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The sequence of events during each visit is shown in figure 4.2. At each visit, volunteers 
were asked to arrive at 8.30am following a 12-hour fast. To limit the variability of baseline 
measurements, participants were asked to avoid drinking alcohol, to refrain from any 
strenuous exercise or unusual amount of food the day prior to their visit. Furthermore they 
were asked to consume the same meal in the same quantity before each visit to avoid the 
effect of evening meal variability on baseline hormone levels the following morning 
(Chandarana et al., 2009). 
 
Figure 4.2: Study day schedule 
Participants were asked to arrive at 8.30am following an overnight fast. The test meal was consumed 
between 0 and 15 minutes. Blood samples and visual analogue scales (VAS) were completed at 
regular intervals throughout a 3-hour period. An ad-libitum meal was served at 180 minutes. 
Upon arrival, participants had a cannula placed in the antecubital vein by a trained research 
nurse and were allowed to relax for 30 minutes before baseline measurements were taken. 
Subjective feelings of appetite were rated by the participant on visual analogue scales (VAS) 
throughout the study period as described in Chapter 2 section 2.3.2. Fasting blood samples 
and VAS were taken -15 and 0 minutes following which the test food was consumed within a 
10-minute timeframe. Blood samples and VAS were taken at 15, 30, 45, 60, 90, 120, 150 
and 180 minutes after the test meal as shown in figure 4.2. At the end of the study day, 3 
hours after the consumption of the test meal, the cannula was removed and subjects were 
invited to eat an ad-libitum standardised meal until they felt comfortably full. Participants 
were then free to leave the investigation unit but were asked to record their food intake 
during the next 24 hours in a food diary.  
4.3.4.2 Processing of the samples 
Plasma and serum samples were collected and processed at each time point for insulin, 
glucose, and gut hormone analysis as described in Chapter 2 section 2.5. Samples were 
stored at -20°C until analysis. 
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4.3.4.3 Ad-Libitum energy intake  
Participants were invited to consume an ad-libitum meal at the end of the visit. The same 
meal was served at the end of each visit. Energy intake was calculated from the 
manufacturer‟s nutritional information as described in Chapter 2 section 2.3.1. Meals were 
commercially available ready-meals approximately matched for macronutrient composition 
(chilli con carne, tomato and cheese pasta, chicken tikka masala)  
4.3.4.4 Visual Analogue Scales scores  
Visual analogue scales (VAS) were collected at regular intervals to assess hunger, nausea, 
desire to eat, prospective food intake and fullness as described in Chapter 2 section 2.3.2. 
The corrected Area Under the Curve (cAUC) was calculated for each scale. 
4.3.4.5 24-hour energy intake 
At the end of each visit, the volunteers were asked to complete an unweighed 24-hour food 
diary. Instructions and examples were provided to the participants and they were trained in 
completing the form before leaving the unit. Food diaries were analysed using DietPlan 6.50 
by an independent member of the Nutrition and Dietetics research team who was blinded to 
the randomisation of the visits as described in Chapter 2 section 2.3.3.  
4.3.5 Analysis of the results 
Analysis of plasma glucose, serum insulin and plasma GLP-1 and PYY were carried out as 
described in Chapter 2 section 2.5.4. 
4.3.6 Statistics 
All results were tested for Gaussian distribution by d‟Agostino and Pearson omnibus 
normality test. Normally distributed results are expressed as statistic mean ± standard error 
of the mean (SEM). Non-normally distributed data are presented as geometric mean with the 
95% confidence interval of the mean.  
All results were analysed by repeated-measurement linear mixed model unless otherwise 
stated. The main effects included protein type (chicken vs mycoprotein), protein level (low, 
medium, high) and time for time-related variables such as hormones and appetite time-
profiles. Relevant covariates, such as sex, age, BMI, and weight were included in the initial 
model and removed if their effect was not significant. For time-profile, the baseline value was 
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also included as a covariate in order to correct for baseline differences. Correlation matrices 
were chosen by assessing the model by -2 log likelihood. For each model, the distribution of 
the residuals was checked for normality. The homoscedasticity of the residuals was checked 
by plotting the observed values against the predicted values.  
When the mixed model was not validated, data was log transformed and analysed by mixed 
model or analysed directly by non-parametric tests. 
All results were analysed on SPSS version 21 (IBM Corporation). Graphics were prepared 
using GraphPad Prism version 5.01 (GraphPad Software, Inc). 
4.4 Investigation 1: mycoprotein compared with whey protein  
4.4.1 Design of the test meal 
For the purpose of this study, participants consumed a 455g mushroom-flavoured test soup 
containing low (7g), medium (11g) and high (16g) levels of protein from mycoprotein powder 
or whey protein isolate and a control soup with no mycoprotein or whey protein (2.5g protein) 
as described in table 4.1.  
The final protein content originated mainly from freeze-dried mycoprotein powder (44g of 
protein per 100g) or whey protein (87g of protein per 100g); and small amounts originated 
from full fat milk (26g of protein per 100g). 
Table 4.1: Quantities of mycoprotein and whey protein in the test meals 
Table shows quantities of mycoprotein powder or whey protein isolate in each of the test meal and the 
resulting protein content in the control, low, medium and high protein test meals. The final protein 
content originated from the combination of protein from full fat milk (26g of protein per 100g), 
mycoprotein powder (44g of protein per 100g) or whey protein isolate (87g of protein per 100g). 
 Quantity (g)  
Test meal 
mycoprotein 
powder 
whey protein  
isolate 
Final protein 
content 
High protein meal 31 15 16 
Medium protein meal 20 10 11 
Low protein meal 10 5 7 
Control meal 0 3 
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No previous study had investigated the effect of mycoprotein on appetite using dried 
mycoprotein powder, therefore the protein levels were chosen to compare with previous 
work using mycoprotein paste. In the study by Williamson et al., an equivalent of 10g 
mycoprotein powder induced significant reduction of appetite at 20 min but not at 4 hours 
(Williamson et al., 2006). This amount was therefore chosen as the minimal dose. In their 
studies, Turnbull and Burley used the equivalent of 32.5g and 37.5g of mycoprotein powder 
respectively (Turnbull et al., 1993, Burley et al., 1993). However, a dose of more than 30g of 
mycoprotein powder would possibly have a noticeable after-taste which would lead to 
significant changes in test meal palatability. The maximal dose was therefore set at 30g. 
The seven test meals were designed to be matched for serving size (55g powder + 400mL 
water). Viscosity, energy content (mean energy content 215kcal ± 3kcal) and fat content 
were matched as closely as possible for all meals. Protein and carbohydrate content were 
pair-matched at each protein level as closely as possible through the addition of fat powder 
and maize starch. Nutritional analysis of the final test meals is shown in table 4.2.  
Table 4.2: Nutritional analysis of the test meals 
 
Per serving 
 
Energy 
(kcal) 
CHO 
(g) 
Fat 
(g) 
Protein 
(g) 
Fibre 
(g) 
High MP 199 26.3 6.3 16.0 7.5 
High WP 217 26.4 5.5 15.6 0 
Medium MP 208 30.6 6.5 11.4 4.8 
Medium WP 220 30.4 6.0 11.3 0 
Low MP 215 35.3 6.1 6.9 2.4 
Low WP 224 34.6 6.4 7.0 0 
Control 221 40.6 5.5 2.5 0 
Meals were matched as closely as possible for energy content and fat. At each level, protein and 
carbohydrate content were pair-matched as closely as possible. Key: CHO, carbohydrates; MP, 
mycoprotein; WP, whey protein  
The main difference in composition resulted from dietary fibre naturally present in 
mycoprotein and the amino acid profile of the two meals. An approximate amino acid profile 
was determined from food tables and available internal data from Marlow Foods (Miller SA, 
184 
 
1999) for the two high protein meals and is shown in table 4.3. It was impossible to match 
the amino acid profiles of the two meals without adding isolated amino acids.  
Table 4.3: Essential amino acid profile of the mycoprotein and whey protein meal 
Amino acids content (mg) High WP High MP 
Histidine 222 477 
Isoleucine 835 708 
Leucine 1383 1171 
Lysine 1253 1130 
Methionine 287 286 
Phenylalanine 391 667 
Threonine 874 749 
Tryptophan 183 218 
Valine 770 844 
The table shows differences in amino acid content between the two meals. The whey protein was 
higher in isoleucine, leucine, lysine and threonine. The mycoprotein meal was higher in histidine, 
phenylalanine, tryptophan and valine. 
Soups were prepared using a hand blender (Russel Hobbs 13891, Spectrum Brands Ltd., 
UK) following a standard protocol as described in appendix 12 and served on separate 
occasions in a randomised order. 
4.4.2 State of the recruitment at interim analysis 
At 50% of the recruitment target, an interim analysis was carried out. A total of 13 overweight 
participants had been randomised into the study. Figure 4.3 shows the flow diagram of the 
progress from eligibility assessment to analysis.  
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Figure 4.3: Recruitment process from screening visit to interim analysis  
Age and BMI were checked by initial contact by phone or email and suitable volunteers were invited 
for a screening visit. Reasons for exclusion after the screening included wrong initial BMI estimation 
over the phone, abnormal blood count, medications or declined to participate when explained the 
study. Once enrolled onto the study, discontinuation reasons included dislike of the test meals, time 
commitment issues, and repeated difficulties with catheter insertion leading to significant discomfort 
for the participant. 
4.4.3 Results of investigation 1 interim analysis 
The interim analysis included 9 participants. As the study was a cross-over design, the 
analysis was based on a „per protocol‟ analysis, which means that participants who did not 
complete the whole of the study were excluded from analysis. 
4.4.3.1 Baseline characteristics of the volunteers 
The sample population is described in table 4.4. DEBQ restraint scores were elevated for 
most screened volunteers.  
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Table 4.4: Baseline characteristics of volunteers in investigation 1 
Age (years) 42 ± 6 
Sex 4 males / 5 females 
Height (cm) 173 ± 4 
Weight (kg) 84.4 ± 3.5 
BMI (kg/m2) 28.3 ± 0.6  
Ethnic origin 
       European 
       Asian 
       Black African or Caribbean 
 
6 
1 
2 
DEBQ restrain score (out of 50) 23.1 ± 3.1 
SCOFF score (out of 5) 0.8 ± 0.3 
Units of alcohol per week 6.7 ± 2.6 
Data presented as mean ± standard error of the mean.  
4.4.3.2 Energy intake at ad-libitum meal 
Energy intake at the ad-libitum meal is represented in figure 4.4.  
 
Figure 4.4: Energy intake at the ad-libitum meal  
The ad-libitum meal was served 3 hours following the whey or mycoprotein test meal. Data presented 
as mean ± standard error. Number of participants matched across groups (n=9) 
187 
 
4.4.3.2.1 Effect of the protein type on acute energy intake 
There was no significant effect of the type of protein (whey protein vs mycoprotein) on 
energy. Mycoprotein did not reduce energy intake at the ad-libitum meal compared with 
whey protein.  
4.4.3.2.2 Effect of protein level on acute energy intake 
There was no significant effect of protein level on energy intake, namely: a higher level of 
protein did not reduce energy intake further than medium and low levels of protein. 
4.4.3.3 Appetite scores 
Appetite scores are presented in figure 4.5.  
As expected, there was a significant effect of time (p<0.001) on hunger, desire-to-eat, 
prospective food intake and fullness.  
4.4.3.3.1 Effect of protein type on appetite scores 
There was no significant effect of the type of protein on any of the appetite feelings. 
Consequently, there were no significant differences in appetite cAUC between whey protein 
and mycoprotein overall and at each level separately. Mycoprotein did not induce greater 
satiety or reduce hunger compared with whey protein. 
4.4.3.3.2 Effect of protein level on appetite scores 
There was no significant effect of the level of protein on appetite scores over time. 
Consequently, there was no significant effect of the level of protein on any of the appetite 
cAUC overall and for mycoprotein and whey protein separately. A higher level of protein did 
not induce greater satiety than a lower level of protein in any of the meals. 
4.4.3.3.3 Nausea  
Analysis of the nausea scores over time showed a significant effect of time (p<0.001), type 
of protein (p=0.001) and time*type of protein interaction (p<0.001). Nausea scores following 
the consumption of the whey protein meals were significantly higher than those following the 
consumption of the mycoprotein meal. However mean nausea scores remained low (<20) 
throughout the visit and differences were due to individual cases. 
188 
 
 
Figure 4.5: Comparison of appetite feelings following the consumption of the test meal 
VAS scores for hunger (A), desire-to-eat (B), prospective food intake (C), and fullness (D) with 
corresponding corrected area under the curve for hunger (E), desire-to-eat (F), prospective food 
intake (G) and fullness (H). Data presented as mean ± standard error. Participants are matched 
across all groups (n=9 in each group). 
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4.4.3.4 Glucose concentrations 
Plasma glucose levels were compared between the control (NP), high mycoprotein (high 
MP) and high whey protein (high WP) protein meals. Plasma glucose concentrations are 
shown in figure 4.6.  
4.4.3.4.1 Time-profile of glucose concentrations 
  
Figure 4.6: Plasma glucose concentrations following the test meals 
NP: control, high WP:  high whey protein, and high MP: high mycoprotein. The test meal was 
consumed between 0 and 15min. Data presented as mean with standard error. Participant are 
matched across groups (n=9) 
There was a significant effect of the time (p<0.001) on glucose levels with levels increasing 
following ingestion of the meal and decreasing after 30 or 45 min.  
As expected from the carbohydrate content of the meals (NP: 40.6g, high MP: 26.3g, high 
WP: 26.3g) plasma glucose levels were significantly higher following the consumption of the 
control (NP) compared with both mycoprotein and whey protein meals (high WP, high MP). 
Post-tests with Bonferroni corrections showed significant differences between the NP meal 
and both the high WP and high MP meals at 30, 45, 60, and 180 min. At 15 min, glycaemia 
was significantly higher following the control meal compared with the mycoprotein meal (NP 
vs high MP, p=0.005) but not the whey protein meal. 
There were no significant differences in plasma glucose concentrations following the 
consumption of the high mycoprotein and high whey protein meals at any time-points. 
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4.4.3.4.2 Comparison of Area under the curve for glucose concentrations 
As expected from the time profile analysis, the AUC and cAUC were significantly higher 
during the control (NP) study visit compared with the high WP and high MP visits with no 
significant differences between high WP and high MP as described on table 4.5. 
Table 4.5: Comparison of glycaemic response by AUC and corrected AUC.  
 
NP HIGH WP HIGH MP p value 
Glucose AUC 1098 ( ± 48)a 1000 (± 38)b 994 (± 27)b 0.0013 
Glucose cAUC 168 (26)a 59 (11)b 46 (7)b <0.001 
NP: control, WP: whey protein, MP: mycoprotein. Data presented as mean with standard error. 
Values not sharing the same letters are significantly different (mixed model with Bonferroni 
corrections) 
4.4.3.5 Insulin concentrations 
Similarly to the glycaemia analysis, serum insulin levels were analysed during the control 
(NP), and high protein level (high WP and high MP) visits. Insulin concentrations are shown 
in figure 4.7.  
 
Figure 4.7: Serum insulin concentrations following test meal  
NP: control, high WP:  high whey protein, and high MP: high mycoprotein. The test meal was 
consumed between 0 and 15min. Data presented as mean with standard error. Participant are 
matched across groups (n=9) *p<0.05 adjusted for Bonferroni corrections 
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4.4.3.5.1 Time-profile of insulin concentrations 
As expected, the analysis showed a significant effect of time on insulin concentrations 
(p<0.001). Insulin concentrations increased following the ingestion of the test meal and later 
decreased after reaching a peak at 30 min. 
There was a significant effect of the type of protein * time interaction (p=0.021). Post-tests 
showed that serum insulin concentrations were significantly lower following the consumption 
of the high MP meal compared with high WP meal at 30min (p=0.047), and almost 
significantly lower at 45min (p=0.069). Serum insulin concentrations were also significantly 
lower following the high MP meal compared with the control (NP) at 45min (p=0.031). Serum 
insulin concentration were 38% (88.9 µU/mL (CI 64.1-113.7 µU/mL) vs 55.3 µU/mL (CI 30.3-
80.3 µU/mL)), 26% (123.7 µU/mL (CI 100.1-147.2 µU/mL) vs 91.5 µU/mL (CI 67.7-115.2 
µU/mL)) and 30% (111 µU/mL (CI 85.8-136.2 µU/mL)  vs 77.8 µU/mL (CI 52.4-103.1 
µU/mL)) lower at 15, 30 and 45 min respectively following the mycoprotein test meal than 
following the matched whey protein test meal after adjusting for baseline concentrations. 
No significant differences following the high whey protein and the control meals were found. 
4.4.3.5.2 Comparison of Area under the curve for glucose concentrations  
Insulin AUC and cAUC are reported in table 4.6.  
Table 4.6: Comparison of insulin response by AUC and cAUC  
 
NP HIGH WP HIGH MP p value 
Insulin AUC 9300 ( ± 1041)a 8957 (± 581)a 6846 (± 1154)b 0.0200 
Insulin cAUC 9490 (645)a 9310 (410)a 7510 (840)b 0.0123 
Data presented as mean with standard error. Values not sharing the same letters are significantly 
different (mixed model with Bonferroni corrections). NP: control, WP: whey protein, MP: mycoprotein 
The AUC and cAUC were significantly lower following the consumption of the high 
mycoprotein  meal compared with the control and high whey protein meals (p=0.02 and 
p=0.012 respectively). 
  
192 
 
4.4.3.6 Insulin sensitivity and beta cell function 
Insulin sensitivity, beta cell output and beta cell function as estimated using the Matsuda 
index, insulinogenic index and disposition index are presented in figure 4.8. Indices were 
only compared between the high protein meals with matched carbohydrate content.  
 
Figure 4.8: Insulin sensitivity following the consumption of the high protein meals 
A: Matsuda Index, B: Insulinogenic Index, C: Disposition Index. MP: Mycoprotein, WP: Whey protein. 
Data presented as mean with standard error. Participants are matched across groups (n=9) *p<0.05. 
Analysis of the Matsuda Index showed that insulin sensitivity was significantly improved 
following the consumption of the high MP meal compared with the high WP meal (high WP: 
59.4, CI: 47.1-74.8; high MP: 79.4, CI: 50.9-123.7; p=0.033 for log transformed data). The 
Matsuda index was 34% higher following the consumption of the mycoprotein meal 
compared with the whey protein meal.  
There was a trend towards significantly lower insulinogenic index following the consumption 
of mycoprotein compared with whey protein (high WP: 71.5 CI: 53.3-95.9; high MP: 50.9  CI: 
30.7-84.5; p=0.07 for log transformed data).  
There was no significant difference in disposition index following the consumption of the two 
meals.  
4.4.3.7 24-hour energy intake 
Energy intake, calculated from the 24-hour food diaries completed by each participant at the 
end of each visit, is presented in figure 4.9.  
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Figure 4.9: 24-hour energy intake following the study visit  
Energy intake was recorded by food diary for 24 hours following the study visit. Data presented as 
mean with standard error. Number of participants matched across groups (n=9) 
4.4.3.7.1 Effect of protein type and level on 24-hour energy intake 
There was no effect of the type of protein overall and at each level. There were no significant 
differences in energy intake over 24 hours following the different levels of protein overall and 
within each type of protein.  
4.4.3.7.2 Assessment of under- and over-reporting 
Under-reporting was calculated as described in Chapter 2 section 2.3.3.2 after estimating 
the resting metabolic rate RMR by the Mifflin St Jeor equations (Mifflin et al., 1990). The 
energy intake on RMR ratio (EI/RMR), calculated for each participant, fell outside the 
Goldberg cut-off (0.87 < EI/BMR < 2.75) on 9 occasions out of 63 (14%) with 8 out of these 9 
due to under reporting. Verification of the diaries on the 8 occasions showed that participants 
had skipped either lunch or breakfast on the following day. Exclusion of the 24-hour energy 
intake data from these diaries did not significantly affect the results. 
4.4.3.8 Mycoprotein filament length 
Samples of the test meal were sent to Premier Analytical Services to assess filament length 
and composition. Dry and rehydrated samples of the high mycoprotein soup (high MP) were 
imaged by Premier Analytical Services by stereomicroscopy, scanning electron microscopy 
and optical microscopy with specific staining. Stereomicroscopy and scanning electron 
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microscopy showed that the soup mix comprised a range of particle size ranging from very 
fine to larger (1.5mm) particles as seen in figure 4.10. Scanning electron and optical 
microscopy showed that the dry and rehydrated soup mix contained a wide range of hyphal 
length, with short filaments within the fine particles, medium filaments within small particles 
and significantly longer filaments of undetermined length within larger particles as shown in 
figure 4.11.  
The soup mix was then prepared following a similar protocol than that observed during study 
visits (hydration followed by a 30-second blend). Further images acquired by optical 
microscopy showed that similarly to the rehydrated dry soup mix, the prepared soup 
contained a combination of short and long mycoprotein filaments as seen in figure 4.12. 
Some large particles remained highly particulate while others demonstrated some hyphal 
separation as seen in figure 4.12. 
The analysis highlighted the importance of the soup preparation as further blending or 
rehydrating may induce further separation of hyphae within the particles which may, in turn, 
influence the physical matrix of the product. 
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Figure 4.10: Mycoprotein dry soup mix  
Observed by stereomicroscopy (A) and scanning electron microscopy (B) comprises of small (S), 
medium (M), and large (L) particles. 
 
Figure 4.11: Mycoprotein filaments in dry (A) and rehydrated (B) mycoprotein soup mix  
A: Mycoprotein filaments within large particle in dry mycoprotein seen by scanning electron 
microscopy. B:  Short filaments (SF) and long filaments (LF) remaining highly particulate after 
hydration or showing hyphal separation, seen by optical microscopy. 
 
Figure 4.12: Prepared mycoprotein soup with short (SF), medium (MF) and long filaments (LF). 
Optical microscopy showing that rehydration and blending caused hyphal separation in some longer 
filaments while others remain highly aggregated. 
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4.4.4 Summary of findings from investigation 1 
 Mycoprotein powder did not affect energy intake at an ad-libitum meal 3 hours later 
compared with whey protein meals or a control meal. There were no significant 
differences in perceived appetite following the consumption of the mycoprotein and 
whey protein test meals. There was no difference in 24-hour energy intake between the 
mycoprotein and the whey protein test meals or the control test meal. This study did not 
confirm the hypothesis that mycoprotein reduces energy intake further than a control 
protein and that mycoprotein reduces appetite in a dose-dependent way. As the initial 
hypothesis that mycoprotein would reduce food intake significantly compared with whey 
protein was not confirmed, the analysis of gut hormones was not carried out in this 
investigation.  
 Glycaemia was not significantly different following the consumption of the high MP or 
high WP meal matched for macronutrient content. The high MP test meal resulted in a 
38%, 26% and 30% reduction of serum insulin concentration at 15, 30 and 45 min 
respectively following consumption. The insulin corrected AUC was 19% lower following 
the consumption of high MP. The Matsuda index was 34% higher following the 
consumption of the high MP meal compared with the matched high WP meal. This 
suggests that 31g of dried mycoprotein powder induces better insulin sensitivity than 
whey protein acutely. There was a trend towards reduced insulinogenic index, 
suggesting that mycoprotein may reduce beta-cell output. No difference in disposition 
index following the consumption of the high MP and WP test meals was found. 
 Results from microscopic observation studies suggest that rehydration and blending are 
of significant importance in the physical properties of the test meal. The soups showed a 
high amount of mycoprotein particles with aggregated filaments which were partly 
disaggregated by hydration and blending.  
4.4.5 Reasons for designing investigation 2 
Investigation 1 aimed to investigate the effect of 3 different doses of mycoprotein on appetite 
compared with whey protein and a control test meal without protein from mycoprotein or 
whey protein. Results were reviewed in an interim analysis following the recruitment of half 
of the volunteers as part of the protocol. Therefore, the total number of volunteers included 
in the analysis did not reach the sample size initially calculated and results should be 
interpreted with caution. However, while power may not be sufficient to achieve significance, 
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these preliminary results indicate several limitations of this study. Based on this interim 
analysis, the recruitment was therefore terminated and the limitations were addressed by 
amending the protocol. 
This is the first study investigating the effect of dried mycoprotein powder on energy intake 
using a randomised controlled design therefore results cannot be directly compared with 
previous findings. The amounts of dried mycoprotein powder used in this study were chosen 
to reflect those of mycoprotein paste that were previously shown to reduce energy intake 
compared with a control protein (Turnbull et al., 1993, Burley et al., 1993, Williamson et al., 
2006). However, a maximal dose of 30g was set in order to prevent any change in meal 
palatability. The results from investigation 1 suggest that dried mycoprotein powder, used at 
this level, does not significantly reduce appetite and energy intake compared with whey 
protein. Previous studies found a significant effect of mycoprotein on energy intake using the 
equivalent of 32.5g and 37.5g of mycoprotein powder. Williamson et al. used the equivalent 
of 10g of powder but did not find any significant effect on energy intake at 4 hours. It is 
possible that the minimal amount of mycoprotein powder needed to observe effects on 
energy intake at 3 hours is higher than the equivalent minimal amount of mycoprotein paste. 
Indeed mycoprotein paste and powder present different physico-chemical properties.  
4.4.6 Optimisation of investigation 2 
The following aspects were considered in the design of the new study:  
 The levels of mycoprotein were increased. However, it was impossible to do so using 
mycoprotein powder due to significant after-taste and change in palatability.  
 The results of this first investigation suggest that the physical structure of the 
mycoprotein is important. Results from the microscopic analysis showed that 
mycoprotein powder may present a different structure with aggregates of 
mycoprotein filaments rather than the normal matrix typically observed in the paste. 
Investigation 2 was therefore redesigned to incorporate mycoprotein paste instead of 
mycoprotein powder. However, as my aim is to investigate the effect of a standard portion of 
mycoprotein on appetite and glucose homeostasis, the maximal portion size of mycoprotein 
was set at 150g. 
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4.5 Investigation 2: mycoprotein compared with chicken  
4.5.1 Design of the test meal 
In this second study, the test meal was a mycoprotein pieces or chicken risotto. Protein 
content was increased at each level so that the highest mycoprotein level would match that 
of previous studies from Burley et al. (150g paste). However, the 400g test meal was found 
to be too large to be consumed at breakfast by volunteers. The portion size was therefore 
reduced to 350g and the high mycoprotein content matched to previous study from Turnbull 
et al. (130g paste). The lowest mycoprotein level matched that of the study from Williamson 
et al. (44.3g). Table 4.7 shows the protein content of the mycoprotein and chicken test meals 
at each level.  
Table 4.7: Quantities of mycoprotein and chicken in the test meals 
Table shows the amount of mycoprotein and chicken in each meal. The final protein content 
originated from mycoprotein paste (11g of protein per 100g) or chicken (22g of protein per 100g) as 
well as cheese. 
The meals were designed to be equal 350g portion. Meals were matched to the nearest 5% 
for energy content (425 ± 14 kcal) and pair-matched for all macronutrients across protein 
levels by the addition of rice, vegetables, rapeseed oil, parmesan and vegetable stock. The 
nutritional analysis of the meals is shown in table 4.8.  
 Quantity (g)  
Test meal Mycoprotein paste chicken 
Final protein 
content 
High protein 132 66 39g 
Medium protein 88 44 31g 
Low protein 44 22 24g 
199 
 
Table 4.8: Nutritional analysis of the test meals 
 
Per serving 
 
Energy 
(kcal) 
CHO 
(g) 
Fat 
(g) 
Protein 
(g) 
Fibre 
(g) 
High MP 445 26 8 37 10 
High C 424 25 9 40 3 
Medium MP 435 26 9 31 8 
Medium C 418 29 8 30 3 
Low MP 418 28 9 24 6 
Low C 407 30 9 23 4 
Meals were matched as closely as possible for energy content and fat. At each level, protein and 
carbohydrate content were pair-matched as closely as possible. Key: CHO, carbohydrates; MP, 
mycoprotein; C, chicken  
Meals were not matched for fibre content as mycoprotein contains significantly higher 
amounts of dietary fibre than chicken. Although matched for protein content, meals were not 
matched for amino acid profile. An approximate amino acid profile for the high protein meal 
was determined from the nutritional information of chicken breast and mycoprotein paste 
available in food tables and is presented in table 4.9. Both meals had similar essential amino 
acid composition. 
Table 4.9: Essential amino acid composition of the test meals 
Amino acids content (mg) High Chicken High Mycoprotein 
Histidine 473 515 
Isoleucine 805 752 
Leucine 1143 1254 
Lysine 1295 1201 
Methionine 422 304 
Phenylalanine 605 713 
Threonine 644 805 
Tryptophan 178 238 
Valine 756 792 
The table shows small differences in amino acid content between the two meals.  
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4.5.2 Recruitment  
A total of 51 participants were randomised into the study. Figure 4.13 shows the flow 
diagram of the progress from eligibility assessment to analysis. Participants who did not 
complete the whole of the study were excluded from analysis. The final analysis included 36 
completed participants.  
 
Figure 4.13: Flow diagram of progress from screening visit to analysis of the results 
Age and BMI were checked by initial contact by phone or email and suitable volunteers were invited 
for a screening visit. Reasons for exclusion after the screening included wrong initial BMI estimation 
over the phone, abnormal blood count, medications or declined to participate when explained the 
study. Once enrolled onto the study, discontinuation reasons included dislike of the test meals, time 
commitment issues, and repeated difficulties with catheter insertion leading to significant discomfort 
for the participant and unexpected pregnancy within the study duration. 
4.5.3 Results of investigation 2 
4.5.3.1 Baseline characteristics of the volunteers 
The sample population is described in table 4.10.  
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Table 4.10: Baseline characteristics of the volunteers 
Age (years) 33 ± 2 
Sex 19 males / 17 females 
Height (cm) 168.5 ± 1.5 
Weight (kg) 80.2 ± 2.0 
BMI (kg/m2) 28.1 ± 0.4  
Ethnic origin 
        European 
        Asian 
        African 
        Other 
 
20 
6 
3 
7 
DEBQ restrain score (out of 50) 25.5 ± 1.1 
SCOFF score (out of 5) 0.5 ± 0.1 
Units of alcohol per week 4.6 ± 0.9 
Data presented as mean with standard error of the mean.  
4.5.3.2 Energy intake at ad-libitum meal 
The energy intake at the ad-libitum lunch following the different test meals is shown in figure 
4.14.  
 
Figure 4.14: Comparison of energy intake at the ad-libitum meal following the consumption of 
the test meals 
Data presented as mean with standard error. Participants are matched across all groups (n=36). 
**p<0.01 adjusted for Bonferroni corrections 
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4.5.3.2.1 Effect of protein type on acute energy intake 
Overall, there was a significant effect of the type of protein (mycoprotein vs chicken) on 
energy intake (p=0.008): Mycoprotein significantly decreased energy intake at the ad-libitum 
meal further than the chicken test meal (chicken 635 ± 37 kcal, mycoprotein 596 ± 37 kcal). 
Post-tests with Bonferroni corrections showed that energy intake following the high 
mycoprotein meal was 10% (67kcal) lower than following the chicken test meal (mean EI 
high C: 648 ± 56 kcal, mean EI high MP: 581 ± 50 kcal, p=0.009). Differences in energy 
intake between chicken and mycoprotein at the low and medium level were not significant 
when adjusted with Bonferroni corrections.  
4.5.3.2.2 Effect of protein level on acute energy intake 
The level of protein did not have any significant effect on energy intake.  
4.5.3.2.3 Effect of sex on acute energy intake 
There was a significant effect of sex on energy intake (p<0.001) with males eating 
significantly more than females. Energy intake was analysed separately for males and 
females and is shown in figure 4.15. The effect of the type of protein remained significant in 
males (chicken: 797 ± 52 kcal vs mycoprotein 752± 52 kcal, p=0.027) but not in females 
(chicken: 428 ± 45 kcal, mycoprotein: 406 ± 45 kcal, p=0.129). However, the study was not 
powered to look at gender differences. 
 
Figure 4.15: Energy intake at ad-libitum meal in males (A) and females (B) 
Data presented as mean with standard error. Participants are matched across all groups (males n=19, 
females n=17). *p<0.05 adjusted for Bonferroni corrections 
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4.5.3.2.4 Palatability of the test meal 
There was a significant effect of the type of protein on the pleasantness of the test meal. 
Participants found the mycoprotein significantly less pleasant than the chicken meal. 
However mean scores remained well above 50 (out of 100) for both meals (mean VAS score 
chicken: 71 95% CI: 64-77, mycoprotein: 65 95% CI: 59-72, p=0.023).  
4.5.3.3 Appetite scores 
Figure 4.16 shows differences in prospective food intake and fullness over time at low, 
medium and high level of protein. Similar results were obtained for hunger, desire to eat and 
composite (weighted mean of hunger desire-to-eat, prospective food intake and fullness 
scores) scores (data not shown).  
Corrected AUC for hunger, nausea, desire-to-eat, prospective food intake, fullness and 
composite scores are displayed in figure 4.17.  
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Figure 4.16: Prospective food intake and fullness at each level of protein 
Data presented as mean with standard error. Participants are matched across all groups (n=36 in each group). 
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Figure 4.17: IAUC for hunger (G), nausea (H), desire-to-eat (I), prospective food intake (J), fullness (K), and composite (L) VAS 
Data presented as mean with standard error. Participants are matched across all groups (n=36 in each group). 
206 
 
All VAS scores showed a significant effect of time. Hunger, desire-to-eat, prospective food 
intake and composite scores significantly decreased following the consumption of the test 
meal between 0 and 15 min and thereafter increased slowly. Conversely, fullness 
significantly increased following the consumption of the test meal and slowly decreased 
throughout the following 3 hours. Nausea significantly increased following the consumption 
of the test meal but remained relatively low (as seen in figure 4.17 H). There were no 
differences in nausea following the consumption of mycoprotein compared with chicken. 
4.5.3.3.1 Effect of the protein type on appetite scores 
Mycoprotein did not induce significant differences in hunger, desire-to-eat, prospective food 
intake and composite scores at any time points compared with chicken. There was a trend 
towards increased fullness following the consumption of mycoprotein compared with chicken 
(p=0.066). Post-test with Bonferroni corrections showed a significant effect of the treatment 
at the high protein level at 150 min (chicken 46 ± 4, mycoprotein 55 ± 4, p=0.03) and 180 
min (chicken 39 ± 4, mycoprotein 47 ± 4, p=0.04). 
Analysis of the corrected AUC showed no overall differences in any of the appetite scores 
between mycoprotein and chicken. The effect of mycoprotein on fullness was lost in the 
overall analysis. 
4.5.3.3.2 Effect of the protein level on appetite scores 
There was no effect of the protein level on any of the appetite scores overall or in 
mycoprotein and chicken separately.  
4.5.3.4 GLP-1 and PYY 
Plasma GLP-1 and PYY concentrations were measured at baseline and following the 
consumption of the high protein test meal (between 0 and 15 minutes) and are shown in 
figure 4.18. 
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Figure 4.18: Comparison of GLP-1 (A) and PYY (B) plasma concentrations following the 
mycoprotein and chicken test meal 
Data presented as mean with standard error. Participants were matched across groups (n=36) 
There was a significant effect of time on GLP-1 concentrations (p<0.001). Following the 
consumption of the test meal, GLP-1 levels increased then decreased. PYY did not show 
such a pronounced post-prandial excursion.  Interestingly, there was a significant negative 
effect of BMI on GLP-1 levels (p=0.001). 
4.5.3.4.1 Effect of the protein type on GLP-1 and PYY concentrations 
No significant effect of the protein type was observed on GLP-1 and PYY concentrations. 
Mycoprotein did not induce significant changes in GLP-1 and PYY concentrations compared 
with chicken.  
4.5.3.4.2 Variability of the results 
The variability of the results for PYY concentrations makes the interpretation difficult. No 
effect of time on PYY concentrations was observed although it would be expected that PYY 
levels rise in response to nutrient ingestion.  
4.5.3.4.3 GLP-1 and PYY levels at medium and low protein levels  
GLP-1 and PYY concentrations at the medium and low levels were not measured as there 
was no significant reduction in energy intake following the consumption of mycoprotein 
compared with chicken at these levels. 
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4.5.3.5 24-hour energy intake 
Figure 4.19 shows the energy intake for 24 hours following the study visit.  
 
Figure 4.19: Energy intake over 24 hours following the study visit 
Data presented as mean with standard error. Participants are matched across all groups (n=36). 
*p<0.05 adjusted for Bonferroni corrections 
4.5.3.5.1 Effect of protein type on 24-hour energy intake 
Overall, there was a significant effect of the type of protein on energy intake at 24 hours 
(p=0.027). Mean overall energy intake over 24 hours was reduced by 188kcal (9%) following 
the consumption of mycoprotein compared with chicken (chicken: 2201 kcal CI 1996-2407 
kcal, mycoprotein: 2013 kcal CI 1805-2220 kcal). Post-tests with Bonferroni corrections 
showed a significant difference at the low level (p=0.047) and approaching significance at 
the high level (p=0.083) but no significant difference at the medium level.  
4.5.3.5.2 Effect of the protein level on 24-hour energy intake  
The analysis showed no significant effect of protein level on energy intake at 24 hours 
overall or in mycoprotein and chicken separately. 
4.5.3.5.3 Assessment of under- and over-reporting 
Under-reporting was estimated as previously described in investigation 1. RMR was 
estimated for each participant (Mifflin et al., 1990) and the EI/RMR was compared with the 
Goldberg cut-off values of 0.87 and 2.75. The results showed that 21% of the reported 24-
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hour energy intake fell outside the Goldberg cut-off. Out of the 46 values outside the cut-off, 
38 (83%) were due to under-reporting. Under-reporting was spread across all volunteers on 
few occasions rather than due to repeated under-reporting in the same individuals. This 
showed that under-reporting was not a result of altered eating behaviour or conscious under-
reporting but rather an occasional occurrence of skipping a meal or consuming less on that 
day. Sex and age did not have an influence on under-reporting or over-reporting.  
4.5.3.6 Glucose concentrations 
Figure 4.20 (A, B, C) shows the glycaemic response to the test meal at the low, medium and 
high level of protein. Corrected AUC are presented in figure 4.20 D.  
As expected, there was a significant effect of time on glucose concentrations (p<0.001). 
Following consumption of the test meal, glucose concentrations increased to reach a 
maximum at 30 min and thereafter returned to baseline concentrations.  
4.5.3.6.1 Effect of protein type on glucose concentrations  
There was no significant effect of the type of protein on glucose concentrations at any time 
point. This was confirmed by the analysis of the corrected AUC showing no significant effect 
of the protein type on glucose concentrations overall. 
4.5.3.6.2 Effect of protein level on glucose concentrations 
There was no significant effect of the level of protein on glucose concentrations at any time 
point. This was confirmed by the analysis of the corrected AUC showing no significant effect 
of the protein level on glucose concentrations overall. 
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Figure 4.20: Plasma glucose concentrations over time at each level and corresponding AUC 
Plasma glucose at at low (A), medium (B) and high (C) level of protein and glucose corrected Area Under the Curve (cAUC) over 180 min (D). Data presented 
as mean with standard error. Participants are matched across all groups (n=36).  
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Figure 4.21: Serum insulin concentrations over time at each level and corresponding AUC  
Serum insulin at low (E), medium (F), and high (G) level of protein and for all levels combined (H). Insulin Area Under the Curve (cAUC) for all levels (I) Data 
presented as mean with standard error. Participants are matched across all groups (n=36). *p<0.05, **p<0.01, ***p<0.001 adjusted for Bonferroni corrections
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4.5.3.7 Insulin concentrations 
Figure 4.21 shows baseline and post-prandial serum concentrations of insulin at low, 
medium and high levels over 180 min and corresponding corrected AUC. 
As expected, there was a significant effect of time on insulin concentrations (p<0.001). 
Insulin concentrations increased following the consumption of the test meal to reach a 
maximum at 30-45 min and returned to baseline within 2 hours.  
4.5.3.7.1 Effect of protein type on insulin concentrations 
There was a significant effect of the time * type of protein interaction (p=0.002) on insulin 
serum concentrations. Mycoprotein significantly reduced insulin concentration compared 
with chicken at several time-points as seen in figure 4.21 E, F and G. Post-tests results with 
Bonferroni corrections are shown in appendix 13. 
At the high protein level, mycoprotein significantly reduced insulin levels compared with 
chicken by 41% at 15min, 27% at 30min, 20% at 45min, 21% at 60min, and 26% at 90min. 
At the medium level of protein, mycoprotein reduced insulin concentrations compared with 
chicken by 22% at 15min, 12% at 30min, 12% at 45min, 13% at 60min, and 24% at 90min.  
Analysis of the corrected AUC showed a significant effect of the type of protein overall 
(p=0.004). Post-tests showed significant 8% reduction in insulin cAUC at low (p=0.024), 12% 
at medium (p=0.001) and 21% high level of protein (p<0.001) as seen in table 4.11. 
4.5.3.7.2 Effect of protein level on insulin concentrations 
The analysis of the serum insulin concentrations over time showed no significant effect of 
the level at different time points. 
However, analysis of the corrected AUC showed a significant effect of level (p=0.005) with 
significantly lower insulin response at the medium meal compared with the low and high 
protein meals. Post-tests with Bonferroni corrections showed that level of protein was 
significant for chicken (p=0.016) but not for mycoprotein as seen in table 4.11. The high level 
of chicken induced significantly higher insulin concentrations compared with the medium 
level. 
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Table 4.11: Insulin corrected AUC at low, medium and high level of protein.  
 LOW  MEDIUM  HIGH  
 
C M 
p 
value 
C M 
p 
value 
C M 
p 
value 
Insulin 
cAUC 
10364ab 
(8837-11891) 
9481 
(7954-11008) 
0.024 9650
a 
(8571-10728) 
8510 
(7431-9588) 
0.001 11178
b$ 
(9604-12752) 
8884 
(7311-10458) 
<0.001 
Data presented as means with 95% confidence interval adjusted for age (p=0.029). P values and letters correspond to mixed model post-test comparisons 
between low, medium and high level for each treatment and are given with Bonferroni correction.  
ab
:Values sharing the same letters are not significantly 
different. 
$
: p<0.05 
 
Figure 4.22: Comparison of Matsuda Index (A), Insulinogenic Index (B) and disposition Index (C) between mycoprotein and chicken.  
Data presented as mean with standard error, Participants are matched across all groups (n=36) *: p≤0.05 adjusted for Bonferroni correction 
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4.5.3.8 Insulin sensitivity and beta cell function 
Matsuda, Insulinogenic and Disposition indices are presented in figure 4.22. Matsuda, 
Insulinogenic and Disposition Indices were log transformed prior to analysis. 
4.5.3.8.1 Matsuda Index 
Overall, there was a significant effect of the type of protein (p=0.026) on log transformed 
Matsuda Index. Mycoprotein improved insulin sensitivity compared with chicken as shown by 
significantly higher Matsuda Index (chicken: 78 CI: 70-86, mycoprotein: 84 CI: 76-92, 
p=0.026 for log transformed data). Post-tests with Bonferroni corrections at each level 
showed a significant difference between mycoprotein and chicken at the high protein level 
(high chicken: 64.0 CI: 54.7-74.8, high mycoprotein: 70.9 CI: 62.0-81.0, p=0.041 for log 
transformed data) but not at the medium and low levels. 
Overall, there was significant effect of the level of protein on log transformed Matsuda Index 
(p<0.001). Post-test within protein types showed a significant effect of the level in both 
mycoprotein (p=0.017) and chicken (p=0.002). The Matsuda Index following the high protein 
level was significantly lower compared with that from the low protein level for chicken (high 
chicken: 64 CI: 55-65, low chicken: 78 CI: 68-90, p=0.012) and almost significantly lower for 
mycoprotein (high mycoprotein: 71 CI: 62-81, low mycoprotein 83 CI: 72-95, p=0.059).  
4.5.3.8.2 Insulinogenic Index 
There was a significant effect of the type of protein (p=0.001) on the Insulinogenic Index. 
Mycoprotein significantly reduced beta-cell output by 21% compared with chicken as 
estimated by the significantly lower Insulinogenic Index (chicken: 43 CI: 37-48, mycoprotein: 
34 CI:29-39, p=0.001 for log transformed data). Post-tests with Bonferroni corrections 
showed that mycoprotein reduced the Insulinogenic Index compared with chicken by 18% at 
the low protein level (low chicken: 38 CI: 31-47, low mycoprotein: 31 CI: 25-39, p=0.011), 
15% at the medium protein level (medium chicken: 33 CI:25-43, medium mycoprotein: 28 
CI:22-37, p=0.09) and 30% at the high protein level (high chicken: 43 CI:36-53, high 
mycoprotein: 30 CI:23-39, p=0.006).  
4.5.3.8 3 Disposition index 
There was a significant effect of the type of protein (p=0.007) on the Disposition Index. 
Mycoprotein significantly reduced beta-cell function by 16% compared with chicken as 
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estimated by the significantly lower Disposition Index (chicken: 3355 CI: 2944-3766 
mycoprotein 2832 CI: 2421-3244, p=0.007 for log transformed data). Post-tests with 
Bonferroni corrections showed borderline significant differences between mycoprotein and 
chicken at the high protein level (high chicken: 3392 CI: 2398-4384, high mycoprotein: 2461 
CI: 1903-3020, p=0.028) but not at medium and low levels.  
4.5.4 Summary of findings from investigation 2 
 Energy intake 
In this study, 132g of mycoprotein paste significantly reduced energy intake by 10% at an 
ad-libitum meal 3 hours later compared with a macronutrient-matched chicken meal in 
overweight healthy volunteers. Smaller amounts of 88g and 44g of mycoprotein paste did 
not have any significant effect on energy intake compared with chicken. For both chicken 
and mycoprotein, increasing the protein content of the meal did not have any significant 
effect per se on energy intake at the ad-libitum meal. The mycoprotein meal was found 
significantly less palatable than the chicken meal; however mean palatability scores 
remained well above 50 out of 100 for all meals. 
The reduction in energy intake induced by mycoprotein consumption was not compensated 
by an increase in energy intake over 24 hours following the study visit. On the contrary, this 
study shows that mycoprotein reduced energy intake by a further 9% over 24 hours 
compared with chicken. Although 21% of the 24-hour food diaries energy intake fell outside 
of the Goldberg cut-off, this was the result of isolated under-reporting rather that consistent 
under-reporting in some individuals. Furthermore, although the Goldberg cut-off was the 
most appropriate tool to assess under-reporting, the method has poor sensitivity and 
specificity at individual level. 
 Appetite 
Mycoprotein did not affect hunger, desire-to-eat and prospective food intake. There was a 
trend towards increased fullness following the consumption of mycoprotein compared with 
chicken. Increased protein content of the meal did not significantly affect any of the appetite 
scores. Nausea scores remained low throughout the study visit and did not significantly differ 
between the meals 
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 Gastro-intestinal hormones 
Mycoprotein paste did not significantly affect GLP-1 and PYY levels compared with chicken 
at the high protein level. GLP-1 and PYY concentrations were not measured at medium and 
low levels as no significant differences in energy intake were found.  
 Glucose homeostasis 
Mycoprotein did not have any significant effect on glycaemia compared with chicken. Protein 
level did not significantly affect plasma glucose concentrations.  
Mycoprotein significantly reduced overall insulin profiles by 8%, 12% and 21% at low, 
medium and high level of protein respectively compared with chicken. More specifically, 
mycoprotein reduced serum insulin concentrations by 41% at 15 min, 27% at 30 min, 20% at 
45 min, 21% at 60 min and 26% at 90min at the high level of protein (38.5g) and by 22% at 
15min, 12% at 30min, and 24% at 90min at the medium protein level (30.5g).There were no 
significant differences in insulin response between the 3 levels of mycoprotein. The high 
chicken meal induced higher insulin response then the medium meal.  
Analysis of the Matsuda, Insulinogenic and Disposition indices suggested that mycoprotein 
improves insulin sensitivity and reduces beta cell output and function compared with chicken 
in overweight individuals. Overall, mycoprotein improved Matsuda index by 7%, and reduced 
Insulinogenic Index and disposition index by 21% and 16% respectively compared with 
chicken. 
4.5.5 Reasons for designing investigation 3 
Investigation 2 aimed to show that mycoprotein reduces energy intake further than chicken 
by altering GI hormones GLP-1 and PYY. However, the results of the study do not support 
this hypothesis; Mycoprotein did not significantly affect GLP-1 or PYY levels compared with 
a macronutrient-matched chicken meal therefore the effect of mycoprotein on energy intake 
does not seem to be mediated by increased satiety hormones GLP-1 and PYY. Other 
mechanisms may be involved in the short-term effect of mycoprotein on appetite such as 
other GI hormones or gastric distension.  
Previous authors have suggested that the effect of mycoprotein on energy intake may be 
due to its bulkiness and its effect on gastric emptying. The aim of the next study will 
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therefore be to clarify the effects of mycoprotein on gastric emptying in overweight 
volunteers. 
Furthermore, this study showed that mycoprotein induced significantly lower serum insulin 
concentration compared with chicken despite similar plasma glucose levels. As discussed 
previously, low GI diets have been suggested to have an impact on substrate oxidation. 
However, the evidence in humans is limited. Evidence in rodents shows that high GI diets 
induce impaired fatty acid oxidation leading to a reduction in metabolic flexibility over the 
long-term (Isken et al., 2010).  It could therefore be hypothesised that diets rich in dietary 
fibre, which normally have low GI, have beneficial effects on substrate oxidation. The next 
investigation will therefore aim to determine whether mycoprotein induces any changes in 
substrate oxidation when compared with chicken in overweight individuals. 
4.6 Investigation 3: exploring potential mechanisms of action of 
mycoprotein 
4.6.1 Design of the study 
In this third investigation, the test meal from investigation 2 was used to investigate potential 
effects of mycoprotein on gastric emptying and substrate oxidation. Volunteers were asked 
to consume the high protein (39g) risotto from mycoprotein or chicken in a randomised order 
on 2 separate occasions. The sequence of events for the study day is shown in figure 4.23. 
The test meal was served with 2g of paracetamol dissolved in 250mL of water. Participants 
were asked to consume both food and drink within 15 minutes at the same rate of both 
occasions. Upon arrival, they were asked to void and subsequently collect their urine into a 
container throughout the study visit and at the end of the visit for the measurement of urinary 
nitrogen excretion. Resting energy expenditure was measured at baseline and every hour for 
3 hours by indirect calorimetry (Gas Exchange Monitor, GEM Nutrition, Daresbury, Cheshire, 
UK). Before each measurement, the calorimeter was calibrated with zero (0.00% O2, 0.00% 
CO2) and span (20.00% O2, 1.00% CO2) gases (BOC Gases, Surrey, UK).  The volunteers 
were asked to lie in a semi-recumbent position under the canopy and were allowed to watch 
television, read or listen to music. The measurements were first allowed to stabilise for 5 to 
10 minutes following which the VO2 and VCO2 were recorded every minute for 15 minutes. 
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Figure 4.23: Study day schedule 
Fasting indirect calorimetry was performed between -45 and -15 minutes and post-prandially between 
30 and 60 minutes, 90 and 120 minutes, and 150 and 180 minutes. No ad-libitum meal was served at 
180 minutes. The test meal was consumed between 0 and 15 minutes with 2g of paracetamol.  
4.6.2 Results of investigation 3 
4.6.2.1 Baseline characteristics of the volunteers 
A total of 14 volunteers completed the study. Fat mass, FFM and body fat percentage were 
estimated by bioelectrical impedance analysis as described in Chapter 2 section 2.2.3. 
Baseline characteristics are presented in table 4.12.  
Table 4.12: Baseline characteristics of the volunteers 
Age (years) 37 ± 5 
Sex 5 males / 9 females 
Height (cm) 170 ± 2  
Weight (kg) 82 ± 3 
BMI (kg/m2) 28.4 ± 0.6 
Ethnic origin 
        European 
        Asian 
        African 
        Other 
5 
2 
5 
2 
Fat mass (kg)  26.8 ± 2.3 
Fat free mass (kg) 54.6 ± 2.8 
Body fat % 32.9 ± 2.1 
Data presented as mean with standard error of the mean for 14 volunteers 
4.6.2.2 Appetite scores 
VAS scores over time and corresponding AUC are shown in figure 4.24.  
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Figure 4.24: Hunger (A), nausea (B), desire-to-eat (C), prospective food intake (D) and fullness (E) and associated corrected AUC (F) between 
mycoprotein and chicken 
Data presented as mean with standard error. Participants are matched across all groups (n=14 in each group). 
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There was a significant effect of time (p<0.001) on all appetite scores apart from nausea. 
Hunger, Desire-to-eat and prospective food intake significantly decreased following the 
consumption of the test meal in both occasions and slowly returned to baseline afterwards. 
Conversely, fullness significantly increased following the consumption of the meal and 
decreased slowly over the following 3 hours. 
There was no significant effect of mycoprotein on hunger, nausea, desire-to-eat, prospective 
food intake, and fullness at any time point compared with chicken. This was confirmed 
overall by the analysis of the AUC showing no significant effect of the protein type.  
4.6.2.3 Glucose concentrations 
Plasma glucose concentrations over time are presented in figure 4.25. Corrected AUC were 
calculated as previously described and are shown in table 4.13. 
There was a significant effect of time (p<0.001) on glucose concentrations with glucose 
concentrations increasing significantly following the consumption of the test meal and 
returning to baseline levels within 3 hours. 
In line with previous findings from investigations 1 and 2 there was no significant difference 
in plasma glucose levels following the two treatments. 
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Figure 4.25: Baseline and post-prandial plasma glucose (A), serum insulin (B) and serum paracetamol concentrations (C) between chicken and 
mycoprotein 
Data presented as mean with standard error. Participants are matched across all groups (n=14).  
Table 4.13: AUC for glucose, insulin, and paracetamol and paracetamol time to peak. 
 Chicken Mycoprotein p value 
Glucose cAUC (mm2) 1006 (±25) 1004 (±25) NS 
Insulin cAUC (mm2) 10693 (±1100) 9288 (±822) 0.015 
Paracetamol cAUC (mm2) 2759 (±200) 2780 (±219) NS 
Paracetamol time to peak (min) 48.2 (±8.2) 39.6 (±5.6) NS 
Data presented as means with standard error. Participants are matched across all groups (n=14). 
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4.6.2.4 Insulin concentrations 
Serum insulin concentrations over time are presented in figure 4.25 with corresponding AUC 
shown in table 4.13. There was a significant effect of time (p<0.001) on serum insulin 
concentrations with insulin concentrations increasing significantly following the consumption 
of the test meal and returning to baseline levels within 3 hours. 
There was no significant effect of the protein type on insulin levels at any time points. 
However, analysis of the insulin corrected AUC showed a significant effect of the type of 
protein on insulin (p=0.015). Insulin corrected AUC following the consumption of 
mycoprotein was significantly lower than following the consumption of chicken as seen in 
table 4.13. 
4.6.2.5 Gastric emptying 
Gastric emptying was assessed by paracetamol analysis as described in Chapter 2 section 
2.5.3. Baseline and post-prandial serum pararacetamol concentrations are shown in figure 
4.25 with corresponding AUC presented in table 4.13. The time-to-peak, calculated as the 
time needed to reach the first maximum in paracetamol concentration, is shown in table 
4.13. 
As expected, there was a significant effect of time (p<0.001) on paracetamol concentrations 
with paracetamol concetrations increasing following consumption of the test meal and slowly 
decreasing over the following 3 hours. 
There was no effect of the type of protein on paracetamol concentrations at any time point. 
Analysis of the AUC showed no significant differences in paracetamol concentrations 
between mycoprotein and chicken overall. Furthermore, no significant differences in time-to-
peak were observed. 
4.6.2.6 Energy expenditure and substrate oxidation 
Energy expenditure, respiratory quotient and substrate oxidation were measured by indirect 
calorimetry as described in Chapter 2 section 2.4.  
4.6.2.6.1 Energy expenditure  
Baseline and post-prandial measures of resting energy expenditure and resting energy 
expenditure corrected for lean mass are shown in figure 4.26 D and E. 
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Figure 4.26: Resting energy expenditure and substrate oxidation between chicken and mycoprotein. 
D: resting energy expenditure, E: daily energy expenditure corrected for lean mass, F: change in respiratory quotient, G: carbohydrate oxidation and H: fat 
oxidation between chicken and mycoprotein. Data presented as mean with standard error. Participants are matched across groups (n=14) 
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There was a significant effect of time on resting energy expenditure (p<0.001). Energy 
expenditure increased following the consumption of the test meal. As expected from the 
composition of the meals (isocaloric and matched for protein content) there was no 
significant difference in resting energy expenditure following the consumption of mycoprotein 
compared with chicken.  
4.6.2.6.2 Respiratory quotient and substrate oxidation 
Respiratory Quotient (RQ), carbohydrate oxidation and fat oxidation are shown in figure 4.26 
F, G and H. There was no significant effect of time on the RQ and the fat oxidation (OXFAT). 
Analysis of the carbohydrate oxidation (OXCHO) showed a significant effect of time (p<0.001) 
with carbohydrate oxidation increasing following consumption of the test meal. 
The analysis showed no significant effect of the protein type on RQ, OXCHO, and OXFAT at 
any time points.  
4.6.3 Summary of findings from investigation 3 
 Appetite 
In line with the previous findings, this investigation showed no significant changes in VAS 
scores.  
 Glucose and insulin profiles 
This investigation showed no significant differences in glucose profile between mycoprotein 
and chicken which confirms findings from investigation 1 and 2. As seen in investigation 2, 
the overall insulin profile showed a significant reduction compared with chicken.  However, 
the analysis of insulin concentrations over-time showed no significant difference. This may 
be due to the smaller number of participants in the study.  
 Gastric emptying 
Investigation 3 did not confirm that mycoprotein significantly delays gastric emptying 
compared with chicken as measured by serum paracetamol recovery. 
 Energy expenditure and substrate oxidation 
As expected by the matched protein content of the meals, mycoprotein did not induce any 
significant changes in post-prandial energy expenditure compared with chicken. There were 
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no significant differences in respiratory quotient, carbohydrate and fat oxidation following the 
consumption of mycoprotein compared with chicken.  
4.7 Investigation 4: metabonomics  
In the previous section, the response to mycoprotein based on a metabolite target analysis 
was explored, i.e. specific metabolites, which were chosen based on previous research 
findings, were compared following the consumption of mycoprotein and chicken. For 
example, mycoprotein has been shown to reduce glucose levels in previous studies, 
therefore differences in glucose concentrations were analysed by biochemistry in this study 
as changes were expected. However, this type of analysis is limited by the fact that it is 
based on previous findings. 
For this reason, in the next section of this set of studies, the analysis was carried out using a 
different strategy called metabolic fingerprinting. Metabolic fingerprinting is a non-targeted 
explorative tool which aims to classify samples through overall metabolite pattern 
recognition. Therefore the method does not intend to identify differences in specific 
metabolites but rather take a „snapshot‟ of the whole profile of metabolites in a sample 
instead aiming to compare patterns in response to environmental, genetic or nutritional 
alterations for example. Metabonomics (described in Chapter 2 section 2.6) was applied to 
explore the effect of mycoprotein on metabolism.  
4.7.1 Design of investigation 4 
Metabolic fingerprinting using 1H NMR (principles previously described in Chapter 2 section 
2.2.5.3) was applied to urine and plasma samples in order to clarify the effects of 
mycoprotein compared with chicken on the metabolome. Methods of analysis are described 
in Chapter 2 section 2.6. Sample collection was performed at Imperial College London 
Hammersmith Hospital research centre. Samples were stored at -20°C until analysis. 
Samples preparation was carried out at the University of Reading, Department of Food and 
Nutritional Sciences. 1H NMR analysis was carried out by Dr J Swann. The data was 
prepared by manually pre-processing the NMR spectra. The data analysis by Principal 
Components Analysis (PCA) and Orthogonal Partial Least Square Discriminant Analysis 
(OPLS-DA) was carried out by Dr J Swann. Metabolites were then identified with the help of 
Dr J Swann and Dr Isabel Garcia Perez. 
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From the total of plasma samples from investigation 2, three plasma samples were retained 
for the purpose of this analysis: One fasting (-15min) and two post-prandial (30 min, 180 
min). Urine samples from investigation 3, collected over 3 hours following the consumption 
of mycoprotein and chicken (see Chapter 4 section 4.6.1) were retained for the analysis. 
Figure 4.27 illustrates the sequence of events followed during the metabonomics analysis.  
 
Figure 4.27: Sequence of events for the metabonomics analysis from sample collection to the 
identification of metabolites 
Key: 
1
H NMR: proton spectroscopy, PCA: principal component analysis, OPLS-DA: Orthogonal Partial 
Least Square Discriminant Analysis 
4.7.2 Results 
4.7.2.1 Identification of metabolites 
Glucose, creatinine, citrate, leucine, isoleucine and valine were identified. The identification 
of metabolites was based on (2D) 1H NMR experiments. For all other metabolites, final 
confirmation will be done by spiking commercial standards as a future work. 
4.7.2.2 Comparison of mycoprotein and chicken using urine samples 
Data from the mycoprotein and chicken groups in the study were examined for differences 
using unsupervised PCA. Separation between the 2 classes was not very pronounced based 
on PCA (data not shown) therefore a new analysis was carried out using OPLS-DA in order 
to remove any variation unrelated to the difference between mycoprotein and chicken intake. 
This separation between the two classes increased after applying OPLS-DA. 7-fold crossed 
validated OPLS-DA scores plot can be seen in figure 4.28.  
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Figure 4.28: Scores plot of 7-fold crossed validated OPLS-DA  
Blue dots: mycoprotein, Red dots: chicken 
The corresponding loading plots (figure 4.29) showed significant differences (highlighted in 
red) between mycoprotein and chicken: 
- Guanidinoacetate and an unknown metabolite (singlet at δ 2.48) were found to be 
potential biomarkers increasing after mycoprotein intake.  
- N-acetylcarnitine, carnitine, and anserine were found to be potential biomarkers 
increasing after chicken intake. 
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Figure 4.29: Loading plot corresponfind to the OPLS-DA model showing significant differences in metabolites between mycoprotein and chicken 
urine samples  
Significant differences are highlighted in red 
Increasing following chicken intake: N-acetylcarnitine, carnitine and anserine. 
Increasing following mycoprotein intake: guanidinoacetate (GAA) and unknown (U1) 
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4.7.2.3 Time-effect of mycoprotein consumption using plasma samples 
Data from the mycoprotein group at different time points were examined for differences 
using unsupervised Principle Components Analysis (PCA) (data not shown). Once again, the 
separation was not clear enough therefore OPLS-DA was applied.  
As expected, the separation increased after applying OPLS-DA. The corresponding loading 
plots (figure 4.30 and figure 4.31) showed significant differences (highlighted in red) between 
the time points: 
 Baseline vs 30 min: 
- Glucose significantly increased at 30 min following mycroprotein intake compared with 
baseline.  
- Creatinine, an unknown metabolite (doublet at δ 3.66), citrate and possibly N-acetyl 
glycoprotein decreased at 30 min following mycroprotein intake compared with baseline 
 30 min vs 180 min 
- Glucose significantly decreased between 30 min and 180 min following mycoprotein intake 
- Leucine, Valine, Isoleucine, tyrosine and possibly N-acetyl glycoprotein increased between 
30 min and 180 min following mycoprotein intake. 
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Figure 4.30: Loading plot showing significant differences in metabolites in plasma between 
baseline and 30 min following the intake of mycoprotein  
Significant differences are highlighted in red. Increasing at 30 min: glucose. Decreasing at 30 min: N-
acetyl-glycoprotein, creatinine and unknown (U2). 
 
Figure 4.31: Loading plot showing significant differences in metabolites in plasma between 30 
min and 180 min following the intake of mycoprotein 
Significant differences are highlighted in red. Increasing at 180min: valine, isoleucine, leucine, N-
acetyl-glycoprotein. Decreasing at 180 min: glucose. 
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4.7.2.4 Comparison of mycoprotein and chicken using plasma samples 
Plasma data from the mycoprotein and chicken groups in the study were examined for 
differences using unsupervised Principal Components Analysis (PCA). OPLS-DA models 
were obtained but no significant difference between chicken and mycoprotein were found at 
any time point. 
4.7.3 Conclusions and future work 
Metabonomic analysis of the urine samples showed significant increase in metabolites 
involved in meat consumption following the consumption of chicken compared with 
mycoprotein. Indeed, a previous study showed that, in a randomized cross-over study of 12 
healthy male participants comparing vegetarian, high meat concentration, and low meat 
concentration diets, meat diets were characterized by higher levels of urinary creatine, 
carnitine, and acetylcarnitine, whereas higher amounts of 4- hydroxyphenylacetate typified 
the consumption of vegetarian diet (Stella et al., 2006). Moreover, Cross et al. also identified 
creatinine, taurine, 1-methylhistidine, 3-methylhistidine as meat intake biomarkers in a 
previous study (Cross et al., 2011). Other metabolites will need further confirmation.  
Differences within the mycoprotein plasma samples confirmed the changes observed by 
biochemical target analysis. Glucose was increased by 30 min and decreased at 180 min. 
Amino acids leucine, isoleucine, valine and tyrosine were elevated at 180 min but not at 
30min, showing that the digestion of protein took longer than that of carbohydrates. The 
increase in amino acids corresponds to the intake of protein from mycoprotein. Other 
metabolites will need further confirmation and clarification.  
No significant differences between chicken and mycoprotein were found in plasma. It is 
possible that differences in plasma were too small to be detected with this analysis by 1H 
NMR.  
I would like to extend this work to confirm all metabolites by spiking commercial standards. 
To identify unknown metabolites, an analytical platform on UPLC-MS, GS-MS and CE-MS 
could be used to cover as many types of metabolites that could be altered as possible. 
Because mycoprotein contains dietary fibres that are not normally found in the human diet, it 
is possible that some the metabolites have never been identified in humans metabonomics.  
A recent type of analysis, multi-level PLS-DA, has been developed as a new method in order 
to improve the modelling of biological data compared with PLS-DA and OPLS-DA during 
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nutritional intervention studies characterised by large between-subject variability (Westerhuis 
et al., 2010, van Velzen et al., 2008). Multilevel scaling is based on the same principle as the 
paired t-test for multivariate analyses and aims to minimize the between-subject variation 
before conducting PLS-DA. This type of analysis may be used as a future method as it may 
possibly enhance small differences undetectable otherwise. It is, however, complicated, and 
time-consuming.  
4.8 Overall discussion 
4.8.1 Appetite and energy intake 
The main hypothesis of this set of investigations was that mycoprotein would induce 
significant reductions in energy intake compared with a control protein in overweight 
volunteers in a dose-dependent way. 
4.8.1.1 Acute energy intake in investigation 1 
Investigation 1 showed no significant effect of mycoprotein powder on energy intake 
compared with whey protein. There are several reasons why mycoprotein may not have 
reduced energy intake compared with whey protein in investigation 1.  
Firstly, the protein content of the meal may have been insufficient to induce significant 
changes in appetite. Indeed, the amounts used in my study were significantly lower than 
those used in previous studies (Turnbull et al., 1993, Burley et al., 1993). Investigation 1 
showed no significant effect of the protein level. Previous studies showed a dose-dependent 
effect of the protein content using whey protein (Astbury et al., 2010). However, the amounts 
of protein used in their study were 12.5g, 25.4g and 50.4g of protein compared with 7g, 11g 
and 16g in this study. The differences in protein levels may have therefore been too small to 
induce significant changes in energy intake. However, the maximal level of mycoprotein was 
chosen to prevent any after-taste in the test meal. 
Secondly, previous studies used soy or chicken as a control for mycoprotein (Turnbull et al., 
1993, Burley et al., 1993, Williamson et al., 2006). In investigation 1, a whey-based control 
test meal was used. It is known that different sources of protein may have different impact on 
appetite. Previous studies have suggested that whey protein may induce satiety and reduce 
energy intake compared with other sources of protein such as casein or soy (Hall et al., 
2003, Veldhorst et al., 2009). It is therefore possible that mycoprotein induces similar 
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changes in appetite as whey protein and that their effect is not distinguishable. The whey 
protein soup contained higher amount of branched-chain amino acids such as leucine which 
has been shown to reduce food intake in rodents in several studies (Zhang et al., 2007, Cota 
et al., 2006).  
Finally, the microscopic analysis suggests that the physical structure of mycoprotein may be 
altered when mycoprotein powder is rehydrated and blended in a test meal. Further 
rehydration may lead to hyphal separation from particles which could impact on gastric 
emptying and therefore satiety. Although the test meal was prepared in a consistent manner 
by accurately following the protocol, small differences in rehydration time might have 
occurred occasionally. Further microscopic analysis of the sample with different hydration 
time may help to understand the properties of the rehydrated mycoprotein powder. Native 
mycoprotein paste is composed of mycoprotein filaments of various length randomly 
oriented in all directions and bound by a gel matrix (Miri et al., 2003). One study showed that 
food processing such as extrusion may affect the orientation of the filaments especially the 
longer ones (Miri et al., 2003). The fibre matrix observed in mycoprotein paste may therefore 
be altered by the grinding process used in the production of freeze dried mycoprotein 
powder. It is also possible that individualised hyphae in aggregates or in suspension in the 
soup have different physico-chemical properties compared with the filaments in mycoprotein 
paste and may therefore not exert the same effects on appetite. 
4.8.1.2 Acute energy intake in investigation 2  
Investigation 2 showed that the consumption of 132g of mycoprotein paste reduced energy 
intake by 10% at an ad-libitum meal compared with a macronutrient-matched meal 
containing chicken. The results are in line with findings from previous studies although 
mycoprotein reduced energy intake to a smaller extent in my study (Turnbull et al., 1993, 
Burley et al., 1993).  In their studies, Burley et al. found an 18% reduction in energy intake at 
an ad-libitum meal 4 ½ hours following the consumption of 150g of mycoprotein paste and 
Turnbull et al. found a 24% reduction in energy intake from lunch until the end of the day 
following the consumption  of 130g of mycoprotein paste. However, significant variations 
between the protocol of this and other studies may explain why mycoprotein may have 
reduced energy intake to a lesser extent in this study compared with previous findings. 
Firstly, the volunteers included lean females only in Turnbull et al.‟s study and both lean 
females and lean males in Burley et al.‟s study. My study looked at the effect of mycoprotein 
in overweight volunteers. While efforts were made to control for restrained eaters in this 
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study, the mean restraint score on the DEBQ was 25.5 meaning that most overweight 
volunteers in this study were restrained eaters. It is acknowledged that restrained eaters 
may have different response to questions regarding appetite, a different attitude to hunger 
and altered eating behaviour (Polivy et al., 2010, Herman and Mack, 1975). While eating 
behaviour and appetite might be altered and results less reliable in these individuals, they 
are probably more representative of the general overweight population‟s eating behaviour.  
Secondly, the test meal was served at lunch after an overnight and morning fast in Turnbull 
et al.‟s study and at lunch after a standard breakfast in Burley et al.‟s study. Volunteers were 
able to leave the research unit during the study day in Burley‟s study.  In my study, the test 
meal was given at breakfast following an overnight fast. Whilst this may not be 
representative of normal intake time of mycoprotein and chicken, it prevented any influence 
of breakfast and daily activities on appetite feelings and energy expenditure to a certain 
extent. In Turnbull et al.‟s study, energy intake was evaluated by weighed food diary as 
opposed to an ad-libitum meal in this study and in Burley et al.‟s study. This is equivalent to 
measuring energy intake in free-living subjects and is therefore more representative of 
normal behaviour in individuals but means that results are subject to variations in daily 
activities. Food diaries are also known to be an unreliable method of energy intake 
assessment. As the test meal was served at lunch in both aforementioned studies, the 
energy content of the test meal was higher and may have therefore induced significantly 
higher reductions in appetite (579kcal in Turnbull et al.‟s study and 884kcal in Burley et al.‟s 
study as opposed to 425kcal in this study). In addition both test meals were served with 
other ingredients such as fruits, cookies and desserts. These were served in different 
amount in order to balance the macronutrient content of the test meal, which may have had 
an additional effect on energy intake.  
In my study, 88g and 44g of mycoprotein paste had no significant effect on energy intake 
compared with chicken. This is in line with the previous findings from investigation 1 using 
mycoprotein powder and confirms that the amounts given in the previous study may have 
been insufficient to have any satiating effects. However, it is important to note that a 
standard portion of mycoprotein included in a commercialised Quorn™ ready-meal varies 
between 48g for a cottage pie to 98g for a Quorn steak. This means that standardised 
portions of mycoprotein included in ready-meals might not be sufficient to induce a 
significant reduction at a later meal. 
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This study showed that mycoprotein significantly reduced energy intake at an ad-libitum 
meal in males but not in females. Because energy intake was generally lower in females 
compared with males, the differences in energy intake between mycoprotein and chicken 
were proportionally smaller. This means that a greater number of females would be needed 
in order to achieve the same significant reduction observed in males. In Burley et al.‟s study, 
a significant effect of sex was also noted. Mycoprotein induced a 24% decrease in energy 
intake in males whereas the reduction in energy intake was only 14% in females. 
Furthermore, this study involved 7 visits over 7-9 weeks. Over that period of time, females 
may be prone to hormonal fluctuations during their menstrual cycle, which has been 
previously shown to affect appetite and induce variations in energy intake (Cross et al., 
2001, Bryant et al., 2006). Consequently, variations in appetite and energy intake due to 
hormonal influences may have masked small differences induced by mycoprotein intake in 
females in this study. 
4.8.1.3 Effect of the protein level  
The protein content of the meal (low, medium or high), did not have any significant effect per 
se on energy intake at the ad-libitum meal in this study, which means that energy intake 
following the high protein level overall was not significantly reduced compared with energy 
intake following the consumption of the low and medium protein level meals. Previous 
studies have suggested a negative dose-response in appetite or energy intake to increasing 
levels of protein (Belza et al., 2013, Astbury et al., 2010, Bertenshaw et al., 2009). In Astbury 
et al.‟s study, significant differences in energy intake at the ad-libitum meal following 
isocaloric meal of varying protein content were observed between the control (0g protein) 
meal, medium protein (12.5g and 25g) meal, and the high protein (50g) meal. No significant 
differences in energy intake were observed between the other protein concentrations (12.5g 
and 50g protein, and 6.8g, 13.1g and 25.4g protein). In Belza et al.‟s study, the protein 
content of the meal was 24.3, 44.5, and 88.4g. Although the different meals induced 
significant changes in appetite feelings and GI hormones, there were no differences in 
energy intake at the ad-libitum meal in their study. In Bertenshaw et al.‟s study, test drinks 
with a protein content of 2.4g, 8.8g, 17.3g, and 34.4g were offered to participants prior to the 
consumption of an ad-libitum meal. Energy intake at the ad-libitum meal following the 
consumption of the 17.3g and 34.4g protein drinks was significantly lower than following that 
of the control (2.4 with reduced energy content compared with the other drinks). No 
significant differences in energy intake were noted between the 17.3 and 34.4g protein 
meals. The protein levels of the test meals in this study were 23.5g, 31.5g and 38.5g. 
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Consequently, it is possible that in line with the findings from previous studies, the 
differences in protein content may not have been sufficiently large to induce significant 
differences in energy intake. 
4.8.1.4 24-hour energy intake 
Investigation 2 showed that mycoprotein reduced energy intake by 9% over 24 hours 
following the ad-libitum meal compared with chicken. In Turnbull et al.‟s study, energy intake 
over the next day was 16.5% less following the consumption of mycoprotein than that of 
chicken and in Burley et al.‟s study, no significant differences over 24 hours were noted. As 
a limitation to these results, 21% of the diaries fell outside the Goldberg cut-off. However, no 
physical activity was recorded for the participants and therefore the Goldberg cut-off could 
not be adjusted for differences in physical activity. Instead, an average physical activity level 
value of 1.55 was chosen based on the estimation that most overweight participants did little 
or no exercise. This may however, not be true for all participants.  
4.8.1.5 Appetite scores 
Investigation 1, 2 and 3 showed no significant effect of mycoprotein consumption of appetite 
scores which is in line with previous findings from Burley et al. and Marks (Burley et al., 
1993, Marks LI, 2005).  
4.8.1.6 Potential mechanisms 
In this study, the main difference between the meals was the fibre content and the amino 
acid profile of the meals which were not matched. The amino acid profile of different sources 
of protein was shown to be of particular importance in animal studies. Several amino acids 
were shown to be more potent than others at reducing appetite or increasing GI hormones. 
Leucine, for example, was shown to limit weight gain when supplemented to rodents fed on 
a high-fat diet (Zhang et al., 2007, Ropelle et al., 2008). L-arginine is also a potent insulin 
secretatogue and was recently shown to reduce energy intake, increase GLP-1 and PYY 
levels and improve glucose tolerance in rodents (Floyd et al., 1966, Clemmensen et al., 
2013, Greenwood, 2012). Due to inherent differences in amino acid composition of the 
mycoprotein and control protein, the amino acid profile of the test meals was not matched in 
this set of investigations. However, differences in amino acid profile, presented at the 
beginning of each section, were minimal. 
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The fibre contained in mycoprotein is composed of chitin and β-glucan linked in a strong 
matrix. It is 88% insoluble. Although the remaining 12% is soluble, it is unlikely to have 
affected energy intake to such an extent. This suggests that the insoluble fibre may be the 
main active ingredient in mycoprotein. Chitin is generally not found in the diet of humans, 
therefore its effects in the gastro-intestinal tract remain to be clarified. The β-glucan in 
mycoprotein is different from plant-derived β-glucan originating from barley and oat, which 
have been shown to reduce energy intake in several animal and human studies (Vitaglione 
et al., 2009, Beck et al., 2009, Lin et al., 2013). It is possible that although of different 
structure and properties, mycoprotein β-glucan has common characteristics and acts in a 
similar way. 
However, considering that the effect of mycoprotein on satiety was observed within 3 hours, 
it is unlikely that these effects would be driven by the fermentation of fibre from mycoprotein 
and the formation of short-chain fatty acids. Mycoprotein, previously described as „bulky‟, 
may have an impact on gastric distension and gastric emptying. This study showed no 
difference in gastric emptying using the paracetamol method. It is possible that subtle 
differences in gastric emptying were not detected by the paracetamol method. As 
mycoprotein is less energy dense than meat, and because the meals were matched for 
weight, the volume of the mycoprotein meal was greater than that of the chicken meal. This 
may have impacted on gastric distension which may be signalled to the brain by neural 
pathways. Other gastro-intestinal hormones involved in appetite regulation and gastric 
distension, such as cholecystokinin, may have been involved in the reduction of appetite 
following mycoprotein consumption. 
4.8.1.7 Future work in appetite and body weight maintenance  
No previous study has investigated the long-term effects of mycoprotein on energy intake 
and body weight. Two previous studies investigated the effect of mycoprotein on blood lipids 
for 3 weeks and 8 weeks. In the 3-week study from Turnbull et al., 17 subjects were 
assigned to a specific diet containing 191g mycoprotein paste daily or an isocaloric diet. 
Because subjects were required to eat the prepared meals which were isocaloric, it is 
impossible to assess the effect of mycoprotein on body weight. In the 8-week study from 
Turnbull et al., 21 free-living subjects consumed an average of 8-8.5 cookies per day 
supplemented with mycoprotein or soya concentrate control. The daily portion of 
mycoprotein powder was 27g. Although significant reductions in total cholesterol and low-
density lipoprotein were observed, the supplementation of mycoprotein did not result in 
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significant changes in body weight throughout the study. However, firstly, the study was not 
designed and powered to investigate changes in body weight (the specific effect of 
mycoprotein on blood lipids could only be shown if body weight was not different in the two 
arms of the study). Secondly, the daily supplementation was 27g of mycoprotein powder 
which did not show any effect on energy intake in our study. To confirm whether mycoprotein 
exerts any long-term effects on energy intake and body weight, a double-blinded study could 
be designed using mycoprotein paste and isocaloric nutrient matched meat products in 
overweight subjects. 
4.8.2 Gastro-intestinal hormones GLP-1 and PYY 
4.8.2.1 Effect of the protein type  
My hypothesis was that mycoprotein would reduce energy intake further than chicken by 
increasing the release of GI hormones GLP-1 and PYY. The results of the study do not 
support the initial hypothesis; Investigation 2 showed that 132g of mycoprotein paste had no 
significant effect on GLP-1 and PYY plasma concentrations while there was a 10% reduction 
in energy intake. Previous work from Marks suggested that mycoprotein may increase GLP-
1 levels, however the meals given were not matched for macronutrient composition and it is 
therefore difficult to interpret the results (Marks LI, 2005). While there was a clear increase in 
GLP-1 levels following the consumption of the test meal, no post-prandial increase in PYY 
concentrations could be detected. This may be due to the sensitivity of the assay which 
could not reliably measure PYY concentrations. Or it is possible that the caloric load of the 
meal was not sufficient to induce a detectable increase in PYY.  
4.8.2.2 Effect of the protein level 
I chose to measure GLP-1 and PYY concentrations at the high protein level because 
differences in energy intake at the ad-libitum meal were shown to be significant. A previous 
study showed that increasing proportion of protein within a test meal significantly induces 
greater GLP-1 and PYY responses in humans (Belza et al., 2013). However, the authors 
also found significant differences in appetite feelings between protein levels whereas 
appetite feelings and energy intake did not significantly differ at different protein levels in this 
study, suggesting that no differences in GI hormones would occur. 
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4.8.2.3 Other potential mechanisms 
The results of my study suggest that the effect of mycoprotein on energy intake is mediated 
by another mechanism than increased plasma concentrations of the hormones examined. 
Other mechanisms involved in the short-term effect of mycoprotein on appetite may include 
other GI hormones or gastric distension.  
4.8.2.4 Future work 
Whether the small amount of soluble fibre contained in mycoprotein or the greater insoluble 
fibre content can be partly or totally fermented upon digestion in the GI tract remains to be 
clarified. However, if any fermentation does occur, the production of short-chain fatty acids in 
the colon may exert effects on appetite through the action of GLP-1 and PYY. This would, 
however, only take place at a later stage following ingestion. A new study could therefore be 
designed giving a test meal containing mycoprotein or a control protein for breakfast, a set 
lunch containing no mycoprotein, followed by an ad-libitum meal in the evening. Energy 
intake at the ad-libitum meal would therefore confirm whether mycoprotein exerts any effect 
on long-term satiety as suggested by the analysis of the 24-hour food diaries in this study. 
4.8.3 Gastric emptying 
The hypothesis of investigation 3 was that mycoprotein would significantly delay gastric 
emptying compared with chicken. Indeed, previous work investigating the effect of 
mycoprotein on gastric emptying showed no difference compared with ham (Marks LI, 2005). 
However, meals were not matched for macronutrient composition and further clarification 
was needed. Using the paracetamol method, no significant difference in gastric emptying 
following the consumption of the mycoprotein and chicken test meals were found in my 
study. The paracetamol method has been widely used to estimate gastric emptying as it is a 
relatively inexpensive replacement to the scintigraphic, polyethylene glycol dilution and 13C 
acetate breath test methods. Several studies have found that the method can be used as a 
proxy to estimate gastric emptying rate in solid meals (Naslund et al., 2000, Glerup et al., 
2007). However, in these studies, paracetamol was given with 150mL of water immediately 
after the consumption of a solid meal. In this investigation, however, the paracetamol was 
given with 250mL of water with the test meal and participants were instructed to drink and 
eat at the same rate. This was to ensure that the paracetamol would mix with the test meal. 
It is possible that the rate of drinking and eating may have affected the rate of absorption of 
paracetamol into the blood.  
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Although this study showed no effect on gastric emptying, it is possible that the bulkiness of 
mycoprotein may have induced greater gastric distension which is difficult to measure 
without the use of imaging techniques.  
4.8.4 Glucose and insulin concentrations 
My hypothesis was that the consumption of mycoprotein would result in reductions in insulin 
levels compared with chicken, which would lead to significant improvements in insulin 
sensitivity. 
4.8.4.1 Effect of the protein type and level on glucose concentrations 
Investigation 1, 2 and 3 showed that mycoprotein did not induce any significant changes in 
glycaemic response compared with whey protein and chicken. This is in line with the findings 
from Marks et al. (Marks LI, 2005, Marks LI, 2004). Turnbull et al., however, found a 
significant reduction in glucose concentration at 60 min following the consumption of 
mycoprotein compared with a soy control drink. However, their design was considerably 
different, with the use of a liquid OGTT-like test meal containing soy and milk and 
mycoprotein powder. Investigation 2 showed no significant effect of the protein level on 
glucose concentrations. 
4.8.4.2 Effect of the protein type and level on insulin concentrations 
Results from investigation 1, 2 and 3 showed that mycoprotein reduces post-prandial serum 
insulin concentrations compared with both whey protein and chicken at several time points 
and overall using the corrected AUC. These results are in line with previous findings from 
Turnbull et al.‟s study showing a significant reduction in insulin concentrations at 30 and 60 
min respectively using 20g of mycoprotein powder. This is the first time that mycoprotein 
paste is shown to decrease insulin concentrations compared with a macronutrient and 
energy matched control meal.  
Furthermore, although a significant effect of the protein level was observed following the 
consumption of chicken (with the high protein chicken meal inducing significantly higher 
insulin response than the medium chicken meal), no significant differences were noted 
between protein levels following the consumption of mycoprotein. Previous studies have 
showed increased insulin concentrations in response to greater protein intake (Blom et al., 
2006, Spiller et al., 1987) although other studies showed no differences or opposite changes 
in insulin concentrations in response to increased protein content (Bowen et al., 2006, Leidy 
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et al., 2010, Belza et al., 2013). The results of my study suggest that increasing amounts of 
mycoprotein do not induce protein-induced hyperinsulinemia as it does with increasing 
amounts of chicken.  
4.8.4.3 Insulin sensitivity 
Investigation 1 and 2 suggested improved insulin sensitivity following the consumption of 
mycoprotein: As no significant differences in glucose concentrations were observed, less 
insulin was required to maintain glucose homeostasis at a given glucose concentration. As a 
result, the pancreas produces less insulin, which may prevent β-cell damage in the long-
term. Analysis of the Matsuda, Insulinogenic and Disposition Index confirmed that 
mycoprotein improved insulin sensitivity and decreased beta-cell output at the high protein 
level compared with chicken. Previous studies have not investigated and reported changes 
in insulin sensitivity. In Turnbull et al.‟s study, no significant changes in glucose and insulin 
concentrations were observed in an OGTT following 3 weeks of supplementation with 
mycoprotein paste or a control diet. This suggests that the effect of mycoprotein on insulin 
sensitivity may be acute and not prolonged over the long-term.  
4.8.4.4 Potential mechanisms 
Soluble dietary fibres have previously been shown to improve insulin sensitivity acutely. For 
example, viscous fibres rich in β-glucan found in cereals such as barley and oats are thought 
to act on intestinal transit, glucose homeostasis and modulate GI hormone production 
through their fermentation to short-chain fatty acids (Slavin, 2005). It is possible that, 
although of different structure and properties, mycoprotein β-glucan present common 
characteristics and act in a similar way. However, it is unlikely that short-chain fatty acids 
would be fermented from mycoprotein fibre within the studied time frame (3 hours). 
Furthermore, β-glucan fibres in mycoprotein are mainly insoluble.  
As previously discussed, mycoprotein filaments form a strong β-glucan-chitin matrix (Miller 
SA, 1999). My original hypothesis was that the fibre matrix may be responsible for delayed 
gastric emptying as suggested by previous studies (Marks LI, 2004) or that it would 
modulate the absorption of nutrients in the intestine. However, results from investigation 3 do 
not support this hypothesis. Previous authors also suggested that chitin may be transformed 
into soluble fibre chitosan in the GI tract (Turnbull and Ward, 1995). However, no study has 
been able to investigate and confirm this. Chitin may be resistant to digestion as its structure 
is similar to that of cellulose and xylose. The effects of the digestion of the mycoprotein beta-
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glucan-chitin matrix in the GI tract remain unclear as this matrix is specific to this ingredient 
and rarely consumed in a normal diet. Potentially the physical barrier created by the 
mycoprotein fibre matrix may have prevented glucose absorption and lead to gastric 
distension. This is however, difficult to confirm in a clinical trial.  
Although matched for protein content, meals had different amino acid profiles. In 
investigation 1, the whey protein meal contained higher levels of branched chain amino 
acids such as leucine and isoleucine. Whey protein and branched-chain amino acids 
leucine, isoleucine, and valine have been previously shown to have potent insulinotropic 
effects compared with other sources of protein (Frid et al., 2005, Nilsson et al., 2007). In line 
with these findings, this study showed that post-prandial insulin concentrations following the 
high whey protein meal were not different to those following the control meal although the 
control meal had greater carbohydrate content (control NP: 40.6g, high WP: 26.3g). In 
investigation 2, however, the amino acid profile of the meals was very similar. It is therefore 
unlikely that they would be responsible for such an effect on insulin concentrations. 
4.8.5 Energy expenditure and substrate oxidation 
Investigation 3 aimed to explore the effect of mycoprotein on energy expenditure and 
substrate oxidation. Protein has been shown to increase energy expenditure independently 
of the energy content (Raben et al., 2003). Because the test meals used in investigation 3 
were matched for protein content, it is therefore not surprising that mycoprotein did not 
induce significant changes in resting energy expenditure. Changes in respiratory quotient 
and substrate oxidation were not significant. This area of research is relatively new and 
requires more investigation. There are no studies directly investigating the effect of fibre 
supplementation on substrate oxidation. It is possible that the amount of fibre in mycoprotein 
is too small to induce acute changes in substrate oxidation. Whether prolonged 
supplementation of mycoprotein could induce significant alterations in substrate oxidation 
over the long-term is unknown.  
4.8.6 Metabonomics 
The metabonomics analysis was carried out in order to identify novel markers of 
mycoprotein intake, with the view to understand the mechanism of action of mycoprotein on 
appetite and glucose homeostasis. Results from investigation 4 showed significant 
differences in urine metabolites following the consumption of mycoprotein and chicken.  
Several markers of meat intake were significantly increased following the consumption of 
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chicken compared with mycoprotein, which was predictable as mycoprotein is not meat. 
Previous metabonomics studies have also characterised the effect of meat intake on the 
metabolome (Cross et al., 2011, Stella et al., 2006). The results of this study suggest that 
such markers could be used in future studies to identify and quantify meat intake in acute 
nutrition studies. Other markers, such as guanidinoacetate and an unknown metabolite, 
were increased following mycoprotein intake. Guanidinoacetate is a precursor of creatine, 
which plays an important role as energy carrier and mediator in the cell. However, at the 
present time, the identification of these metabolites could not be confirmed and the results 
are therefore limited until the identification can be completed. It is possible that the unknown 
metabolites could not be identified because they are specific to mycoprotein and have 
therefore never been characterised in previous nutritional studies. Once the identification of 
the metabolites is completed, the results of the metabonomics analysis may help to identify 
markers of mycoprotein intake previously shown to be involved in appetite regulation or 
glucose homeostasis, thereby clarify how mycoprotein exerts its effects on metabolism. 
The study investigated time-related changes in plasma samples using metabonomics. The 
results obtained were in line with the results from the biochemistry analysis. Furthermore, 
the results showed that branched-chain amino acids increased in the plasma 3 hours 
following the consumption of mycoprotein. However, the changes were not significantly 
different than chicken, suggesting that the digestibility of mycoprotein may be similar to that 
of chicken. This would then support the gastric emptying results showing no difference in 
protein absorption between mycoprotein and chicken.  
4.8.7 Future recommendations 
This study did not provide sufficient material to understand how mycoprotein affects energy 
intake and insulin concentrations. Isolating the components of mycoprotein, such as the β-
glucan and chitin may help to understand the effect of each component on energy intake 
and glucose homeostasis. However, it is also possible that the effects of mycoprotein come 
from the complex interaction of its components and isolating them may lead to a loss of 
activity. No previous study has investigated the digestion of mycoprotein in the GI tract. It 
would be interesting to extract digested mycoprotein from the GI tract of animals and 
analyse its composition at regular time intervals following oral ingestion. 
Results on insulin sensitivity are of great importance and suggest that mycoprotein may be 
of interest in the dietetic prevention of T2DM. However, results were estimated by indices 
and further research should be carried out using more rigorous measures of insulin 
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sensitivity. Furthermore, results may vary considerably in insulin resistant or diabetic 
individuals. Consequently, further research should be carried out in specific sub-population 
such as individuals who are at risk of developing T2DM or non-insulin dependent diabetic 
individuals. 
The application of metabonomics to nutrition is a relatively new area of research and 
therefore much work remains to be done. One of the most difficult tasks in metabonomics is 
the identification of metabolites. To further this line of investigation, I would like to complete 
the identification of all metabolites and find novel markers of mycoprotein intake which may 
give an indication of the mechanism of action of mycoprotein. In this study, the test meal was 
a mixed meal containing rice, vegetables and cheese which may have affected the results. 
The metabonomic analysis could be repeated using pure mycoprotein and chicken in order 
to identify specific markers of these foods.  
4.9 Conclusion 
The present set of studies showed that mycoprotein significantly reduces acute energy 
intake at an ad-libitum meal compared with chicken in overweight volunteers. The results 
suggest that the effect of mycoprotein on energy intake is not mediated by changes in GI 
hormones GLP-1 and PYY or changes in gastric emptying. The difference in energy intake 
was only significant at the high protein level, thus suggesting that a minimal amount of 132g 
of mycoprotein paste is needed to achieve significant reductions in energy intake compared 
with a control protein. This set of investigations suggests that energy intake during the 
following 24 hours was also significantly decreased following the consumption of 
mycoprotein although this will require further clarification using a validated method. There 
were no significant effects of the protein level on energy intake at the ad-libitum meal or over 
24 hours and on the appetite ratings.   
Mycoprotein significantly decreased serum insulin concentrations and improved insulin 
sensitivity compared with both whey protein and chicken. Mycoprotein did not induce 
significant changes in substrate oxidation. 
Combined with the literature, the results of this study suggest that mycoprotein may be of 
interest in the dietary prevention of obesity by reducing energy intake acutely and improving 
lipidic and glycaemic profiles.  
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Chapter 5 
General discussion 
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5.1 Introduction 
Obesity has reached epidemic proportions worldwide. Recently, the concept of abdominal or 
„central‟ adiposity, characterised by the accumulation of adipose tissue around the abdomen 
and increased waist circumference, has emerged to better recognise obese subjects who 
are at high risks of cardiovascular disease (CVD) and type-2 diabetes mellitus (T2DM) 
(Despres and Lemieux, 2006, Yusuf et al., 2005, Chan et al., 1994). In particular, visceral 
adipose tissue (VAT), surrounding vital organs inside the abdominal cavity such as the liver, 
the pancreas and the heart, has been associated with impairment of glucose and lipid 
metabolism. Consequently, increased VAT has been recognised as a greater risk factor for 
the metabolic syndrome, CVD and T2DM than abdominal adiposity alone (Fujioka et al., 
1987, Kuk et al., 2006, Neeland et al., 2012).Over the long-term, excessive intake of energy 
and dietary fat may also lead to the redirection of the lipid supply towards non adipose 
organs such as the liver and the pancreas. The accumulation of lipids within non adipose 
organs, known as ectopic fat, exacerbates insulin resistance in the skeletal muscle and liver 
(Koska et al., 2008, Barzilai et al., 1999) and has been associated with increased risk of 
CVD and T2DM. 
In the present context of worldwide-prevalent obesity, it has become a priority to first, 
optimise the outcome of current treatments for obesity and second, find novel affordable and 
low-risk treatments or preventive tools suitable to the scale of the obesity problem. Whilst 
weight loss and energy restriction may be the first-line aim of such treatments, improvement 
of metabolic variables such as lipid profiles, glycaemia and insulin sensitivity may also be of 
benefit. This thesis aimed to provide an insight into these two concepts by adding knowledge 
on nutritional and surgical influences on appetite regulation and body composition in 
overweight and obese humans. The first part of my work focussed on the optimisation of one 
of the gold standard treatment for obesity, Roux-en-Y gastric bypass (RYGB), and the 
second set of investigations explored the effect of a novel food, mycoprotein, on appetite 
and post-prandial metabolism in overweight individuals.  
5.2 Clinical relevance of the weight loss and body composition 
study  
Increased liver fat and size represents the greatest risk of complications and liver laceration 
during RYGB (Schwartz et al., 2003). Indeed, as many as 90% of obese individuals 
undergoing RYGB have high liver fat (Machado et al., 2006). Previous studies have 
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suggested that pre-operative weight loss may result in reduced liver size and improved 
surgical outcomes (Benotti et al., 2009, Alami et al., 2007, Alvarado et al., 2005). However, 
the optimal duration and type of the pre-operative diet are unclear. My study aimed to 
investigate the effect of 3 pre-operative diets on liver fat and body composition prior to Roux-
en-Y gastric bypass in morbidly obese individuals. The primary hypothesis of this study was 
that a 6-week pre-operative low-calorie diet (LCD) would significantly reduce liver fat 
compared with a conventional food pre-operative diet routinely prescribed in a bariatric clinic 
and a 2-week pre-operative LCD. 
The study successfully showed that both 2-week and 6-week pre-operative LCD induced 
significant reductions in liver fat compared with the conventional food pre-operative diet 
prescribed as a standard of care at the Imperial Weight Centre for bariatric surgery. 
However, no significant difference in liver fat reduction following the pre-operative diet was 
found between the 2-week and 6-week LCD. Similar findings have been reported in previous 
studies (Colles et al., 2006). This suggests that for bariatric patients at normal risk prior to 
RYGB, a 2-week LCD may be optimal to induce significant reduction in liver fat whilst limiting 
the burden associated with energy restriction. 
At baseline, liver fat correlated modestly with visceral adipose tissue content (r=0.54) and 
waist circumference (r=0.48) but not with body weight. This suggests that, in order to 
estimate the risks of complications prior to surgery, pre-operative assessment should focus 
on anthropometric measurements particularly in the abdominal area although they will not 
necessarily predict liver fat. The reduction in liver fat during the pre-operative diet correlated 
with the decrease in body weight (r=0.72) confirming that pre-operative weight loss before 
RYGB is of benefit. 
Interestingly, liver fat content was not reduced in the first month after RYGB in participants 
from the 2-week and 6-week LCD groups despite significant weight loss and improvements 
in insulin sensitivity. Such findings have been previously reported (Johansson et al., 2008). 
Possibly, in the early period following RYGB, changes in lipid mobilisation from the adipose 
tissue and free fatty acids flux may prevent reductions in liver fat content normally 
associated with energy restriction. In the control group, conversely, liver fat content was 
reduced following RYGB while insulin sensitivity improved, thus showing the „expected‟ 
relationship between liver fat and insulin sensitivity. Whether the discrepancy between 
groups is due to differences in the pre-operative weight loss or to differences in baseline liver 
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fat is unclear. More research should be carried out in patients with fatty liver disease in order 
to clarify these results. 
Weight loss during the 2-week and 6-week LCD diets was 2.3kg per week which is greater 
than previously reported weight loss during VLCD or LCD (Lewis et al., 2006, Edholm et al., 
2011, Van Nieuwenhove et al., 2011).  Previous studies have suggested that greater weight 
loss could be achieved with behavioural therapy and it is possible that the compliance visits 
during this study helped in the achievement of greater weight loss (Pekkarinen and 
Mustajoki, 1997). However, pre-operative weight loss in the control group was lower than the 
predicted weight loss, suggesting a lack of compliance in the control group. The better 
adherence in the LCD groups could be explained by the suppression of food choices, limited 
contact with normal food or intensity of the treatment. Furthermore, participants on the LCD 
may have felt that the LCD was a preparation for their diet after the procedure as the post-
operative diet is of similar nature in the first month. Therefore, participants may have 
considered the pre-operative LCD as a challenge to see whether they were willing to make 
changes in their lifestyle.  The great variability in most results in the control group shows that 
a conventional food diet may rely more on individual willpower. In the light of these results, it 
may therefore be of benefit for both patients and surgeons to offer different pre-operative 
diet options at bariatric clinics. The final choice of the optimal pre-operative diet for each 
individual should be made as a joint decision between the patient and the dietitian based on 
the physical characteristics and weight loss required as well as the eating behaviour of the 
patient.  
In the whole cohort of participants, hunger, desire-to-eat, and prospective food intake were 
greatly reduced following RYGB while post-prandial fullness remained elevated for several 
hours compared with baseline which is in line with previous studies (le Roux et al., 2007, 
Korner et al., 2005). Consequently, acute food intake at the ad-libitum meal was reduced by 
80% at 1-month post-surgery and 61% 6-month post-surgery compared with baseline. Daily 
energy intake, assessed by detailed 3-day food diary, was also reduced by 73% at 1-month 
post-surgery and 40% at 6-month post-surgery. Previous studies have shown that several GI 
hormones are elevated after RYGB and may be the main mechanism explaining the 
persistent satiety observed in post-RYGB patients (le Roux et al., 2006a, Korner et al., 2005, 
le Roux et al., 2007). Furthermore, other studies have reported alterations in the food reward 
pathways following RYGB (Naslund et al., 1997, Ochner et al., 2011). As a consequence, 
gastric bypass patients may experience a decrease of interest in energy-dense food and a 
change of sensitivity to sweet taste therefore increasing the appeal of unsweetened fresh 
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products which results in healthier eating habits. The results confirm that RYGB induces a 
significant reduction in energy intake compared with LCD. Indeed, although LCDs have been 
shown to successfully induce weight loss, maintenance of weight loss in the long-term is 
often challenging. To date, no other treatment than metabolic surgery has been able to 
reproduce the satiating effects of RYGB. However, research in the appetite regulation 
system may lead to the discovery of new drugs capable to mimic the effects of the GI 
hormones. 
This study showed that insulin sensitivity was improved following both LCD and RYGB. 
However, pre-operative weight loss improved insulin sensitivity to a lesser extent than 
RYGB. Following RYGB, a typical „left‟ shift in the glucose and insulin concentrations was 
observed. The rapidity in glucose absorption is likely to be due to the rearrangement of the 
GI tract and rapid gastric emptying while the shift in insulin release may be due to both rapid 
glucose absorption and elevated GLP-1 levels (Falken et al., 2011). Over the long-term, 
better glycaemic control induced by RYGB may lead to the restoration of beta-cell function, 
as estimated by the insulinogenic and disposition indices in this study. 
Importantly, this study did not show any differences in subjective rating of surgery difficulty 
and operative time. However, firstly, the number of participants was limited and may not 
have been sufficient to detect such changes (Edholm et al., 2011, Van Nieuwenhove et al., 
2011). Secondly, participants in the study were of relatively small size compared with the 
general bariatric population and may therefore not be at risk of complications and surgery 
difficulty to start with. Lastly, the designated surgeon in this study was experienced and 
operated on a large number of cases. Surgeon‟s experience and number of cases have 
been previously shown to be major predictors of surgery success (Perugini et al., 2003, 
Kelles et al., 2009).  Pre-operative weight loss and liver reduction may therefore be more 
beneficial in small bariatric clinics with a limited number of cases. Obesity is increasing more 
rapidly in developing countries than in developed countries. Therefore, it could be expected 
that the numbers of procedures performed will increase in these countries in the next 
decades. The results of this study may therefore be more relevant to emerging bariatric 
clinics. Furthermore, in larger centres, pre-operative weight lost may result in decreased 
operative time and, consequently, reduced cost. 
To conclude, this study has highlighted several limitations in the current optimisation of 
morbidly obese individuals for gastric surgery and showed that LCD may be of benefit to 
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induce pre-operative weight loss and reduce liver fat prior to RYGB compared with other 
routinely prescribed diets.  
5.3 Limitations and future recommendations  
There are several limitations to this work. The main limitation of the study was that the 
number of participants who had completed the study at the time of analysis was limited. This 
induced large variability in the results and possibly lack of significant differences. 
Recruitment was largely slowed by the exclusion criteria and particularly the compatibility of 
participants with the MRI scanner. A large number of obese patients reported being 
claustrophobic or constricted in the scanner. As for any clinical trial, the recruitment was 
done on a voluntary basis. Furthermore, as the study was randomised, patients had to agree 
to follow any one of the 3 pre-operative diets before entering the study. This may have 
induced a significant bias as only motivated patients would have enrolled in the study. 
Furthermore, although the study was initially designed to recruit males only, the eligibility 
criteria were changed at a later date to include both males and females because of 
recruitment difficulties. Although this increased the recruitment rate, it also led to greater 
variability in the results due to gender differences in body composition. Similarly, in order to 
improve the recruitment rate, patients of different ethnicity, age and medical history were 
recruited, which may have led to further variability in the results. 
As discussed, the sample population was not entirely representative of the general bariatric 
population because they needed to be able to have an MRI scan to be eligible. This 
restricted the study sample to relatively small patients and may have biased the results, 
particularly surgical outcomes. The study shows that increased pre-operative weight loss 
may not be necessary in smaller patients as the surgical difficulty was similar for each group. 
Investigating the effect of different pre-operative diets in super-obese patients with BMI ≥50 
may show that surgical difficulty is lessened by increased pre-operative weight loss. 
Increased pre-operative weight loss by liquid LCD prior to RYGB may be more beneficial to 
super-obese patients as increased BMI is associated with a greater risk of surgical 
complications (Mason et al., 1992, Flum et al., 2009). To extend the work, it would therefore 
be interesting to carry out a similar investigation in super-obese patients using an open-MRI 
scanner.  
In order to prevent any variability in the rating of the surgical difficulty, a single surgeon 
operated on the participants. However, on 3 occasions, the surgeon was replaced by a 
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colleague and data from these participants was therefore excluded from the analysis to 
uphold the integrity of the results. The rating of the surgery difficulty by the surgeon may also 
be subject to individual variability between days and within days. Ideally, the rating of 
surgery by both surgeons present during the procedure may be more accurate. However, in 
reality, it is unlikely that the two same surgeons would operate on each patient on a regular 
basis. Previous studies have used similar subjective measurements to assess difficulty 
surgery. However, such measurements, as any VAS, are highly dependent on the person 
using them. It may therefore be of interest to develop a more scientific approach to measure 
objective surgery outcomes.  
Once recruitment targets are met, GLP-1, PYY and ghrelin levels will be analysed to confirm 
whether weight loss by LCD is associated with changes in GI hormones and whether any 
changes are dependent on weight loss or diet duration. GI hormones levels will also be 
compared before and after RYGB to confirm results from previous studies.  
Although this study found significant differences in liver fat content reduction following the 
pre-operative diet, liver volume was not measured. While there is a known correlation 
between liver fat content and liver volume, the relationship between the two is not fully 
understood (Edholm et al., 2011, Lewis et al., 2006). Previous studies have reported 
inconsistent results where the decreases in liver fat and volume are not linearly proportional. 
Both reductions in liver fat and volume may be dependent on water content which may 
decrease as liver glycogen stores reduce during weight loss. To clarify the effect of pre-
operative and surgical weight loss on liver volume, liver volumes could be manually 
calculated with a semi-automated software for each participant. Liver volume prior to RYGB 
could then be correlated with liver volume assessed by the surgeon and to surgery difficulty 
in order to confirm whether decreased liver size is associated with better subjective surgical 
field of view and surgical outcomes.  
5.4 Nutritional relevance of the mycoprotein investigations  
Mycoprotein is a meat-replacement product, of fungal origin, popular among vegetarians, 
meat-avoiders but also „normal‟ consumers. Previous research has shown that mycoprotein 
may reduce appetite in lean individuals (Burley et al., 1993, Turnbull et al., 1993).  The aim 
of my project was to investigate the acute effect of mycoprotein on energy intake in 
overweight individuals.  
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Mycoprotein contains protein and fibre, and is characterised by its specific fibre matrix, not 
usually found in other food. The texture of mycoprotein has been previously described as 
„bulky‟ or „chewy‟, which implies that mycoprotein may induce changes in gastric emptying 
and GI hormone release as do other fibre-rich foods. In this study, my main hypothesis was 
that mycoprotein would reduce energy intake at an ad-libitum meal in a dose-dependent 
fashion compared with a control protein and that this would be mediated by changes in GI 
hormones concentrations PYY and GLP-1.  
My results showed that 132g of mycoprotein paste induced a 10% reduction in energy intake 
at the ad-libitum meal compared with a macronutrient matched meal containing chicken in 
overweight volunteers, which confirms previous findings in lean individuals (Burley et al., 
1993, Turnbull et al., 1993). However, energy intake was reduced to a much smaller extent 
in my study. This could be due to differences in study design because mycoprotein was 
given in a controlled environment at breakfast in this study while other studies used free-
livings subjects and a lunch meal. Furthermore, this study involved overweight volunteers 
and it is possible that mycoprotein reduces energy intake to a smaller extent in overweight 
subjects or that appetite in overweight individuals is less regulated by homeostatic cues such 
as GI hormones and more driven by hedonic, environmental or emotional cues. 
The study showed that both mycoprotein powder and paste improve insulin sensitivity and 
reduce beta-cell output without altering glucose concentrations as assessed by standard 
indices. This suggests that, in the long-term, mycoprotein may result in the sparing of the 
beta-cells. However, more robust measurements of insulin sensitivity assessment, such as 
the hyperinsulinemic euglycaemic clamp, should be used to confirm this.  
The investigations of the mechanisms underlying the mode of action of mycoprotein were 
inconclusive. Mycoprotein intake did not induce a significant increase in GLP-1 and PYY, 
suggesting that the reduction in energy intake is not mediated by changes in the release of 
these hormones. Furthermore, investigation 3 showed that mycoprotein did not delay gastric 
emptying, although it is possible that changes in gastric emptying were below the detection 
level of the paracetamol recovery method. No previous study has investigated the effect of 
chitin and β-glucan (specific to mycoprotein) on energy intake or insulin concentrations. One 
reason for this is that investigating mechanisms in humans is difficult due to high natural 
variability. Animal models may, however, overcome this difficulty. Indeed, previous studies 
have shown that mycoprotein reduces total cholesterol in rodents, suggesting that rodent 
models can be successfully used (Owen et al., 1976a, Owen et al., 1976b). Furthermore, 
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using metabonomics, this study has showed differences in urine metabolites following the 
consumption of mycoprotein compared with chicken. Several urine metabolites associated 
with meat consumption were significantly increased in urine following the consumption of 
chicken compared with mycoprotein while other, unidentified metabolites, were increased 
following mycoprotein intake. Further work should be carried out in order to identify these 
metabolites which may give an indication of the mechanism by which mycoprotein reduces 
energy intake and insulin concentrations. 
The results of the study suggest that mycoprotein, impacting on both energy intake and 
glucose homeostasis may be a useful tool in the dietetic prevention of overweight and 
obesity. Indeed, based on the results from this study, the intake of 132g of mycoprotein 
every day may result in an energy deficit of 67kcal per day, thus potentially leading to a 
weight loss of 2.9 to 6.2kg per year. This result is of significant importance for the prevention 
of weight gain in the obese population. This study has also added to the scientific knowledge 
by confirming that mycoprotein also reduces energy intake in overweight individuals and that 
the short-term reduction in energy intake is not mediated via changes in GI hormones PYY 
and GLP-1 or gastric emptying. 
At the present time, the nutritional and environmental impact of red meat consumption is 
receiving much scientific and media attention. The carbon footprint of mycoprotein is two to 
five times lower than that of beef depending on the final product and the country of 
marketing (Marlow Foods Limited, 2013a). In the United-Kingdom, particularly, mycoprotein 
is locally produced, therefore further reducing its carbon footprint induced by travel. 
Mycoprotein only requires a carbohydrate substrate to grow and can grow indefinitely if 
harvested regularly. Consequently, this makes mycoprotein an attractive alternative to meat 
protein. Therefore, mycoprotein could be incorporated as part of a vegetarian diet or for 
individuals concerned with the environmental impact of meat. The protein content of 
mycoprotein is also higher than most other vegetarian sources such as tofu, and may 
therefore be used as an effective protein source for vegetarians. Furthermore, previous 
research has highlighted the beneficial effects of other fungal β-glucans in the prevention of 
allergies and cancer (Rop et al., 2009). While these properties are highly dependent on the 
physico-chemical properties of the β-glucans, fungal β-glucan do seem to share marked 
immunity-stimulating effects in humans.  
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5.5 Limitations and future recommendations 
Several limitations in the design of the study may have affected the results. Firstly, although 
an attempt was made to match the macronutrient content of the test meals as closely as 
possible, it was impossible to match them exactly for all macronutrients and energy content. 
As a result, there were small differences in energy content, fat or carbohydrate content 
between the test meals. It is difficult to assess the impact of these differences. It is 
challenging to give mycoprotein in a blinded design because the food has such characteristic 
texture that it is easily recognisable. In this study, the risotto meal was designed to hide 
mycoprotein as much as possible in a homogenous paste and most participants did not 
report significant differences between the meals.  However, although palatability was well 
above 50 out of 100, the study showed significant differences between the chicken meal and 
the mycoprotein meal suggesting that participants may have not been totally blinded to the 
meal. Secondly, there was large phenotypic heterogeneity within participants. Although all 
participants were recruited within the overweight and obese BMI range of 25-32kg/m2, large 
differences were observed in terms of body fat content, physical activity levels, and eating 
behaviour. Most participants were restrained eaters which may have affected energy intake 
in response to the test meal. Great variability was also observed in appetite scores between 
males and females and individuals of different stature. Ideally, to ensure the homogenous 
recruitment of overweight individuals at risk of metabolic syndrome, another inclusion 
criterion such as increased waist circumference, or raised LDL levels should have been set. 
Lastly, this study used unweighed food diaries to assess energy-intake over 24-hours. 
Although instructions were given to the participants and food diaries were checked, the 
analysis showed significant under-reporting on several occasions, which diminishes the 
credibility of the 24-hour intake results. 
The main limitations of the results were that the portion of mycoprotein shown to decrease 
appetite was higher than what would normally be consumed in a commercial mycoprotein 
meal. Indeed, this study showed that 132g of mycoprotein induced a significant reduction in 
energy intake compared with chicken. However, 44g and 88g of mycoprotein paste did not 
result in any significant differences in energy intake. Most commercialised Quorn™ meals 
contain between 50 and 100g of mycoprotein. Therefore the impact of mycoprotein in regular 
portion sizes may be limited.  
Furthermore, the decrease in energy intake, although significant, was relatively small (10%, 
67kcal). Therefore the clinical relevance of the results may be limited. If mycoprotein was 
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consumed daily at the level used in my study, the reduction in energy intake would result in a 
weight loss of 8 to 17g per day. A body weight loss of 1kg would therefore necessitate 
between 59 to 125 days of supplementation. This greatly limits the potential of mycoprotein 
as a weight loss product. However, results on insulin sensitivity suggest that even if the 
potential of mycoprotein as an obesity treatment seems limited, it might still induce health 
benefits when consumed regularly as part of a diet. 
In the light of the results, three further investigations could be carried out. Firstly, the effect of 
mycoprotein on insulin concentrations in either pre-diabetic or diabetic individuals could be 
investigated. Indeed, for diabetic subjects, lifestyle changes with dietary modifications 
remain the first-line treatment to better control glycaemia. At the present time, it is unclear 
whether mycoprotein exerts beneficial effects on beta-cell function in pre-diabetic or diabetic 
individuals. A long-term study using mycoprotein-based and meat-based control meals could 
be designed with regular acute study days. Since mycoprotein powder showed significant 
effects on insulin sensitivity, the supplementation of mycoprotein in bread rolls or soups 
would also be easily achievable. Acute study days to measure glucose and insulin response 
to a standard meal should be designed and supplemented by a robust technique to measure 
insulin sensitivity such as the hyperinsulinemic euglycemic clamp considered the gold-
standard method to assess insulin sensitivity. 
Secondly, the long-term effect of mycoprotein on energy intake and body weight could be 
investigated in a clinical trial. As this study showed that 132g of mycoprotein was sufficient to 
induce a significant reduction in acute energy intake, a long-term study could be designed 
from this dose. Mycoprotein should be supplemented daily to overweight volunteers in the 
form of meals, and compared with energy and macronutrient-matched meat-based meals in 
a randomised controlled cross-over trial. Acute study days could investigate acute energy 
intake, glucose homeostasis and body composition at baseline and following 
supplementation. This could be done as a weight maintenance study or a weight loss study. 
This study has suggested that GI hormones and gastric emptying do not play a role in the 
regulation of energy intake at the ad-libitum meal by mycoprotein. However, it is possible 
that GI hormones play a role on the regulation of energy intake later following the ingestion 
of mycoprotein if partial colonic fermentation occurs. Designing a longer acute study day 
where mycoprotein is given in the morning in a test meal, followed by a set lunch and ad-
libitum dinner could help clarify the effects of mycoprotein in the GI tract.  
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Finally, this study has shown that the effect of mycoprotein on energy intake was not 
mediated by the protein content as test meals were matched for protein content. Previous 
studies as well as this study point to the direction of the fibre content of mycoprotein. 
However, because the type of fibre in mycoprotein is not found in other foods, it is difficult to 
compare its effect with the effect of other fibres. As a pilot study, isolation of the β-glucan 
from mycoprotein was initiated at Bangor University. However, the quantities were too 
limited to carry out any mechanistic rodent feeding investigations. Research into this area 
could lead to the development of an active component in mycoprotein, which may be more 
potent at reducing energy intake as with many cereals and their fibre content.  
5.6 General conclusion 
In the present context of obesity, there are limited options for individuals to achieve 
sustained weight loss. Dietary interventions and public health communication have shown to 
be of limited impact to date. Metabolic surgery is accessible to morbidly obese individuals 
only, therefore lifestyle changes and dietary modifications remain the first-line treatment for 
overweight individuals at risk of developing the metabolic syndrome.  
RYGB, although considered the gold-standard method for weight loss in morbidly obese 
individuals, is associated with several peri-operative complications. Liver steatosis is one of 
the main predictors of such complications and liver laceration during RYGB surgery. Current 
guidelines therefore require patients to lose weight prior to surgery in order to reduce liver 
size. To date, the optimal type and duration of the pre-operative diet remains unclear.  
The results of the study suggest that the currently prescribed pre-operative diet used at 
Imperial Weight Centre may not be sufficient to induce significant reduction in liver fat prior 
to RYGB and that the use of a liquid formula low-calorie diet may help patients achieve 
greater weight loss and liver fat reduction in preparation for their surgery. 
Fibre and protein have been shown to be of benefit in the regulation of energy intake and 
body weight. Therefore, mycoprotein, combining both fibre and protein in a novel food, may 
help in the regulation of appetite. Previous studies have shown that mycoprotein reduces 
energy intake compared with chicken in lean volunteers. However, the level of mycoprotein 
required to induce a significant reduction in energy intake remained to be clarified. 
Furthermore, the mechanisms of action of mycoprotein were largely unknown.  
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I have shown that, in overweight volunteers, 132g of mycoprotein paste reduced energy 
intake compared with chicken and that mycoprotein significantly improved insulin sensitivity. 
However, the reduction in energy intake was not mediated by changes in GI hormones GLP-
1 and PYY or gastric emptying in this study. Although the effect of mycoprotein on energy 
intake may be of limited clinical relevance, the results of my study still suggest that 
mycoprotein may be of benefit in the dietetic prevention of type-2 diabetes mellitus. Further 
research will be needed to confirm this. 
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Appendix 1: MRI safety checklist  
The MRI checklist was completed by participants prior to each MRI scan 
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Appendix 2: Consent form (weight loss study)  
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Appendix 3: Consent form (weight loss study) 
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Appendix 4: Nutritional composition of the Complan test meal  
 
 Complan Milk Total 
 Vanilla Strawberry Chocolate (%)  
Weight (g) 57 57 57 200 257 
Energy (kcal) 251 251 246 132 383-388 
Protein (g) 8.8 8.8 8.9 6.6 15.5 
Carbohydrate (g) 34.9 35.1 33.9 9.0 42.9-44.1 
 - of which sugars (g) 26.2 26.5 27.0 9.0 35.2-36.0 
Fat (g) of which 8.4 8.4 8.3 7.8 16.2 
  - SAF (g) 3.9 3.9 3.8 5.0 8.9 
  - PUFA (g) 1 1 1 0.3 1.3 
Fibre (g) 0.2 0.1 0.9 0 0.1-0.9 
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Appendix 5: Nutritional composition ice cream ad-libitum meal 
Participants were offered a bowl of ice-cream from the Häagen-Dazs range, provided in 
excess. Participants were required to keep the same flavour at each visit. 
Per 100mL Vanilla Strawberry Chocolate Praline 
Energy (kcal) 216 226 216 237 
Protein (g) 3.6 3.3 3.8 3.4 
Carbohydrate (g) 17.4 24.9 17.2 24.2 
    - of which sugars (g) 16.4 18.8 15.8 22.0 
Fat (g) 14.7 12.6 14.5 14 
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Appendix 6: Composition of the control diet 
The control diet was given as a booklet to the participant by the bariatric dietitian during their 
appointment at Imperial Weight loss centre. The booklet was explained to the participants 
and further advice was available upon request by the patient. The Control diet was a low-
carbohydrate 800-1000kcal/day conventional food diet. 
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Appendix 7: Instruction sheet for low-calorie diet 
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Appendix 8: Nutritional information of the Cambridge Weight Plan meals 
 
 
Cambridge meal 
(x4 per day) 
Skimmed milk Total 
 Shake Soup   
Weight (g) 40 40 750 910 
Energy (kcal) 146 137 240 788-824 
Protein (g) 14.1 13.5 25.5 79.5-83.1 
Carbohydrate (g) 14.4 13.6 33.0 87.4-90.6 
   - of which sugars (g) 12.8 4.5 33.0 51-84.2 
Fat (g) of which 2.9 2.5 1.5 11.5-13.1 
   - SAF (g) 0.7 0.4 1.0 2.6-3.8 
   - MUFA (g) 0.5 0.4 0 1.6-2.0 
   - PUFA (g) 1.1 1.2 0 4.4-4.8 
Fibre (g) 3.3 3.3 0 13.2 
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Appendix 9: Assessment of Surgery Questionnaire  
The surgery questionnaire was completed immediately after the procedure by the operating 
surgeon. To prevent any variability in the results, a single surgeon operated in all 
participants. The surgeon was blinded to the pre-operative diet followed by the participants. 
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Appendix 10: Participant Information Sheet for mycoprotein study  
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Appendix 11: Consent form for mycoprotein study  
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Appendix 12: Protocol for the preparation of the mycoprotein test meal 
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Appendix 13: Comparison of serum insulin concentrations between mycoprotein and chicken  
Serum insulin concentrations were compared between mycoprotein (M) and chicken (C) at low, medium and high level of protein.  
 LOW  MEDIUM  HIGH  
 C M  C M  C M  
0 12.0 12.0 p-value 13.6 13.6 p-value 17.7 17.7 p-value 
15 
53.1 
(42.5-63.7) 
42.8 
(32.2-53.4) 
NS 
47.3 
(39.0-55.6) 
36.8 
(28.5-45.1) 
0.006 
59.9 
(40.7-61.2) 
35.2 
(25-45.5) 
0.008 
30 
119.8 
(101.8-137.7) 
94.3 
(76.3-112.2) 
<0.001 
108.3 
(90.7-126.0) 
94.8 
(77.1-112.4) 
0.018 
125.4 
(109.6-141.2) 
92.1 
(76.3-107.9) 
<0.001 
45 
106.0 
(89.5-122.5) 
93.0 
(76.5-109.6) 
0.06 
98.7 
(84.6-112.7) 
86.6 
(72.5-100.6) 
0.065 
119.2 
(99.7-138.7) 
95.2 
(75.7-114.7) 
0.015 
60 
78.8 
(63.8-93.7) 
73.9 
(58.9-88.8) 
NS 
69.6 
(58.4-80.8) 
60.5 
(49.4-71.7) 
0.079 
88.1 
(75.0-101.1) 
69.2 
(56.5-82.5) 
0.003 
90 
46.0 
(38.3-53.8) 
40.0 
(32.3-47.7) 
NS 
44.0 
(37.8-50.1) 
33.4 
(27.2-39.5) 
<0.001 
54.9 
(44.4-65.4) 
40.9 
(30.3-51.4) 
0.003 
120 
31.8 
(26.1-37.6) 
28.3 
(22.5-34.1) 
NS 
30.1 
(24.8-35.4) 
28.1 
(22.8-33.4) 
NS 
41.4 
(32.7-50.0) 
34.2 
(25.6-42.9) 
NS 
150 
20.8 
(16.9-24.8) 
23.5 
(19.5-27.4) 
NS 
23.0 
(19.7-26.3) 
21.9 
(18.7-25.2) 
NS 
31.3 
(24.4-38.2) 
27.1 
(20.2-34.0) 
NS 
180 
17.1 
(14.3-19.9) 
17.1 
(14.3-20.0) 
NS 
16.6 
(14.6-18.6) 
18.4 
(16.3-20.5) 
NS 
27.1 
(20.1-34.1) 
24.9 
(17.9-31.8) 
NS 
C: chicken, M: mycoprotein. Results are presented as mean adjusted for baseline insulin concentrations, weight and age, with 95% confidence intervals. 
Mixed model p-values are given with Bonferroni correction. Significant and borderline significant differences are highlighted in bold 
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